Original Article
A Randomized Trial of the Angiotensin-Receptor Blocker Valsartan in Chronic Heart Failure
N Engl J Med 2001; 345:1667-1675December 6, 2001
- Abstract
Background
Actions of angiotensin II may contribute to the progression of heart failure despite treatment with currently recommended drugs. We therefore evaluated the long-term effects of the addition of the angiotensin-receptor blocker valsartan to standard therapy for heart failure.
Methods
A total of 5010 patients with heart failure of New York Heart Association (NYHA) class II, III, or IV were randomly assigned to receive 160 mg of valsartan or placebo twice daily. The primary outcomes were mortality and the combined end point of mortality and morbidity, defined as the incidence of cardiac arrest with resuscitation, hospitalization for heart failure, or receipt of intravenous inotropic or vasodilator therapy for at least four hours.
Results
Overall mortality was similar in the two groups. The incidence of the combined end point, however, was 13.2 percent lower with valsartan than with placebo (relative risk, 0.87; 97.5 percent confidence interval, 0.77 to 0.97; P=0.009), predominantly because of a lower number of patients hospitalized for heart failure: 455 (18.2 percent) in the placebo group and 346 (13.8 percent) in the valsartan group (P<0.001). Treatment with valsartan also resulted in significant improvements in NYHA class, ejection fraction, signs and symptoms of heart failure, and quality of life as compared with placebo (P<0.01). In a post hoc analysis of the combined end point and mortality in subgroups defined according to base-line treatment with angiotensin-converting–enzyme (ACE) inhibitors or beta-blockers, valsartan had a favorable effect in patients receiving neither or one of these types of drugs but an adverse effect in patients receiving both types of drugs.
Conclusions
Valsartan significantly reduces the combined end point of mortality and morbidity and improves clinical signs and symptoms in patients with heart failure, when added to prescribed therapy. However, the post hoc observation of an adverse effect on mortality and morbidity in the subgroup receiving valsartan, an ACE inhibitor, and a beta-blocker raises concern about the potential safety of this specific combination.
Media in This Article
Figure 1
Kaplan–Meier Analysis of the Probability of Survival.Figure 2
Kaplan–Meier Analysis of the Probability of Freedom from the Combined End Point (Death from Any Cause, Cardiac Arrest with Resuscitation, Hospitalization for Worsening Heart Failure, or Therapy with Intravenous Inotropes or Vasodilators).Article Activity
- Article
Pharmacotherapy for heart failure has advanced considerably in recent years as clinical trials have demonstrated favorable long-term effects of angiotensin-converting–enzyme (ACE) inhibitors1-3 and beta-blockers4-6 on morbidity and mortality. Despite the use of these potent drugs, heart failure remains the leading reason for hospitalization in the Medicare population,7 mortality among patients with heart failure is high, and the quality of life is low.
Angiotensin II, a potent vasoconstrictor and growth-stimulating hormone, may contribute to the impairment of left ventricular function and the progression of heart failure through increased impedance of left ventricular emptying,8 adverse long-term structural effects on the heart and vasculature,9 and potentially deleterious activation of other neurohormonal agonists, including norepinephrine, aldosterone, and endothelin.10 Since previous studies have shown that physiologically active levels of angiotensin II persisted despite long-term therapy with an ACE inhibitor,11,12 we undertook a study to determine whether the angiotensin-receptor blocker valsartan could further reduce morbidity and mortality among patients who were already receiving the pharmacologic therapy that was considered optimal by their physicians. Descriptions of the rationale for and design of this trial have been published elsewhere.13
Methods
Study Design
The Valsartan Heart Failure Trial (Val-HeFT) was a randomized, placebo-controlled, double-blind, parallel-group trial. Patients at 302 centers in 16 countries gave written informed consent for participation in the trial, which was approved by the institutional review board at each center. The investigation conformed to the principles of the Declaration of Helsinki. Site monitoring, data collection, and data analysis were performed by Novartis Pharmaceuticals. An independent end-points committee adjudicated all reports of primary end points. An independent data and safety monitoring board reviewed biannual interim analyses. The manuscript was prepared by the authors and reviewed by the steering committee and the sponsor.
Eligibility
Men and women 18 years old or older with a history and clinical findings of heart failure for at least three months before screening were eligible. Patients had heart failure of New York Heart Association (NYHA) class II, III, or IV and were clinically stable. To be eligible, they had to have been receiving for at least two weeks a fixed-dose drug regimen that could include ACE inhibitors, diuretics, digoxin, and beta-blockers. In addition, they had to have documented left ventricular dysfunction with an ejection fraction of less than 40 percent and left ventricular dilatation with an echocardiographically measured short-axis internal dimension at end diastole greater than 2.9 cm per square meter of body-surface area. Echocardiograms were analyzed locally after the technical and reader quality at each center had been validated by one of three core laboratories (in Los Angeles; Milan, Italy; or Stockholm, Sweden) that also monitored quality control during the study. Criteria for exclusion have been published previously.13
Placebo Run-in Period
Patients were assessed for two to four weeks to confirm their eligibility, clinical stability, and compliance while taking placebo in a single-blind fashion twice daily. Base-line evaluations included laboratory tests for hematologic variables and blood chemistry; urinalysis; echocardiography; 12-lead electrocardiography; and chest radiography. Quality of life was assessed with the Minnesota Living with Heart Failure questionnaire, which was administered to 60 percent of patients — that is, those in the United States, the United Kingdom, Australia, and Italy.
Randomization and Dose Adjustment
Eligible patients, stratified according to whether or not they were receiving a beta-blocker as background therapy, were randomly assigned to receive oral valsartan or matching placebo. Stratification was performed to ensure the equal distribution of patients receiving these drugs in the two groups. Randomization occurred after the base-line eligibility data were verified by the coordinating centers in Minneapolis and Milan. Valsartan was initiated at a dose of 40 mg twice daily, and the dose was doubled every two weeks until a target dose of 160 mg twice daily was reached. Placebo doses were similarly adjusted. The criteria for increasing the dose included a systolic blood pressure of 90 mm Hg or higher while the patient was standing, the absence of symptoms of hypotension, and a serum creatinine concentration of less than 2.0 mg per deciliter (177 μmol per liter) or no more than 50 percent higher than the base-line concentration. Patients returned for follow-up visits at two, four, and six months and every three months thereafter.
Outcome Measures
The study was designed with two primary end points: mortality and the combined end point of mortality and morbidity, which was defined as cardiac arrest with resuscitation, hospitalization for heart failure, or administration of intravenous inotropic or vasodilator drugs for four hours or more without hospitalization. Secondary cardiovascular outcomes included the changes from base line to the last available observation after treatment had begun in ejection fraction, NYHA functional class, quality-of-life scores, and signs and symptoms of heart failure.
Statistical Analysis
Statistical analyses were performed at an overall significance level of 0.05, adjusted for the two primary end points. Each primary end point was tested at a two-sided significance level of 0.02532, on the basis of the Dunn–Sidak inequality: α'=1–(1–α)1/2. The significance level for the analysis of the time to death was further adjusted for five biannual interim analyses according to the O'Brien–Fleming alpha-spending function. Therefore, the final analysis for the time to death was performed at a two-sided significance level of 0.02.
The calculation of sample size was based on the time-to-death end point. The number of deaths that would be required to detect, with 90 percent power, a 20 percent difference between the death rate with valsartan and that with placebo (estimated at 12 percent per year) was calculated to be 906. We planned to enroll 2500 patients per treatment group.
Comparisons of the primary end points between treatment groups were performed by means of a log-rank test. To estimate the size of the effect, we used a Cox regression model with prespecified base-line covariates, including NYHA class, ejection fraction (above or below the median), cause of heart failure (ischemic or nonischemic), age (younger than 65 years or 65 years old or older), ACE inhibitor use or nonuse, and beta-blocker use or nonuse. Confidence intervals of 98 percent and 97.5 percent were calculated for mortality and the combined end point of mortality and morbidity, respectively. To estimate the size of the effect on the secondary end points and in subgroups, relative risks with 95 percent confidence intervals were calculated with the use of the Cox regression model.
Results
Of the 5010 patients who underwent randomization, 2511 were assigned to receive valsartan and 2499 to receive placebo, all with background therapy for heart failure. There were no clinically relevant differences in the base-line characteristics of the two groups (Table 1Table 1
Base-Line Characteristics of the Patients According to Treatment Group.). A description of the base-line demographic characteristics of this diverse population has been published previously.14 At the time of randomization, 93 percent of the patients were being treated with ACE inhibitors. The average daily doses were 17 mg of enalapril, 19 mg of lisinopril, 80 mg of captopril, 6 mg of ramipril, and 23 mg of quinapril. Thirty-five percent of the patients were receiving beta-blockers (15 percent were receiving carvedilol, 12 percent metoprolol, and 3 percent atenolol), and randomization was stratified according to their use or nonuse; this percentage remained stable throughout the study. Only 5 percent of the patients were treated with spironolactone. The overall mean duration of follow-up was 23 months (range, 0 to 38).The target dose was achieved in 84 percent of the patients receiving valsartan (mean dose, 254 mg) and 93 percent of those receiving placebo (mean equivalent dose, 283 mg). Systolic blood pressure was reduced to a greater extent with valsartan than placebo: at four months, it was reduced by a mean (±SD) of 5.2±15.8 mm Hg in the valsartan group, as compared with 1.2±14.8 mm Hg in the placebo group, and at one year the reductions were 5.2±16.0 mm Hg and 1.3±15.9 mm Hg, respectively. The mean heart rate was unchanged.
Primary End Points
Mortality was similar in the two treatment groups (Figure 1Figure 1
Kaplan–Meier Analysis of the Probability of Survival. and Table 2Table 2
Incidence and Relative Risk of the Primary End Points.). The adjudicated causes of death were also similar in the two treatment groups (there were 262 sudden deaths from cardiac causes in the valsartan group and 258 in the placebo group, and there were 118 deaths due to heart failure in the valsartan group and 125 in the placebo group).The combined end point of mortality and morbidity was significantly reduced among patients receiving valsartan as compared with those receiving placebo (P=0.009) (Figure 2Figure 2
Kaplan–Meier Analysis of the Probability of Freedom from the Combined End Point (Death from Any Cause, Cardiac Arrest with Resuscitation, Hospitalization for Worsening Heart Failure, or Therapy with Intravenous Inotropes or Vasodilators).). The benefit appeared early after randomization and increased throughout the trial. Among the patients in the valsartan group, 723 (28.8 percent) reached the combined end point, as compared with 801 patients (32.1 percent) in the placebo group — a 13.2 percent reduction in risk with valsartan (relative risk, 0.87; 97.5 percent confidence interval, 0.77 to 0.97) (Table 2). The predominant benefit in terms of the combined end point was a 24 percent reduction in the rate of adjudicated hospitalizations for worsening heart failure as a first event in those receiving valsartan (13.8 percent) as compared with those receiving placebo (18.2 percent) (P<0.001) (Table 2).Secondary End Points
The risk of a hospitalization for heart failure (with censoring of the data for patients who died) was reduced by 27.5 percent with valsartan (P<0.001). There were 1189 nonadjudicated hospitalizations for heart failure in the placebo group and 923 in the valsartan group (P=0.002). Since hospitalizations for problems other than heart failure were unaffected, the rate of hospitalizations for any cause was reduced similarly — by 250 events, from 3106 in the placebo group to 2856 in the valsartan group (P=0.14). The mean change in ejection fraction from base line to the last observation was 4.0 percent in the valsartan group and 3.2 percent in the placebo group (P=0.001). More patients in the valsartan group than in the placebo group had improvements in NYHA classification (23.1 percent vs. 20.7 percent) and fewer had worsening (10.1 percent vs. 12.8 percent) (P<0.001). Similarly, dyspnea, fatigue, edema, and rales were more favorably affected by valsartan than by placebo (P<0.01). Among the 1504 patients in the valsartan group to whom the Minnesota Living with Heart Failure questionnaire was administered, there was little change in scores from base line to the end point, but among the 1506 such patients in the placebo group, the mean score worsened by an average of 1.9 (P=0.005 for the comparison between the treatment groups).
Subgroup Analyses
The beneficial effect of valsartan on the combined mortality–morbidity end point was generally consistent among the predefined subgroups of patients. Valsartan improved the outcome in young and old patients, men and women, those with and without diabetes or coronary artery disease, those with ejection fractions or left ventricular dimensions above and below the median, and those with NYHA class II and class III or IV symptoms (Figure 3Figure 3
Relative Risks and 95 Percent Confidence Intervals for the Combined End Point, According to Demographic and Clinical Characteristics.). In the small, heterogeneous black population (which included 344 African-American and South African patients), there was a wide confidence interval for relative risk of the combined end point with valsartan that included 1.0 (relative risk, 1.11; 95 percent confidence interval, 0.77 to 1.61).Background therapy with neurohormonal inhibitors appeared to influence the response to valsartan (Figure 4Figure 4
Relative Risks and 95 Percent Confidence Intervals for the Combined End Point (Death from Any Cause, Cardiac Arrest with Resuscitation, Hospitalization for Worsening Heart Failure, or Therapy with Intravenous Inotropes or Vasodilators), According to the Background Therapy at Base Line, as Calculated by Means of a Cox Regression Model.). The patients were divided into four subgroups on the basis of the use or nonuse of ACE-inhibitor and beta-blocker therapy at base line. The global test for the interaction between treatment and subgroup among the four subgroups was statistically significant for mortality (P=0.009) and the combined end point of mortality and morbidity (P=0.001). In the three groups receiving neither drug or either ACE inhibitors or beta-blockers alone, there was a significantly favorable effect of valsartan on the rate of the combined end point (P=0.003, P=0.002, and P=0.037, respectively) and a favorable point estimate of the odds ratio for death. Mortality was significantly reduced in the 226 patients who were treated with neither an ACE inhibitor nor a beta-blocker (P=0.012). Among those who were receiving both drugs at base line, valsartan had an adverse effect on mortality (P=0.009) and was associated with a trend toward an increase in the combined end point of mortality and morbidity (P=0.10). Among all 366 patients who were not receiving an ACE inhibitor, whether or not a beta-blocker had been prescribed, there was a significantly lower risk of the combined end point in the valsartan group than in the placebo group (relative risk, 0.56; 95 percent confidence interval, 0.39 to 0.81), as well as a lower risk of death (relative risk, 0.67; 95 percent confidence interval, 0.42 to 1.06).Safety
Valsartan therapy was generally well tolerated. Adverse events leading to the discontinuation of the drug occurred in 249 of the patients receiving valsartan (9.9 percent) and 181 patients receiving placebo (7.2 percent) (P<0.001). The adverse events leading to discontinuation and occurring in more than 1 percent of the patients in the valsartan group included dizziness (in 1.6 percent of the patients and 0.4 percent of those in the placebo group; P<0.001), hypotension (1.3 percent and 0.8 percent, respectively; P=0.124), and renal impairment (1.1 percent and 0.2 percent, P<0.001). Overall, the mean change from base line in the blood urea nitrogen concentration was an increase of 5.9 mg per deciliter (2.1 mmol per liter) with valsartan and an increase of 3.3 mg per deciliter (9.2 mmol per liter) with placebo (P<0.001). The mean change in the serum creatinine concentration was an increase of 0.18 mg per deciliter (15.9 μmol per liter) with valsartan and an increase of 0.10 mg per deciliter (8.8 μmol per liter) with placebo (P<0.001). The mean change in the serum potassium concentration was an increase of 0.12 mmol per liter with valsartan and a decrease of 0.07 mmol per liter with placebo (P<0.001).
Discussion
Our study was designed to assess the efficacy of the angiotensin-receptor blocker valsartan when added to prescribed therapy for heart failure. The benefit in terms of morbidity and mortality was achieved in a population in which 93 percent of patients were treated with an ACE inhibitor and 35 percent were treated with a beta-blocker. The outcomes suggest that even with the use of currently prescribed therapy, angiotensin contributes to morbidity but not mortality in patients with heart failure. An unexpected finding emerged, however, from a post hoc analysis of the data on concomitant therapy. Within the 30 percent of the population that was being treated with both an ACE inhibitor and a beta-blocker at base line, there was a significant adverse effect of valsartan on mortality and a nearly significant adverse effect on morbidity. Clarification of whether this finding represents a true interaction or is attributable to chance must await the outcome of ongoing trials evaluating the combination of an angiotensin-receptor blocker with an ACE inhibitor and a beta-blocker. Since only 5 percent of the patients in the trial were receiving spironolactone, an aldosterone-receptor blocker,15 we cannot assess the efficacy or safety of valsartan when given in combination with spironolactone.
The protocol was designed with two primary end points and appropriate statistical adjustment. Although mortality was similar in the two treatment groups, a significant favorable effect of valsartan on cardiovascular morbidity was evident, primarily as a result of a 24 percent reduction in adjudicated (first) hospitalizations for heart failure and a similar reduction in all nonadjudicated (subsequent) hospitalizations for heart failure. The favorable effect was achieved with a target dose of 160 mg twice daily; this dose was chosen because of its hemodynamic and hormonal effects, which were documented in a pilot study involving patients who were receiving ACE-inhibitor therapy.16 The dose was well tolerated; most patients achieved the target dose, and side effects were only slightly more prevalent than in the placebo group.
This study differed from previous trials of angiotensin-receptor blockers in heart failure, such as the Losartan Heart Failure Survival Study17 and the Randomized Evaluation of Strategies for Left Ventricular Dysfunction,18 in terms of the high dose we used, our large sample size, and the use of valsartan as a balanced, placebo-controlled add-on to background therapy.
The reduction in cardiovascular morbidity has relevance for the economic burden of heart failure on the health care system. In addition, the moderate but statistically significant benefit in terms of the secondary end points — NYHA class, quality of life, signs and symptoms of heart failure, and left ventricular ejection fraction — is consistent with an overall incremental benefit of valsartan for patients with heart failure who are receiving medical therapy.
The negative effect of angiotensin II on heart failure could be mediated through a vasoconstrictor-induced increase in blood pressure or a direct effect on cardiac and vascular tissues. Since systolic blood pressure was an average of 5 mm Hg lower in patients who were randomly assigned to receive valsartan than in those assigned to receive placebo, a hemodynamic mechanism may account, at least in part, for the observed benefit. Nonetheless, the growth-promoting and apoptotic effects of angiotensin II have been well demonstrated9,19 and may contribute to the structural remodeling that promotes the progression of heart failure.20-24 A long-term increase in the ejection fraction has been identified as a marker of regression of left ventricular remodeling that is manifested as reduced chamber volume.25,26 This structural effect has been associated with an improvement in survival.27,28 In our study, the increase in the ejection fraction was more moderate than in previous trials of ACE inhibitors and beta-blockers and was not associated with reduced mortality. The absence of a more robust effect may be related to the effectiveness of the other therapy received by the patients (annual mortality in the placebo group was 9 percent, rather than the predicted 12 percent).
Subgroup analysis is used in large-scale trials to confirm the generalizability of the findings or, if inconsistencies are observed, to generate hypotheses about subgroup responses to be tested in subsequent studies. In our study, subgroups defined on the basis of demographic characteristics or base-line clinical characteristics generally had responses that were similar to those in the study population as a whole. Background neurohormonal-inhibitor therapy, however, appeared to influence the outcome. Since this background therapy was not controlled and patients were only partially stratified according to its presence or absence at randomization (according to the use of beta-blockers but not ACE inhibitors), the data generated by this analysis must be interpreted with caution. Nonetheless, in the small subgroup of patients (7 percent) who were not being treated with an ACE inhibitor, there was a 44.0 percent reduction in the combined end point of mortality and morbidity and a 33.1 percent reduction in mortality.
The point estimate of the odds ratio favored valsartan in all subgroups except the subgroup of patients who were being treated with both an ACE inhibitor and a beta-blocker at base line. As previously noted, the apparent adverse effect of valsartan in this subgroup leads to the hypothesis that the extensive blockade of multiple neurohormonal systems in patients with heart failure could be deleterious. Recent clinical-trial experience with moxonidine,29 endothelin-receptor antagonists, and cytokine inhibitors30 is consistent with this hypothesis. Several trials involving substantial numbers of patients who are receiving these three classes of neurohormonal inhibitors are ongoing and can be expected to provide additional data relevant to this safety concern.
Although current guidelines recommend ACE inhibitors and beta-blockers as standard therapy for heart failure because of their demonstrated benefit in terms of mortality, only one third of the patients enrolled in our study were receiving both classes of drugs. Furthermore, patients who were already being treated with angiotensin-receptor blockers, which are widely prescribed for patients who are intolerant of ACE inhibitors, were excluded from the study. Improved compliance with the guidelines may reduce the number of inadequately treated patients. Nonetheless, the benefit of valsartan in terms of the combined end point of mortality and morbidity that was found in all subgroups except that receiving both ACE inhibitors and beta-blockers suggests that the drug could have a role in the management of the syndrome.
Presented in part at the American Heart Association meeting, New Orleans, November 12–15, 2000.
Supported by a grant from Novartis Pharma, Basel, Switzerland. Drs. Cohn and Tognoni have had research support and consultation arrangements with Novartis Pharmaceuticals, the sponsor of this study.
Source Information
From the Cardiovascular Division, Department of Medicine, University of Minnesota Medical School, Minneapolis (J.N.C.); and the Mario Negri Institute, Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico, Milan, Italy (G.T.).
Address reprint requests to Dr. Cohn at the Cardiovascular Division, Mayo Mail Code 508, University of Minnesota Medical School, 420 Delaware St., SE, Minneapolis, MN 55455.
The investigators are listed in the Appendix.
Appendix
The Valsartan Heart Failure Trial Investigators included the following: in the United States: Alabama — R. Bourge, D. Calhoun, B. Foley, L. Lowe, S. Oparil, G. Perry, B. Rayburn, B. Sanders; Arizona — J.E. Boulet, J. Christensen, P. Fenster, S. Heumiller, R. Lee, P. McGowan, J. Ohm, R. Siegel, T. Struiksma; California — J.W. Allen, J. Backman, P. Coleman, D. Costello, T.A. Cox, P. Deedwania, L. Defensor, G. Dennish, W.A. Edmiston, D. Everitt, S. Fabbri, C. Faulkner, J. Gilbert, J.I. Gorwit, S. Harte, L.A. Hawkins, J. Hemphill, J.T. Heywood, B. Jackson, B. Jaski, S. Khan, D. McAdams, P. Pak, N. Parker, R. Shabetai, H. Shively, J. Sklar, L. Sprinkle, R. Stein, P. Waack, R. Wadlington, R. Wright, L.G. Yellen; Connecticut — S. Carolan, I.S. Cohen, M.B. Fowler, M. Martin-O'Brien, A. Mullin, T. Ramahi, K. Rholfs; District of Columbia — D.J. Diver, N. Douglas-Kersellious, D. Lee, S. Singh; Florida — J. Anderson, J. Bauerlein, M. Bayer, G. Cintron, S. Brenner, C. Davenport, S.L. Duncan, P. Green, T.C. Hilton, H. Karunaratne, A. Kinsella, G. Lamas, M. Mayor, M. McIvor, M.R. Milunski, M.A. Nocero, J. O'Bryan, J. Reddinger, D. Samada, C.R. Stastny, M. Taylor, H. Tee, J.L. Walker, V. Wilson; Georgia — S. Beer, A. Carr, J. Grace, J. Guidot, S. Holt, K. Taylor, W.R. Taylor, P. Yaun; Illinois — K. Furlong, M. Johnson, R. Lang, H. Loeb; Indiana — J. Becker, J. Birt, L. Ford; Iowa — R. Oren, P. Scovall, W. Wickemeyer, N. Young; Kansas — M. Bowles; Kentucky — K. Doerschuk, S. Wagner; Louisiana — B. Iteld; Maryland — L. Black, S. Gottlieb, S.O. Gottlieb, N. Greenberg, D. Lowry; Massachusetts — A. Burger, M. Burger, K. Coleman, M. Criasia, W. Dec, C. Haggan, T. Meyer, M. Motta, P. Shrewe, J. Smith; Michigan — P.A. Kaminski, D. Langholtz, A.B. Levine, T.B. Levine, J. Nicklas, R. Rose; Minnesota — I. Anand, S. Berg, A. Holmstrom, B. Merkle, L. Miller; Missouri — K. Aggarwal, E. Geltman, M. Gilbert, B. Lee, C. Hinden, D. Yip; Nevada — A. Cason-Pitcher, R. Croke, A. Steljes; New Jersey — R. Berkowitz, H.S. Ribner, J. Strobeck, P. Tabachnik, M.J. Zucker; New Mexico — M. Conway, P. Doherty, R. Dubroff, S. Justice; New York — M. Applegate, L. Baruch, C. Buchholz-Varley, J. Cappelli, M.E. Coglianese, J. Corbelli, T. Costantino, M.A. Goodman, S. Graham, V. Hart, M. Kukin, O. Ocampo, W. Orlowski, P. Patacsil, N. Schulhoff, P. Stein, R.M. Steingart, B.H. Sung, M.F. Wilson; North Carolina — R. Bilbro, F. Cobb, G. Dodson, D. Framm, K. Harshaw-Ellis, M. Higginbotham, B. Kuzil, G. Weidner; Ohio — D.J. Kereiakes, R. Lengerich, L.L. Wohlford; Oklahoma — J. Anderson, J. Cook, M. Dickson, R.D. Ensley, S. Jameson, J. Kalbfleisch, C. Melson-Alsip, D. Simmons; Oregon — R. Hershberger, L. Keilson; Pennsylvania — M. Amidi, M. Bell, J. Boehmer, E. Loh, P.J. Mather, S. Rubin, R. Shannon, I. Smith, R. Weller-Moore, S. Worley; Rhode Island — A. Sadaniantz; South Carolina — J. Evans, G. Hendrix; Tennessee — L. Chismark, W.G. Friesen, S. Gubin, L. Howerton, J. Jeanes, F. McGrew, J. Osborn, K.B. Ramanathan, R. Smith; Texas — N. Baradhi, L.A. Campos, R. Carney, S.E. El Hafi, R. Gammon, J.D. Jackman, C. Janes, D. McCarroll, F. Navetta, M. Rotman, A. Smith; Utah — J.J. Perry; Virginia — J. Bergin, J. Herre, J. O'Brien; Washington — B. Crane, D. Fishbein, J. Forster, M. Hall; Wisconsin — C.V. Hughes, J. Hosenpud, R. Siegel, C.R. Vander Ark, P.A. Wiederholt; outside the United States: Australia — J. Amerena, I. Button, R. Calvert, M. Croot, P. Garrahy, C. Hall, H. Hankey, D. Hogan, D. Hollens-Riley, J. Horowitz, L. Howes, B. Jackson, I. Jeffrey, J. Karrasch, S. Leslie, H. Krum, L. Martin, B. Singh, P. Taverner, A. Thomson, P. Thompson; Belgium — S. Degré, P. De Vusser, W. Droogné, P. Noyens, A.Z.J. Palfijn, A. Strijckmans, J. Vanhaecke, W. Van Mieghem, J. Vanwelden; Czech Republic — R. Cifkova, J. Gregor, J. Simon, J. Toman, J. Vojacek, J. Widimsky; Denmark — O. Gøtzsche, T. Haghfelt, P. Hildebrandt, E. Kassis, T. Toftegaard Nielsen; Finland — E. Engblom, J. Hartikainen, S. Majahalme, M. Niemelä, K. Peuhkurinen, M. Pietilä, J. Taurio, L.M. Voipio-Pulkki; France — P. Lechat, M. Baudet, M. Bory, A. Cohen, P. Coumel, M. Dahan, J.M. Davy, Y.M. Frances, M. Galinier, M. Guediche, G. Jarry, J.P. Ollivier, L. Slimane, M. Zaouali; Germany — C. Bergmeier, K.O. Bischoff, C.G. Brilla, J. Cyran, W.G. Daniel, M. Dürsch, E. Fleck, L. Goedel-Meinen, R. Griebenow, R. Hambrecht, M. Hamel, K.H. Hauff, G. Haustein, C. Helzer-Arbeiter, D. Hey, T. Hoefs, M. Hofmann, T. Kleemann, D. Koch, N. Kokott, T. Langenickel, E. Lopez, T. Matthes, V. Mitrovic, E. Mueser, K.H. Munderloh, S. Philipp, V. Regitz-Zagrosek, A. Rouwen, R. Rummel, A. Schmidt, J. Senges, K. Stumpe, H. Topp, C. Weiler, R. Willenbrock, S. Winkler; Hungary — M. Csanady, I. Edes, K. Farkas, C. Farsang, T. Forster, T. Fulop, A. Janosi, L. Mezei, M. Nemeth, E. Palkovi, E. Szigeti; Italy — M.C. Albanese, G. Alunni, G. Ansalone, B. Aloisi, I. Belloni, R. Belluschi, D. Bertoli, I. Bisceglia, G.M. Boffa, E. Bosi, A. Branzi, E. Butti, L. Cacciavillani, C. Campana, S. Capomolla, G. Castiglioni, A. Cavalli, V. Ceci, E. Cerè, V. Cirrincione, F. Cobelli, G. Corsini, A.L. Cuzzato, F. De Santis, G. Di Pasquale, M. Farruggio, C. Fresco, G. Ferrari, G. Filorizzo, G. Foti, A. Fraticelli, F.A. Galati, K. Ghebremarian-Tesfau, F. Giancotti, P. Giannuzzi, G. Gibelli, A. Giordano, E. Giovannini, S. Gramenzi, F. Ingrillì, S. Lombroso, F. Longaro, L. Magliani, C. Manes, R. Mangia, G. Misuraca, R. Mocchegiani, A.P. Morciano, G. Occhi, M. Olivieri, M. Palvarini, R. Panciarola, L. Pasetti, S. Pede, R. Pedretti, G.P. Perini, F. Perticone, G. Pettinati, F. Plastina, M. Porcu, C. Porcellati, F. Pozzar, G. Pulignano, C. Rapezzi, F. Rusconi, A. Sanna, M. Santini, V. Santoro, S. Scalvini, F. Scapellato, A.M. Schillaci, C. Schweiger, G. Sinagra, D. Staniscia, P. Tanzi, L. Tavazzi, E. Uslenghi, G. Ventura, A. Vetrano, E. Zanelli; the Netherlands — M. Baselier, P. Bruels, P.W.F. Bruggink, F. Den Hartog, P. Dunselman, P. Fels, G. Geurts, H. Groeneveld, B. Hamer, N. Holwerda, J. Kragten, G. Laarman, J. Levert, A. Liem, P. Lindner, H.R. Michels, G. Paulussen, J.L. Posma, H.J. Schaafsma, W.M. Siesverda, L.C. Slegers, P. van der Burgh, E.C.M. van der Velden, A.J.J. van Es, L. van Kempen, H. van Kesteren, R. van Rijswijk, P. van Rossum, D.J. Heijden, J.C.L. Wesdorp, A. Willems, A. Withagen; Norway — M. Bjurstroem, A. Hervold, T.O. Klemsdal, K. Knutsen, T. Lappegaard, S. Solheim, S. Toft, K.V. Tuseth, A. Westheim, T. Wessel-Aas; South Africa — L.J. Burgess, P.J. Commerford, Y. Govender, E. Klug, P. Manga, F. Maritz, D.P. Naidoo, L. Opie, H.W. Prozesky, D. Smith; Spain — A. Aguilar Llopis, E. Asin Cardiel, V. Barrios Alonso, A. Bayes De Luna, J. Bayon Fernandez, J.L. Diago Torrent, E. Galve Basilio, M. Gil De La Peña, M. Gómez Gerboles, E. Homs Espinach, I. Iglesias Garriz, J. Julia Gibergans, A. López Granados, A. Mallol Kirchner, N. Manito Lorite, R. Masia Martorell, J. Orus, J. Padro Dalmau, F. Pérez Villa, J. Roca Elias, E. Roig Minguell, J. Soler Soler, F. Valles Belsue; Sweden — A. Andersson, H. Brodersson, S. Ekdahl, J. Ellström, S. Hansen, J. Herlitz, L. Hjelmaeus, C. Höglund, B. Karlsson, P. Katzman, L. Ljungdahl, M. Lundblad, H. Tygesen, C. Wettervik, L. Winberg; United Kingdom — A. Baksi, A. Blackwell, C. Cope, D. Connelly, T.R. Cripps, G. Dadahl, M.K. Ghosh, S. Gibbs, S. Gupta, M.E. Heber, P.J.B. Hubner, G.D. Johnston, N. Jones, J. Kooner, R. Levy, D. Lubel, P. Nicholls, A. Rozkovec, P. Schofield, E. Smith, I.B. Squire, L.B. Tan, C. Welsh, S. Williams; Executive Committee — J.N. Cohn (chair), G. Tognoni (co-chair), R.D. Glazer, D. Spormann; Steering Committee — J.N. Cohn (chair), G. Tognoni (co-chair), H. Krum, J. Vanhaecke, J. Widimsky, T. Haghfelt, S. Majahalme, P. Lechat, K. Stumpe, L. Tan, C. Farsang, L. Tavazzi, N.J. Holwerda, A. Westheim, L. Opie, A. Bayes de Luna, C. Höglund, I. Anand; Study Coordination Centers — S. Ziesche, R. Latini, A.P. Maggioni; End-Point Committee — P. Carson (chair), C. Opasich, M. Scherillo, G. Sinagra, A. Volpe, C. O'Connor, I. Piña, F. Tristani, L.W. Stevenson; Data Safety Monitoring Board — W. Parmley (chair), M. Bobbio, D.J. van Veldhuisen, J. Abrams, D. DeMets; Echo Core Laboratory — M. Wong, C. Höglund, L. Staszewsky, A. Volpi; Neurohormone Laboratory — D. Judd, R. Latini, S. Masson.
- References
References
1
The SOLVD Investigators
Full Text | Web of Science | Medline2
The CONSENSUS Trial Study Group
Full Text | Web of Science | Medline3
Cohn JN ,Johnson G ,Ziesche S , et al. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med 1991;325:303-310
Full Text | Web of Science | Medline4
CIBIS-II Investigators and Committees
CrossRef | Web of Science | Medline5
MERIT-HF Study Group
CrossRef | Web of Science | Medline6
Packer M ,Bristow MR ,Cohn JN , et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med 1996;334:1349-1355
Full Text | Web of Science | Medline7
Popovic JR, Kozak LJ. National Hospital Discharge Survey: annual summary, 1998. Vital and health statistics. Series 13. No. 148. Washington, D.C.: Government Printing Office, September 2000. (DHHS publication no. (PHS) 2000-1719.)
8
Cohn JN . Vasodilator therapy for heart failure: the influence of impedance on left ventricular performance. Circulation 1973;48:5-8
Web of Science | Medline9
Dzau VJ . Tissue renin-angiotensin system in myocardial hypertrophy and failure. Arch Intern Med 1993;153:937-942
CrossRef | Web of Science | Medline10
Jilma B ,Krejcy K ,Dirnberger E , et al. Effects of angiotensin-II infusion at pressor and subpressor doses on endothelin-1 plasma levels in healthy men. Life Sci 1997;60:1859-1866
CrossRef | Web of Science | Medline11
Kawamura M ,Imanashi M ,Matsushima Y ,Ito K ,Hiramori K . Circulating angiotensin II levels under repeated administration of lisinopril in normal subjects. Clin Exp Pharmacol Physiol 1992;19:547-553
CrossRef | Web of Science | Medline12
Jorde UP ,Ennezat PV ,Lisker J , et al. Maximally recommended doses of angiotensin-converting enzyme (ACE) inhibitors do not completely prevent ACE-mediated formation of angiotensin II in chronic heart failure. Circulation 2000;101:844-846
Web of Science | Medline13
Cohn JN ,Tognoni G ,Glazer RD ,Spormann D ,Hester A . Rationale and design of the Valsartan Heart Failure trial: a large multinational trial to assess the effects of valsartan, an angiotensin-receptor blocker, on morbidity and mortality in chronic congestive heart failure. J Card Fail 1999;5:155-160
CrossRef | Web of Science | Medline14
Cohn JN ,Tognoni G ,Glazer R ,Spormann D . Baseline demographics of the Valsartan Heart Failure Trial. Eur J Heart Fail 2000;2:439-446
CrossRef | Web of Science | Medline15
Pitt B ,Zannad F ,Remme WJ , et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 1999;341:709-717
Full Text | Web of Science | Medline16
Baruch L ,Anand I ,Cohen IS ,Ziesche S ,Judd D ,Cohn JN . Augmented short- and long-term hemodynamic and hormonal effects of an angiotensin receptor blocker added to angiotensin converting enzyme inhibitor therapy in patients with heart failure. Circulation 1999;99:2658-2664
Web of Science | Medline17
Pitt B ,Poole-Wilson PA ,Segal R , et al. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial -- the Losartan Heart Failure Survival Study ELITE II. Lancet 2000;355:1582-1587
CrossRef | Web of Science | Medline18
McKelvie RS ,Yusuf S ,Pericak D , et al. Comparison of candesartan, enalapril, and their combination in congestive heart failure: Randomized Evaluation of Strategies for Left Ventricular Dysfunction (RESOLVD) pilot study. Circulation 1999;100:1056-1064
Web of Science | Medline19
Leri A ,Liu Y ,Li B , et al. Up-regulation of AT1 and AT2 receptors in postinfarcted hypertrophied myocytes and stretch-mediated apoptotic cell death. Am J Pathol 2000;156:1663-1672
CrossRef | Web of Science | Medline20
Cohn JN ,Ferrari R ,Sharpe N . Cardiac remodeling -- concepts and clinical implications: a consensus paper from an international forum on cardiac remodeling. J Am Coll Cardiol 2000;35:569-582
CrossRef | Web of Science | Medline21
Dostal DE ,Baker KM . Angiotensin II stimulation of left ventricular hypertrophy in adult rat heart: mediation by the AT1 receptor. Am J Hypertens 1992;5:276-280
Web of Science | Medline22
Harrap SB ,Dominiczak AF ,Fraser R , et al. Plasma angiotensin II, predisposition to hypertension, and left ventricular size in healthy young adults. Circulation 1996;93:1148-1154
Web of Science | Medline23
Jacobi J ,Schlaich MP ,Delles C ,Schobel HP ,Schmieder RE . Angiotensin II stimulates left ventricular hypertrophy in hypertensive patients independently of blood pressure. Am J Hypertens 1999;12:418-422
Web of Science | Medline24
Crabos M ,Roth M ,Hahn AWA ,Erne P . Characterization of angiotensin II receptors in cultured adult rat cardiac fibroblasts: coupling to signaling systems and gene expression. J Clin Invest 1994;93:2372-2378
CrossRef | Web of Science | Medline25
Wong M ,Johnson G ,Shabetai R , et al. Echocardiographic variables as prognostic indicators and therapeutic monitors in chronic congestive heart failure: Veterans Affairs cooperative studies V-HeFT I and II. Circulation 1993;87:Suppl VI:VI-6526
Francis GS ,Cohn JN . Heart failure: mechanisms of cardiac and vascular dysfunction and the rationale for pharmacologic intervention. FASEB J 1990;4:3068-3075
Web of Science | Medline27
Cintron G ,Johnson G ,Francis G ,Cobb F ,Cohn JN . Prognostic significance of serial changes in left ventricular ejection fraction in patients with congestive heart failure. Circulation 1993;87:Suppl VI:VI-1728
Patten RD ,Udelson JE ,Konstam MA . Ventricular remodeling and its prevention in the treatment of heart failure. Curr Opin Cardiol 1998;13:162-167
Web of Science | Medline29
Jones CG ,Cleland JGF . Meeting report -- the LIDO, HOPE, MOXCON, and WASH studies. Eur J Heart Fail 1999;1:425-431
CrossRef30
Louis A ,Cleland JGF ,Crabbe F , et al. Clinical trials update: CAPRICORN, COPERNICUS, MIRACLE, STAF, RITZ-2, RECOVER, and RENAISSANCE and cachexia and cholesterol in heart failure: highlights of the scientific sessions of the American College of Cardiology, 2001. Eur J Heart Fail 2001;3:381-387
CrossRef | Web of Science | Medline
- Citing Articles (789)
Citing Articles
1
, Aneta Aleksova, Serge Masson, Aldo P. Maggioni, Donata Lucci, Renato Urso, Lidia Staszewsky, Stefano Ciaffoni, Giuseppe Cacciatore, Gianfranco Misuraca, Michele Gulizia, Lucio Mos, Gianni Proietti, Calogero Minneci, Roberto Latini, Gianfranco Sinagra. (2012) Effects of Candesartan on Left Ventricular Function, Aldosterone and BNP in Chronic Heart Failure. Cardiovascular Drugs and Therapy
CrossRef2
Abdul Ali Abdellatif. (2012) The role of renin inhibition in treating the hypertensive patient with diabetes: a summary of preclinical and clinical evidence. Expert Review of Cardiovascular Therapy 10:2, 251-263
CrossRef3
Hiroshi Hasegawa, Hiroyuki Takano, Yoshihito Kameda, Akihiko Kubota, Yoshio Kobayashi, Issei Komuro. (2012) Effect of Switching from Telmisartan, Valsartan, Olmesartan, or Losartan to Candesartan on Morning Hypertension. Clinical and Experimental Hypertension1-6
CrossRef4
James L. Januzzi. (2012) The role of natriuretic peptide testing in guiding chronic heart failure management: Review of available data and recommendations for use. Archives of Cardiovascular Diseases
CrossRef5
Gail B. Rattinger, Sarah K. Dutcher, Pankdeep T. Chhabra, Christine S. Franey, Linda Simoni-Wastila,, Stephen S. Gottlieb, Bruce Stuart, Ilene H. Zuckerman. (2012) The Effect of Dementia on Medication Use and Adherence Among Medicare Beneficiaries With Chronic Heart Failure. The American Journal of Geriatric Pharmacotherapy
CrossRef6
Chia-Wei Liou, Tung-Chen Yeh, I-Chung Chen, Chi-Hung Huang, Yi-Jen Hung, Kwan-Lih Hsu, Jian-Der Lee, Meng-Huan Lei, Kuan-Cheng Chang, Pei-Yung Liao, Zhih-Cherng Chen, Jackson Wang, Charles Jia-Yin Hou. (2011) Efficacy and safety of valsartan in hypertensive Taiwanese patients: Post-marketing surveillance study. Blood Pressure 20:S2, 13-21
CrossRef7
Maurizio Destro, Francesca Cagnoni, Giuseppina Patrizia Dognini, Vincenzo Galimberti, Carlo Taietti, Chiara Cavalleri, Emilio Galli. (2011) Telmisartan: just an antihypertensive agent? A literature review. Expert Opinion on Pharmacotherapy 12:17, 2719-2735
CrossRef8
, E. Imai, J. C. N. Chan, S. Ito, T. Yamasaki, F. Kobayashi, M. Haneda, H. Makino. (2011) Effects of olmesartan on renal and cardiovascular outcomes in type 2 diabetes with overt nephropathy: a multicentre, randomised, placebo-controlled study. Diabetologia 54:12, 2978-2986
CrossRef9
Alejandro de la Sierra. (2011) Renin–angiotensin system blockade and reduction of cardiovascular risk: future perspectives. Expert Review of Cardiovascular Therapy 9:12, 1585-1591
CrossRef10
John T. Parissis, Pinelopi Rafouli-Stergiou, Alexandre Mebazaa, Ignatios Ikonomidis, Vassiliki Bistola, Maria Nikolaou, Taly Meas, Juan Delgado, Fabio Vilas-Boas, Ioannis Paraskevaidis, Maria Anastasiou-Nana, Ferenc Follath. (2011) Acute heart failure in patients with diabetes mellitus: Clinical characteristics and predictors of in-hospital mortality. International Journal of Cardiology
CrossRef11
Diane L. Frankenfield, Eric D. Weinhandl, Christopher A. Powers, Benjamin L. Howell, Charles A. Herzog, Wendy L. St. Peter. (2011) Utilization and Costs of Cardiovascular Disease Medications in Dialysis Patients in Medicare Part D. American Journal of Kidney Diseases
CrossRef12
E. de Teresa Galván, J.M. García Pinilla, R. de Teresa Herrera. (2011) Tratamiento de la insuficiencia cardiaca. Medicine - Programa de Formación Médica Continuada Acreditado 10:92, 6240-6248
CrossRef13
Sum Lam. (2011) Azilsartan. Cardiology in Review 19:6, 300-304
CrossRef14
Angela Brown, Becky Captain. (2011) 50 Years of Thiazides: Should Thiazide Diuretics Be Considered Third-Line Hypertension Treatment?. American Journal of Therapeutics 18:6, e244-e254
CrossRef15
Daniel Jacoby, Oltjan Albajrami, Lavanya Bellumkonda. (2011) Natural History of End-stage LV Dysfunction: Has It Improved from the Classic Franciosa and Cohn Graph?. Cardiology Clinics 29:4, 485-495
CrossRef16
Anjay Rastogi, Mohamad Rashid, Richard F. Wright. (2011) Reducing Cardiorenal Risk Through Combination Therapy With a Direct Renin Inhibitor. The Journal of Clinical Hypertension 13:11, 848-855
CrossRef17
Kevin E Chan, T Alp Ikizler, Jorge L Gamboa, Chang Yu, Raymond M Hakim, Nancy J Brown. (2011) Combined angiotensin-converting enzyme inhibition and receptor blockade associate with increased risk of cardiovascular death in hemodialysis patients. Kidney International 80:9, 978-985
CrossRef18
A. Tomaschitz, S. Pilz, E. Ritz, A. Morganti, T. Grammer, K. Amrein, B. O. Boehm, W. Marz. (2011) Associations of plasma renin with 10-year cardiovascular mortality, sudden cardiac death, and death due to heart failure. European Heart Journal 32:21, 2642-2649
CrossRef19
Hiroshi Hasegawa, Hiroyuki Takano, Hiroya Narumi, Masashi Ohtsuka, Tadahiko Mizuguchi, Takao Namiki, Yoshio Kobayashi, Issei Komuro. (2011) Effects of telmisartan and losartan on cardiovascular protection in Japanese hypertensive patients. Hypertension Research 34:11, 1179-1184
CrossRef20
Saul Blecker, Robert Herbert, Frederick L. Brancati. (2011) Comorbid Diabetes and End-of-Life Expenditures Among Medicare Beneficiaries With Heart Failure. Journal of Cardiac Failure
CrossRef21
Prashant D. Bhave, Kurt S. Hoffmayer, Ehrin J. Armstrong, Sonia Garg, Ateet Patel, John S. MacGregor, John C. Stein, Scott Kinlay, Peter Ganz, James M. McCabe. (2011) Predictors of Depressed Left Ventricular Function in Patients Presenting With ST-Elevation Myocardial Infarction. The American Journal of Cardiology
CrossRef22
Mihai Gheorghiade, Nancy M. Albert, Anne B. Curtis, J. Thomas Heywood, Mark L. McBride, Patches Johnson Inge, Mandeep R. Mehra, Christopher M. O’Connor, Dwight Reynolds, Mary Norine Walsh, Clyde W. Yancy, Gregg C. Fonarow. (2011) Medication Dosing in Outpatients With Heart Failure After Implementation of a Practice-Based Performance Improvement Intervention: Findings From IMPROVE HF. Congestive Heart Failureno-no
CrossRef23
Fuzheng QU, Shuqin SUN, Zeqiang JIANG, Mengsong SHI, Yiying SUN, Ping WANG, Houxia ZHOU, Shaohua WANG, Linqiang CONG, Zhihua LIU, Bin JIANG, Cao ZOU, Wenping JIANG. (2011) Effects of valsartan on sarcoplasmic reticulum calcium adenodine triphosphatase expression and function in a rabbit model of heart failure. Chinese Journal of Multiple Organ Diseases in the Elderly 10:4, 348-352
CrossRef24
Jonathan P. Man, Bodh I. Jugdutt. (2011) Systolic heart failure in the elderly: optimizing medical management. Heart Failure Reviews
CrossRef25
H Takano, H Hasegawa, H Narumi, S Shindo, H Mizuma, Y Kuwabara, Y Kobayashi, I Komuro. (2011) Effects of valsartan and amlodipine on home blood pressure and cardiovascular events in Japanese hypertensive patients: a subanalysis of the VART. Journal of Human Hypertension
CrossRef26
Kevin E. C. Meyers, Kenneth Lieberman, Susan Solar-Yohay, Guangyang Han, Victor Shi. (2011) The Efficacy and Safety of Valsartan in Obese and Non-Obese Pediatric Hypertensive Patients. The Journal of Clinical Hypertension 13:10, 758-766
CrossRef27
Samir Parikh, Lee Hebert, Brad Rovin. (2011) Protecting the kidneys in lupus nephritis. International Journal of Clinical Rheumatology 6:5, 529-546
CrossRef28
Haroon-Ur Rashid, Christian Mende. (2011) The Role of Direct Renin Inhibition in Clinical Practice. American Journal Cardiovascular Drugs 11:5, 303-315
CrossRef29
Luca Bettari, Salvador Borges-Neto. (2011) Imaging Surrogate End Points in Heart Failure Trials. Heart Failure Clinics 7:4, 509-518
CrossRef30
Elske Sieswerda, Elvira C van Dalen, Aleida Postma, Daniel KL Cheuk, Huib N Caron, Leontien CM Kremer, Elske Sieswerda. 2011. Medical interventions for treating anthracycline-induced symptomatic and asymptomatic cardiotoxicity during and after treatment for childhood cancer. .
CrossRef31
Massimo Volpe, Roberto Pontremoli, Claudio Borghi. (2011) Direct Renin Inhibition. High Blood Pressure & Cardiovascular Prevention 18:3, 93-105
CrossRef32
Robert Petrella, Paul Michailidis. (2011) Retrospective Analysis of Real-World Efficacy of Angiotensin Receptor Blockers Versus Other Classes of Antihypertensive Agents in Blood Pressure Management. Clinical Therapeutics 33:9, 1190-1203
CrossRef33
Andrés A. Herrada, Carmen Campino, Cristián A. Amador, Luis F. Michea, Carlos E. Fardella, Alexis M. Kalergis. (2011) Aldosterone as a modulator of immunity. Journal of Hypertension 29:9, 1684-1692
CrossRef34
Marco A. Caccamo, Peter M. Eckman. (2011) Pharmacologic Therapy for New York Heart Association Class IV Heart Failure. Congestive Heart Failure 17:5, 213-219
CrossRef35
John R. Kapoor, Gregg C. Fonarow, Xin Zhao, Roger Kapoor, Adrian F. Hernandez, Paul A. Heidenreich. (2011) Diabetes, quality of care, and in-hospital outcomes in patients hospitalized with heart failure. American Heart Journal 162:3, 480-486.e3
CrossRef36
J. J. V. McMurray. (2011) CONSENSUS to EMPHASIS: the overwhelming evidence which makes blockade of the renin-angiotensin-aldosterone system the cornerstone of therapy for systolic heart failure. European Journal of Heart Failure 13:9, 929-936
CrossRef37
Marla J. De Jong, Misook L. Chung, Jia-Rong Wu, Barbara Riegel, Mary Kay Rayens, Debra K. Moser. (2011) Linkages between anxiety and outcomes in heart failure. Heart & Lung: The Journal of Acute and Critical Care 40:5, 393-404
CrossRef38
Matthew Movsesian, Omar Wever-Pinzon, Fabrice Vandeput. (2011) PDE3 inhibition in dilated cardiomyopathy. Current Opinion in Pharmacology
CrossRef39
Yao Dao-Kuo, Wang Le-Xin, Curran Shane, Ball Patrick. (2011) Adherence to treatment guidelines in the pharmacological management of chronic heart failure in an Australian population. Journal of Geriatric Cardiology 8:2, 88-92
CrossRef40
Novalia P. Sidik, Scott D. Solomon, Roberto Latini, Aldo P. Maggioni, Melanie Wright, Claudio R. Gimpelewicz, Bertram Pitt, John J. V. McMurray. (2011) Effect of Aliskiren in Patients with Heart Failure According to Background Dose of ACE Inhibitor: A Retrospective Analysis of the Aliskiren Observation of Heart Failure Treatment (ALOFT) Trial. Cardiovascular Drugs and Therapy 25:4, 315-321
CrossRef41
Jujhar Bains, William B Smith. (2011) Valsartan plus hydrochlorothiazide: a review of its use since its introduction. Expert Opinion on Pharmacotherapy 12:12, 1975-1984
CrossRef42
Charles F. Jackson, Nanette K. Wenger. (2011) Enfermedad cardiovascular en el anciano. Revista Española de Cardiología 64:8, 697-712
CrossRef43
Henry Krum, John R Teerlink. (2011) Medical therapy for chronic heart failure. The Lancet 378:9792, 713-721
CrossRef44
Guido Grassi, Gino Seravalle, Giuseppe Mancia. (2011) Cardiovascular consequences of poor compliance to antihypertensive therapy. Blood Pressure 20:4, 196-203
CrossRef45
Charles F. Jackson, Nanette K. Wenger. (2011) Cardiovascular Disease in the Elderly. Revista Española de Cardiología (English Edition) 64:8, 697-712
CrossRef46
Juan A. Sanchez, Lise L. Sanchez, Stanley J. Dudrick. (2011) Nutritional Considerations in Adult Cardiothoracic Surgical Patients. Surgical Clinics of North America 91:4, 857-875
CrossRef47
Tara I. Chang, David Shilane, Steven M. Brunelli, Alfred K. Cheung, Glenn M. Chertow, Wolfgang C. Winkelmayer. (2011) Angiotensin-converting enzyme inhibitors and cardiovascular outcomes in patients on maintenance hemodialysis. American Heart Journal 162:2, 324-330
CrossRef48
Michelle W Krause, Vivian A Fonseca, Sudhir V Shah. (2011) Combination inhibition of the renin–angiotensin system: is more better?. Kidney International 80:3, 245-255
CrossRef49
Ikechi G Okpechi, Brian L Rayner. (2011) Impact of recent landmark clinical trials on hypertension treatment. Clinical Investigation 1:8, 1141-1154
CrossRef50
R. Lowrie, F. S. Mair, N. Greenlaw, P. Forsyth, A. McConnachie, J. Richardson, N. Khan, D. Morrison, C.-M. Messow, B. Rae, J. J. V. McMurray. (2011) The Heart failure and Optimal Outcomes from Pharmacy Study (HOOPS): rationale, design, and baseline characteristics. European Journal of Heart Failure 13:8, 917-924
CrossRef51
Domenic Sica, William B. White, Michael A. Weber, George L. Bakris, Alfonso Perez, Charlie Cao, Alison Handley, Stuart Kupfer. (2011) Comparison of the Novel Angiotensin II Receptor Blocker Azilsartan Medoxomil vs Valsartan by Ambulatory Blood Pressure Monitoring. The Journal of Clinical Hypertension 13:7, 467-472
CrossRef52
B. Pitt, R. Latini, A. P. Maggioni, S. D. Solomon, B. A. Smith, M. Wright, M. F. Prescott, J. J. V. McMurray. (2011) Neurohumoral effects of aliskiren in patients with symptomatic heart failure receiving a mineralocorticoid receptor antagonist: the Aliskiren Observation of Heart Failure Treatment study. European Journal of Heart Failure 13:7, 755-764
CrossRef53
Rishi J. Desai, Carol M. Ashton, Anita Deswal, Robert O. Morgan, Hemalkumar B. Mehta, Hua Chen, Rajender R. Aparasu, Michael L. Johnson. (2011) Comparative effectiveness of individual angiotensin receptor blockers on risk of mortality in patients with chronic heart failure. Pharmacoepidemiology and Drug Safetyn/a-n/a
CrossRef54
Nicolas F. Schroten, Carlo A. J. M. Gaillard, Dirk J. Veldhuisen, Mariusz K. Szymanski, Hans L. Hillege, Rudolf A. Boer. (2011) New roles for renin and prorenin in heart failure and cardiorenal crosstalk. Heart Failure Reviews
CrossRef55
Sameer Goyal, Saurabh Bharti, Kanhei Charan Sahoo, Ashok Kumar Sharma, Dharamvir Singh Arya. (2011) Valsartan, an Angiotensin II Receptor Blocker, Attenuates Cardiac Dysfunction and Oxidative Stress in Isoproterenol-Induced Cardiotoxicity. Cardiovascular Toxicology 11:2, 148-156
CrossRef56
C. Potamitis, P. Chatzigeorgiou, E. Siapi, K. Viras, T. Mavromoustakos, A. Hodzic, G. Pabst, F. Cacho-Nerin, P. Laggner, M. Rappolt. (2011) Interactions of the AT1 antagonist valsartan with dipalmitoyl-phosphatidylcholine bilayers. Biochimica et Biophysica Acta (BBA) - Biomembranes 1808:6, 1753-1763
CrossRef57
Sandhya Murthy, Hannah I. Lipman. (2011) Management of End-Stage Heart Failure. Primary Care: Clinics in Office Practice 38:2, 265-276
CrossRef58
Alex Reyentovich, Stuart D. Katz. (2011) Mineralocorticoid-receptor Antagonists in Heart Failure: A Tale of Serendipity and Success. Current Heart Failure Reports 8:2, 87-90
CrossRef59
Ryan P. Morrissey, Lawrence Czer, Prediman K. Shah. (2011) Chronic Heart Failure. American Journal Cardiovascular Drugs 11:3, 153-171
CrossRef60
Lilit A Sargsyan, Risheng Xu, Alicia Romero, Brett W. Stephens, Donald A Molony. (2011) Recombinant tissue plasminogen activator reduces incidence of catheter malfunction and bacteremia. Dialysis & Transplantation 40:6, 268-271
CrossRef61
S. D. Solomon, S. Hee Shin, A. Shah, H. Skali, A. Desai, L. Kober, A. P. Maggioni, J. L. Rouleau, R. Y. Kelly, A. Hester, J. J. V. McMurray, M. A. Pfeffer, . (2011) Effect of the direct renin inhibitor aliskiren on left ventricular remodelling following myocardial infarction with systolic dysfunction. European Heart Journal 32:10, 1227-1234
CrossRef62
O. R. de Peuter, G. Y. H. Lip, P. C. Souverein, O. H. Klungel, A. de Boer, H. R. Buller, P. W. Kamphuisen. (2011) Time-trends in treatment and cardiovascular events in patients with heart failure: a pharmacosurveillance study. European Journal of Heart Failure 13:5, 489-495
CrossRef63
Gerd K. Rosenkranz. (2011) Another view on the analysis of cardiovascular morbidity/mortality trials. Pharmaceutical Statistics 10:3, 196-202
CrossRef64
M. Azizi, M. Frank, O. Steichen, A. Blanchard. (2011) Intérêts et limites de l’inhibition de la rénine par l’aliskiren. Annales Pharmaceutiques Françaises 69:3, 142-150
CrossRef65
D. Richter, C. Mickel, S. Acharya, P. Brunel, C. Militaru. (2011) Aliskiren-based stepped-care treatment algorithm provides effective blood pressure control. International Journal of Clinical Practice 65:5, 613-623
CrossRef66
V. Barrios, C. Calvo, C. Suárez, M. De La Figuera, C. Escobar, G. Muñoz. (2011) Opinión de los médicos expertos en hipertensión sobre las combinaciones triples en España. Proyecto SINERGIA. Hipertensión y Riesgo Vascular 28:3, 83-90
CrossRef67
Kenneth S. Hershon. (2011) Mechanistic and Clinical Aspects of Renin-Angiotensin-Aldosterone System Blockade in the Prevention of Diabetes Mellitus and Cardiovascular Disease. Endocrine Practice 17:3, 430-440
CrossRef68
Fadi G Hage, Sulaf J Mansur, Suzanne Oparil. (2011) Rationale for the use of multiple blockers of the renin–angiotensin–aldosterone system in specific patient populations. Therapy 8:3, 227-236
CrossRef69
Yuki Kuramoto, Takahisa Yamada, Shunsuke Tamaki, Yuji Okuyama, Takashi Morita, Yoshio Furukawa, Koji Tanaka, Yusuke Iwasaki, Taku Yasui, Hiromichi Ueda, Takeshi Okada, Masato Kawasaki, Wayne C. Levy, Issei Komuro, Masatake Fukunami. (2011) Usefulness of Cardiac Iodine-123 Meta-Iodobenzylguanidine Imaging to Improve Prognostic Power of Seattle Heart Failure Model in Patients With Chronic Heart Failure. The American Journal of Cardiology 107:8, 1185-1190
CrossRef70
James E. Frampton. (2011) Telmisartan. Drugs 71:6, 651-677
CrossRef71
Joseph L. Izzo Jr, Adrienne S. Zion. (2011) Value of Angiotensin Receptor Blocker Therapy in Diabetes. The Journal of Clinical Hypertension 13:4, 290-295
CrossRef72
Wan A. H. Wan Md Adnan, Nur L. Zaharan, Kathleen Bennett, Catherine A. Wall. (2011) Trends in co-prescribing of angiotensin converting enzyme inhibitors and angiotensin receptor blockers in Ireland. British Journal of Clinical Pharmacology 71:3, 458-466
CrossRef73
A. de la Sierra. (2011) Prevención de la progresión y regresión de la lesión orgánica. Estrategias de futuro. Revista Clínica Española 211, 8-14
CrossRef74
Roberto Fogari, Annalisa Zoppi. (2011) A drug safety evaluation of valsartan. Expert Opinion on Drug Safety 10:2, 295-303
CrossRef75
Paul J. Hauptman, Douglas L. Mann. (2011) The vagus nerve and autonomic imbalance in heart failure: past, present, and future. Heart Failure Reviews 16:2, 97-99
CrossRef76
Paolo Verdecchia, Fabio Angeli, Giorgio Gentile, Giovanni Mazzotta, Gianpaolo Reboldi. (2011) Telmisartan for the reduction of cardiovascular morbidity and mortality. Expert Review of Clinical Pharmacology 4:2, 151-161
CrossRef77
Nazha Hamdani, Walter J. Paulus. (2011) Treatment of Heart Failure With Normal Ejection Fraction. Current Treatment Options in Cardiovascular Medicine 13:1, 26-34
CrossRef78
Alberto Palazzuoli, Giovanni Antonelli, Ilaria Quatrini, Ranuccio Nuti. (2011) Natriuretic peptides in heart failure: where we are, where we are going. Internal and Emergency Medicine 6:1, 63-68
CrossRef79
Helmy M. Siragy. (2011) Rationale for Combining a Direct Renin Inhibitor with other Renin- Angiotensin System Blockers. Focus on Aliskiren and Combinations. Cardiovascular Drugs and Therapy 25:1, 87-97
CrossRef80
Joanne Chang, Weiyi Yang, Kristijan H. Kahler, Thomas Fellers, John Orloff, Arielle G. Bensimon, Andrew P. Yu, Chun-Po Steve Fan, Eric Q. Wu. (2011) Compliance, Persistence, Healthcare Resource Use, and Treatment Costs Associated with Aliskiren plus ARB versus ACE Inhibitor plus ARB Combination Therapy. American Journal Cardiovascular Drugs 11:1, 21-32
CrossRef81
Hiroya Narumi, Hiroyuki Takano, Satoshi Shindo, Miwa Fujita, Hiroshi Mizuma, Yoichi Kuwabara, Issei Komuro. (2011) Effects of valsartan and amlodipine on cardiorenal protection in Japanese hypertensive patients: the Valsartan Amlodipine Randomized Trial. Hypertension Research 34:1, 62-69
CrossRef82
Jerome L. Fleg, Wilbert S. Aronow, William H. Frishman. (2011) Cardiovascular drug therapy in the elderly: benefits and challenges. Nature Reviews Cardiology 8:1, 13-28
CrossRef83
Lutz Frankenstein, Andrew L. Clark, Jorge P. Ribeiro. (2011) Influence of Sex on Treatment and Outcome in Chronic Heart Failure. Cardiovascular Therapeuticsno-no
CrossRef84
Marsha A. Raebel. (2011) Hyperkalemia Associated with Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers. Cardiovascular Therapeuticsno-no
CrossRef85
M. Volpe, M. Azizi, A. H. J. Danser, G. Nguyen, L. M. Ruilope. (2011) Twisting arms to angiotensin receptor blockers/antagonists: the turn of cancer. European Heart Journal 32:1, 19-22
CrossRef86
Young Soo Lee, Kee Sik Kim, Jin Bae Lee, Jae Kean Ryu, Ji Yong Choi, Byong-Kyu Kim, Sung Gug Chang, Seung Ho Hur, Bong Ryeol Lee, Byung Chun Jung, Geu Ru Hong, Byung Soo Kim, Tae Ho Park, Young Dae Kim, Tae Ik Kim, Dong Soo Kim. (2011) Effect of Valsartan on N-Terminal Pro-Brain Natriuretic Peptide in Patient With Stable Chronic Heart Failure: Comparison With Enalapril. Korean Circulation Journal 41:2, 61
CrossRef87
H. Krum, B. Massie, W. T. Abraham, K. Dickstein, L. Kober, J. J. V. McMurray, A. Desai, C. Gimpelewicz, A. Kandra, B. Reimund, H. Rattunde, J. Armbrecht, , H. Krum, B. Massie, W. Abraham, K. Dickstein, L. Kober, J. McMurray, K. Swedberg, S. Pocock, B. Pitt, S. Borer Jeffrey, J. Rouleau, M. Wibberg, S. Solomon, S. Desai Akshay, P. Finn, L. Weinrauch, H. Hartley, A.-C. Pouleur, E. Barkoudah, C. Duong, A. Rogers. (2011) Direct renin inhibition in addition to or as an alternative to angiotensin converting enzyme inhibition in patients with chronic systolic heart failure: rationale and design of the Aliskiren Trial to Minimize OutcomeS in Patients with HEart failuRE (ATMOSPHERE) study. European Journal of Heart Failure 13:1, 107-114
CrossRef88
Walmor C. De Mello. (2011) Novel aspects of angiotensin II action in the heart. Implications to myocardial ischemia and heart failure. Regulatory Peptides 166:1-3, 9-14
CrossRef89
Yavuz Beyazit, Tugrul Purnak, Gulay Sain Guven, Ibrahim C. Haznedaroglu. (2011) Local Bone Marrow Renin-Angiotensin System and Atherosclerosis. Cardiology Research and Practice 2011, 1-10
CrossRef90
Sripal Bangalore, Sunil Kumar, Sverre E Kjeldsen, Harikrishna Makani, Ehud Grossman, Jørn Wetterslev, Ajay K Gupta, Peter S Sever, Christian Gluud, Franz H Messerli. (2011) Antihypertensive drugs and risk of cancer: network meta-analyses and trial sequential analyses of 324 168 participants from randomised trials. The Lancet Oncology 12:1, 65-82
CrossRef91
Young-Rak Cho, Young-Dae Kim, Tae-Ho Park, Kyungil Park, Jong-Sung Park, Heekyung Baek, Sun-Young Choi, Kee-Sik Kim, Taek-Jong Hong, Tae-Hyun Yang, Jin-Yong Hwang, Jong-Seon Park, Seung-Ho Hur, Sang-Gon Lee. (2011) The impact of dose of the angiotensin-receptor blocker valsartan on the post-myocardial infarction ventricular remodeling: study protocol for a randomized controlled trial. Trials 12:1, 247
CrossRef92
Gang Liu, Hirofumi Hitomi, Naohisa Hosomi, Bai Lei, Nicolas Pelisch, Daisuke Nakano, Hideyasu Kiyomoto, Hong Ma, Akira Nishiyama. (2010) Mechanical stretch potentiates angiotensin II-induced proliferation in spontaneously hypertensive rat vascular smooth muscle cells. Hypertension Research 33:12, 1250-1257
CrossRef93
Pietro Francia, Cristina Balla, Arianna Uccellini, Agnese Ricotta, Anna Modestino, Alessandra Frattari, Adriano Salvati, Massimo Volpe. (2010) Low-dose angiotensin receptor blockers as an alternative to ACE-inhibitors increase the risk of appropriate ICD interventions in heart failure. International Journal of Cardiology 145:3, 522-524
CrossRef94
Pierre Nantel, Paul René de Cotret. (2010) The evolution of angiotensin blockade in the management of cardiovascular disease. Canadian Journal of Cardiology 26, 7E-13E
CrossRef95
Johan Verjans, Sander Wolters, Ward Laufer, Mark Schellings, Michelle Lax, Dagfinn Lovhaug, Hendrikus Boersma, Gerrit Kemerink, Simon Schalla, Paul Gordon, Jaap Teule, Jagat Narula, Leonard Hofstra. (2010) Early molecular imaging of interstitial changes in patients after myocardial infarction: Comparison with delayed contrast-enhanced magnetic resonance imaging. Journal of Nuclear Cardiology 17:6, 1065-1072
CrossRef96
Sulaf J. Mansur, Fadi G. Hage, Suzanne Oparil. (2010) Have the Renin-Angiotensin-Aldosterone System Perturbations in Cardiovascular Disease Been Exhausted?. Current Cardiology Reports 12:6, 450-463
CrossRef97
Paul Wojciechowski. (2010) Perioperative Optimization of the Heart Failure Patient. International Anesthesiology Clinics 47:4, 121-135
CrossRef98
Ilke Sipahi, James C. Fang. (2010) Treating Heart Failure on Dialysis. Journal of the American College of Cardiology 56:21, 1709-1711
CrossRef99
Vivencio Barrios, Carlos Escobar. (2010) Valsartan–amlodipine–hydrochlorothiazide: the definitive fixed combination?. Expert Review of Cardiovascular Therapy 8:11, 1609-1618
CrossRef100
Mitsuru Ohishi, Yasushi Takeya, Yuji Tatara, Koichi Yamamoto, Miyuki Onishi, Yoshihiro Maekawa, Kei Kamide, Hiromi Rakugi. (2010) Strong suppression of the renin–angiotensin system has a renal-protective effect in hypertensive patients: High-dose ARB with ACE inhibitor (Hawaii) study. Hypertension Research 33:11, 1150-1154
CrossRef101
Gennaro Cice, Attilio Di Benedetto, Salvatore D'Isa, Antonello D'Andrea, Daniele Marcelli, Emanuele Gatti, Raffaele Calabrò. (2010) Effects of Telmisartan Added to Angiotensin-Converting Enzyme Inhibitors on Mortality and Morbidity in Hemodialysis Patients With Chronic Heart Failure. Journal of the American College of Cardiology 56:21, 1701-1708
CrossRef102
Sanjiv M. Narayan. 2010. Preventing Sudden Cardiac Arrest in the Heart Failure Patient. , 177-195.
CrossRef103
Ruchika Dutta, Barry H. Greenberg. 2010. Neurohormonal Blocking Agents in the Treatment of Patients with Left Ventricular Dysfunction and Heart Failure. , 83-116.
CrossRef104
Ronald Freudenberger. 2010. Management of Advanced Heart Failure. , 357-383.
CrossRef105
Vijay U. Rao, John R. Teerlink. 2010. Treating Systolic Heart Failure. , 287-326.
CrossRef106
Doson Chua, Anita Lo, Chris Lo. (2010) Spironolactone Use in Heart Failure Patients With End-Stage Renal Disease on Hemodialysis: Is It Safe?. Clinical Cardiology 33:10, 604-608
CrossRef107
Gianfranco Parati, Roland Asmar, Grzegorz Bilo, Albert Kandra, Robert Di Giovanni, Thomas Mengden. (2010) Effectiveness and safety of high-dose valsartan monotherapy in hypertension treatment: the ValTop study. Hypertension Research 33:10, 986-994
CrossRef108
Giuseppe Boriani, Igor Diemberger, Cinzia Valzania, Mauro Biffi, Cristian Martignani, Emanuel Raschi, Valentina Mantovani, Matteo Ziacchi, Matteo Bertini, Fabrizio De Ponti, Angelo Branzi. (2010) Role of drugs and devices in patients at risk of sudden cardiac death. Fundamental & Clinical Pharmacology 24:5, 575-594
CrossRef109
F. H. Messerli, J. A. Staessen, F. Zannad. (2010) Of fads, fashion, surrogate endpoints and dual RAS blockade. European Heart Journal 31:18, 2205-2208
CrossRef110
Pedro Marques da Silva. (2010) Efficacy of Fixed-Dose Combination Therapy in the Treatment of Patients with Hypertension. Clinical Drug Investigation 30:9, 625-641
CrossRef111
Henry Krum, Aldo Maggioni. (2010) Renin Inhibitors in Chronic Heart Failure: The Aliskiren Observation of Heart Failure Treatment Study in Context. Clinical Cardiology 33:9, 536-541
CrossRef112
Javed Butler, Inder S. Anand, Michael A. Kuskowski, Thomas Rector, Peter Carson, Jay N. Cohn, . (2010) Digoxin Use and Heart Failure Outcomes: Results from the Valsartan Heart Failure Trial (Val-HeFT). Congestive Heart Failure 16:5, 191-195
CrossRef113
Amanda J Edgley, Henry Krum, Darren J Kelly. (2010) Targeting Fibrosis for the Treatment of Heart Failure: A Role for Transforming Growth Factor-β. Cardiovascular Therapeuticsno-no
CrossRef114
Jay N. Cohn. (2010) Role of the Renin-Angiotensin System in Cardiovascular Disease. Cardiovascular Drugs and Therapy 24:4, 341-344
CrossRef115
Thomas J Povsic, Christopher M O’Connor. (2010) Cell therapy for heart failure: the need for a new therapeutic strategy. Expert Review of Cardiovascular Therapy 8:8, 1107-1126
CrossRef116
Finn Gustafsson, Julian Segura, Luis M Ruilope. (2010) How should we manage heart failure developing in patients already treated with angiotensin-converting enzyme inhibitors and beta-blockers for hypertension, diabetes or coronary disease?. Journal of Hypertension 28:8, 1595-1598
CrossRef117
S. M. Chang, C. B. Granger, P. A. Johansson, P. Kosolcharoen, J. J. V. McMurray, E. L. Michelson, D. R. Murray, B. Olofsson, M. A. Pfeffer, S. D. Solomon, K. Swedberg, S. Yusuf, M. E. Dunlap, . (2010) Efficacy and safety of angiotensin receptor blockade are not modified by aspirin in patients with chronic heart failure: a cohort study from the Candesartan in Heart failure - Assessment of Reduction in Mortality and morbidity (CHARM) programme. European Journal of Heart Failure 12:7, 738-745
CrossRef118
Daniel G. Kramer, Thomas A. Trikalinos, David M. Kent, George V. Antonopoulos, Marvin A. Konstam, James E. Udelson. (2010) Quantitative Evaluation of Drug or Device Effects on Ventricular Remodeling as Predictors of Therapeutic Effects on Mortality in Patients With Heart Failure and Reduced Ejection Fraction. Journal of the American College of Cardiology 56:5, 392-406
CrossRef119
Alejandro de la Sierra, Luis Miguel Ruilope. (2010) ¿Es posible conseguir una mayor reducción de la morbimortalidad cardiovascular en los pacientes ya tratados con bloqueadores del sistema renina-angiotensina?. Medicina Clínica 135:5, 212-214
CrossRef120
A. Davenport, S. D. Anker, A. Mebazaa, A. Palazzuoli, G. Vescovo, R. Bellomo, P. Ponikowski, I. Anand, N. Aspromonte, S. Bagshaw, T. Berl, I. Bobek, D. N. Cruz, L. Daliento, M. Haapio, H. Hillege, A. House, N. Katz, A. Maisel, S. Mankad, P. McCullough, F. Ronco, A. Shaw, G. Sheinfeld, S. Soni, N. Zamperetti, P. Zanco, C. Ronco, . (2010) ADQI 7: the clinical management of the Cardio-Renal syndromes: work group statements from the 7th ADQI consensus conference. Nephrology Dialysis Transplantation 25:7, 2077-2089
CrossRef121
Shizu Oyamada, Cesario Bianchi, Shinji Takai, Michael P. Robich, Richard T. Clements, Louis Chu, Frank W. Sellke. (2010) Impact of acute myocardial ischemia reperfusion on the tissue and blood-borne renin–angiotensin system. Basic Research in Cardiology 105:4, 513-522
CrossRef122
Vijayakumar Sukumaran, Kenichi Watanabe, Punniyakoti T Veeraveedu, Rajarajan A Thandavarayan, Narasimman Gurusamy, Meilei Ma, Ken'ichi Yamaguchi, Kenji Suzuki, Makoto Kodama, Yoshifusa Aizawa. (2010) Telmisartan, an angiotensin-II receptor blocker ameliorates cardiac remodeling in rats with dilated cardiomyopathy. Hypertension Research 33:7, 695-702
CrossRef123
Ilke Sipahi, Sara M Debanne, Douglas Y Rowland, Daniel I Simon, James C Fang. (2010) Angiotensin-receptor blockade and risk of cancer: meta-analysis of randomised controlled trials. The Lancet Oncology 11:7, 627-636
CrossRef124
Heart Failure Society of America. (2010) Executive Summary: HFSA 2010 Comprehensive Heart Failure Practice Guideline. Journal of Cardiac Failure 16:6, 475-539
CrossRef125
D. Castagno, P. S. Jhund, J. J. V. McMurray, J. D. Lewsey, E. Erdmann, F. Zannad, W. J. Remme, J. L. Lopez-Sendon, P. Lechat, F. Follath, C. Hoglund, V. Mareev, Z. Sadowski, R. J. Seabra-Gomes, H. J. Dargie. (2010) Improved survival with bisoprolol in patients with heart failure and renal impairment: an analysis of the cardiac insufficiency bisoprolol study II (CIBIS-II) trial. European Journal of Heart Failure 12:6, 607-616
CrossRef126
(2010) Section 13: Evaluation and Therapy for Heart Failure in the Setting of Ischemic Heart Disease. Journal of Cardiac Failure 16:6, e157-e165
CrossRef127
Hiroshi Yoshida, Mitsuyuki Shimizu, Katsunori Ikewaki, Ikuo Taniguchi, Norio Tada, Michihiro Yoshimura, Giuseppe Rosano, Björn Dahlöf, Seibu Mochizuki. (2010) Sex differences in effects of valsartan administration on cardiovascular outcomes in hypertensive patients: findings from the Jikei Heart Study. Journal of Hypertension 28:6, 1150-1157
CrossRef128
(2010) Section 7: Heart Failure in Patients With Reduced Ejection Fraction. Journal of Cardiac Failure 16:6, e73-e97
CrossRef129
Finn Gustafsson, Dan Atar, Bertram Pitt, Faiez Zannad, Marc A. Pfeffer. (2010) Maximizing scientific knowledge from randomized clinical trials. American Heart Journal 159:6, 937-943
CrossRef130
William E. Boden, Marcus D. Flather, Deepak L. Bhatt. (2010) Role of Dual Antiplatelet Therapy in Symptomatic Patients with Established Vascular Disease: Putting the CHARISMA Trial into Therapeutic Perspective. Cardiovascular Drugs and Therapy 24:3, 207-216
CrossRef131
Helmy M. Siragy. (2010) Comparing angiotensin II receptor blockers on benefits beyond blood pressure. Advances in Therapy 27:5, 257-284
CrossRef132
Manuel Martínez-Sellés, Tomás Datino, Marta Alhama, Nelida Barrueco, Isabel Castillo, Francisco Fernández-Avilés. (2010) Rapid carvedilol up-titration in hospitalized patients with left ventricular systolic dysfunction – data from the Carvedilol in Hospital: Up-titration Limits after Acute Patients Admission registry. Journal of Cardiovascular Medicine 11:5, 352-358
CrossRef133
Bodh I Jugdutt. (2010) Heart failure in the elderly: advances and challenges. Expert Review of Cardiovascular Therapy 8:5, 695-715
CrossRef134
Paolo Verdecchia, Fabio Angeli, Giovanni Mazzotta, Giuseppe Ambrosio, Gianpaolo Reboldi. (2010) Angiotensin receptor blockers in hypertension. New insights from Japan. Hypertension Research 33:5, 394-397
CrossRef135
Milan Gupta, George N. Honos, Eric J. Velazquez, Namsik Chung, Willie Oigman, Aldo P. Maggioni. (2010) Evidence for the efficacy of ARBs across the cardiovascular continuum. Current Medical Research and Opinion 26:5, 1203-1218
CrossRef136
Amber L. Beitelshees, Issam Zineh. (2010) Renin–angiotensin–aldosterone system (RAAS) pharmacogenomics: implications in heart failure management. Heart Failure Reviews 15:3, 209-217
CrossRef137
(2010) Systolic Heart Failure. New England Journal of Medicine 362:16, 1545-1546
Full Text138
The NAVIGATOR Study Group. (2010) Effect of Valsartan on the Incidence of Diabetes and Cardiovascular Events. New England Journal of Medicine 362:16, 1477-1490
Full Text139
Darci Phillips, Michiel ten Hove, Jurgen E. Schneider, Colin O. Wu, Liam Sebag-Montefiore, Angel M. Aponte, Craig A. Lygate, Julie Wallis, Kieran Clarke, Hugh Watkins, Robert S. Balaban, Stefan Neubauer. (2010) Mice over-expressing the myocardial creatine transporter develop progressive heart failure and show decreased glycolytic capacity. Journal of Molecular and Cellular Cardiology 48:4, 582-590
CrossRef140
J. Signorovitch, J. Zhang, E.Q. Wu, D. Latremouille-Viau, A.P. Yu, H.B. Dastani, K.H. Kahler. (2010) Economic impact of switching from valsartan to other angiotensin receptor blockers in patients with hypertension. Current Medical Research and Opinion 26:4, 849-860
CrossRef141
Marsha A. Raebel, Colleen Ross, Stanley Xu, Douglas W. Roblin, Craig Cheetham, Christopher M. Blanchette, Gwyn Saylor, David H. Smith. (2010) Diabetes and Drug-Associated Hyperkalemia: Effect of Potassium Monitoring. Journal of General Internal Medicine 25:4, 326-333
CrossRef142
Anju Bhardwaj, Shafiq U. Rehman, Asim Mohammed, Aaron L. Baggish, Stephanie A. Moore, James L. Januzzi. (2010) Design and methods of the Pro-B Type Natriuretic Peptide Outpatient Tailored Chronic Heart Failure Therapy (PROTECT) Study. American Heart Journal 159:4, 532-538.e1
CrossRef143
Jon Bergset, Eugene Storozynsky, John D Bisognano. (2010) Renin Inhibition for Hypertension: Selecting the Right Role for a New Class of Drug. American Journal of Therapeutics 17:2, 182-187
CrossRef144
Ravi V. Shah, Akshay S. Desai, Michael M. Givertz. (2010) The Effect of Renin-Angiotensin System Inhibitors on Mortality and Heart Failure Hospitalization in Patients With Heart Failure and Preserved Ejection Fraction: A Systematic Review and Meta-Analysis. Journal of Cardiac Failure 16:3, 260-267
CrossRef145
Serge Masson, Roberto Latini, Inder S. Anand. (2010) An Update on Cardiac Troponins as Circulating Biomarkers in Heart Failure. Current Heart Failure Reports 7:1, 15-21
CrossRef146
Miyuki Tsuchihashi-Makaya, Tomoo Furumoto, Shintaro Kinugawa, Sanae Hamaguchi, Kazutomo Goto, Daisuke Goto, Satoshi Yamada, Hisashi Yokoshiki, Akira Takeshita, Hiroyuki Tsutsui. (2010) Discharge use of angiotensin receptor blockers provides comparable effects with angiotensin-converting enzyme inhibitors on outcomes in patients hospitalized for heart failure. Hypertension Research 33:3, 197-202
CrossRef147
Hua Chen, Liu Li-jun, Zhu Jian-jun, Xu Bo, Li Rui. (2010) Chemical composition analysis of soybean oligosaccharides and its effect on ATPase activities in hyperlipidemic rats. International Journal of Biological Macromolecules 46:2, 229-231
CrossRef148
Maartje CJ Slagman, Gerjan Navis, Gozewijn D Laverman. (2010) Dual blockade of the renin–angiotensin–aldosterone system in cardiac and renal disease. Current Opinion in Nephrology and Hypertension 19:2, 140-152
CrossRef149
Jan Galle. (2010) Das kardiorenale Syndrom. Medizinische Klinik 105:3, 142-149
CrossRef150
Alexander Doumas, Timothy S. Draper, Edgar C. Schick, William H. Gaasch. (2010) Prevalence and Clinical Characteristics of Nondilated Cardiomyopathy and the Effect of Atrial Fibrillation. The American Journal of Cardiology 105:6, 884-887
CrossRef151
M. Frimodt-Moller, A. Hoj Nielsen, S. Strandgaard, A.-L. Kamper. (2010) Feasibility of combined treatment with enalapril and candesartan in advanced chronic kidney disease. Nephrology Dialysis Transplantation 25:3, 842-847
CrossRef152
Charles R Salters, Alison L Bailey, Thomas F Whayne. (2010) Current treatment of heart failure in the USA. Expert Review of Cardiovascular Therapy 8:2, 279-290
CrossRef153
Jan J. Braszko. (2010) Participation of D1–4 dopamine receptors in the pro-cognitive effects of angiotensin IV and des-Phe6 angiotensin IV. Neuroscience & Biobehavioral Reviews 34:3, 343-350
CrossRef154
J. J.V. McMurray, K. Swedberg. (2010) HEAAL: the final chapter in the story of angiotensin receptor blockers in heart failure--lessons learnt from a decade of trials. European Journal of Heart Failure 12:2, 99-103
CrossRef155
Kanta Fujimi, Yoshinari Uehara, Satomi Abe, Akira Kawamura, Sankar Devarajan, Shin-ichiro Miura, Keijiro Saku, Hidenori Urata. (2010) Homocysteine-induced oxidative stress upregulates chymase in mouse mastocytoma cells. Hypertension Research 33:2, 149-154
CrossRef156
Osman Najam, Nizar Yonan, Simon G. Williams, Steven M. Shaw. (2010) The Usefulness of Chronic Heart Failure Treatments in Chronic Cardiac Graft Failure. Cardiovascular Therapeutics 28:1, 48-58
CrossRef157
Roger E. Kelley. (2010) Neurologic Presentations of Cardiac Disease. Neurologic Clinics 28:1, 17-36
CrossRef158
Mithilesh K Das, Douglas P Zipes. (2010) Antiarrhythmic and Nonantiarrhythmic Drugs for Sudden Cardiac Death Prevention. Journal of Cardiovascular Pharmacology1
CrossRef159
McMurray, John J.V., . (2010) Systolic Heart Failure. New England Journal of Medicine 362:3, 228-238
Full Text160
Roger Hullin. 2010. Treatment of Left Ventricular Failure. , 152-160.
CrossRef161
Tsuyoshi Matsumura, Takuhisa Tamura, Satoshi Kuru, Yasuki Kikuchi, Mitsuru Kawai. (2010) Carvedilol can Prevent Cardiac Events in Duchenne Muscular Dystrophy. Internal Medicine 49:14, 1357-1363
CrossRef162
Thomas S. Rector, Inder S. Anand. (2010) Research Needed to Support Clinical Use of Biomarkers as Prognostic Indicators for Patients with Heart Failure. Cardiology Research and Practice 2010, 1-6
CrossRef163
Nancy Houston Miller. (2010) Cardiovascular Risk Reduction with Renin-Angiotensin Aldosterone System Blockade. Nursing Research and Practice 2010, 1-7
CrossRef164
J.M. Neutel. (2010) Choosing among renin-angiotensin system blockers for the management of hypertension: from pharmacology to clinical efficacy. Current Medical Research and Opinion 26:1, 213-222
CrossRef165
Steen Neldam. (2010) Choosing an angiotensin-receptor blocker: blood pressure lowering, cardiovascular protection or both?. Future Cardiology 6:1, 129-135
CrossRef166
Alejandro Lugo-Baruqui, José Francisco Muñoz-Valle, Sigifredo Arévalo-Gallegos, Juan Armendáriz-Borunda. (2010) Role of angiotensin II in liver fibrosis-induced portal hypertension and therapeutic implications. Hepatology Research 40:1, 95-104
CrossRef167
Yoshihisa Okazaki, Can Zheng, Meihua Li, Masaru Sugimachi. (2010) Effect of the cholinesterase inhibitor donepezil on cardiac remodeling and autonomic balance in rats with heart failure. The Journal of Physiological Sciences 60:1, 67-74
CrossRef168
Susanne W. M. van den Borne, Javier Diez, W. Matthijs Blankesteijn, Johan Verjans, Leo Hofstra, Jagat Narula. (2010) Myocardial remodeling after infarction: the role of myofibroblasts. Nature Reviews Cardiology 7:1, 30-37
CrossRef169
Steven A Yarows. (2010) Aliskiren/valsartan combination for the treatment of cardiovascular and renal diseases. Expert Review of Cardiovascular Therapy 8:1, 19-33
CrossRef170
Marsha A. Raebel, Colleen Ross, Craig Cheetham, Hans Petersen, Gwyn Saylor, David H. Smith, Leslie A. Wright, Douglas W. Roblin, Stanley Xu. (2010) Increasingly restrictive definitions of hyperkalemia outcomes in a database study: effect on incidence estimates. Pharmacoepidemiology and Drug Safety 19:1, 19-25
CrossRef171
Tae-Ho Park. (2010) The Effect of High-Dose Valsartan on Left Ventricular Function Following Primary Percutaneous Coronary Intervention. Journal of Cardiovascular Ultrasound 18:3, 84
CrossRef172
Matthew Movsesian, Josef Stehlik, Fabrice Vandeput, Michael R. Bristow. (2009) Phosphodiesterase inhibition in heart failure. Heart Failure Reviews 14:4, 255-263
CrossRef173
Manish M. Sood, Marisa Battistella, Charmaine E. Lok. (2009) Patterns of cardioprotective medication prescription in incident hemodialysis patients. International Urology and Nephrology 41:4, 1021-1027
CrossRef174
M. Bohm, F. Mahfoud, C. Werner, K. Teo, M. Baumhakel. (2009) Cardiovascular protection: a breakthrough for high-risk patients. European Heart Journal Supplements 11:Suppl F, F19-F26
CrossRef175
Giuseppe Mancia, Stéphane Laurent, Enrico Agabiti-Rosei, Ettore Ambrosioni, Michel Burnier, Mark J. Caulfield, Renata Cifkova, Denis Clément, Antonio Coca, Anna Dominiczak, Serap Erdine, Robert Fagard, Csaba Farsang, Guido Grassi, Hermann Haller, Antony Heagerty, Sverre E. Kjeldsen, Wolfgang Kiowski, Jean Michel Mallion, Athanasios Manolis, Krzysztof Narkiewicz, Peter Nilsson, Michael H. Olsen, Karl Heinz Rahn, Josep Redon, José Rodicio, Luis Ruilope, Roland E. Schmieder, Harry A.J. Struijker-Boudier, Pieter A. Van Zwieten, Margus Viigimaa, Alberto Zanchetti. (2009) Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. Blood Pressure 18:6, 308-347
CrossRef176
Lorenzo Pradelli, Sergio Iannazzo, Orietta Zaniolo. (2009) The Cost Effectiveness and Cost Utility of Valsartan in Chronic Heart Failure Therapy in Italy. American Journal Cardiovascular Drugs 9:6, 383-392
CrossRef177
Farouk Mookadam, Sherif E. Moustafa. (2009) Prevention of late postmyocardial infarction left ventricular remodeling: An update. Current Heart Failure Reports 6:4, 245-253
CrossRef178
Ken Yajima, Akira Shimada, Hiroshi Hirose, Yoichi Oikawa, Satoru Yamada, Shu Meguro, Junichiro Irie, Seiko Irie. (2009) Effect on the Atherogenic Marker Plasminogen Activator Inhibitor Type-1 of Addition of the ACE Inhibitor Imidapril to Angiotensin II Type 1 Receptor Antagonist Therapy in Hypertensive Patients with Abnormal Glucose Metabolism. Clinical Drug Investigation 29:12, 811-819
CrossRef179
Yves Lacourcière, Luc Poirier, Rita Samuel. (2009) Valsartan plus hydrochlorothiazide for first-line therapy in hypertension. Expert Review of Cardiovascular Therapy 7:12, 1491-1501
CrossRef180
Domenic A. Sica. (2009) Class-Effect With Antihypertensive Medications: Pharmacologic Considerations. The Journal of Clinical Hypertension 11, S13-S18
CrossRef181
Henry R. Black, Jacqueline Bailey, Dion Zappe, Rita Samuel. (2009) Valsartan. Drugs 69:17, 2393-2414
CrossRef182
K. K. Teo. (2009) Clinical evidence from ONTARGET: proven cardio- and vascular protection. European Heart Journal Supplements 11:Suppl F, F9-F15
CrossRef183
W B White, G Davidai, H Schumacher. (2009) Impact of angiotensin receptor blockade in combination with hydrochlorothiazide 25 mg in 2121 patients with stage 1–2 hypertension. Journal of Human Hypertension 23:12, 817-825
CrossRef184
S. W.M. van den Borne, V. A.M. van de Schans, A. E. Strzelecka, H. T.M. Vervoort-Peters, P. M. Lijnen, J. P.M. Cleutjens, J. F.M. Smits, M. J.A.P. Daemen, B. J.A. Janssen, W. M. Blankesteijn. (2009) Mouse strain determines the outcome of wound healing after myocardial infarction. Cardiovascular Research 84:2, 273-282
CrossRef185
F. Zannad, N. Agrinier, F. Alla. (2009) Heart failure burden and therapy. Europace 11:Supplement 5, v1-v9
CrossRef186
Benjamin J Epstein, Steven M Smith, Rushab Choksi. (2009) Recent changes in the landscape of combination RAS blockade. Expert Review of Cardiovascular Therapy 7:11, 1373-1384
CrossRef187
M. Klapholz, W. T. Abraham, J. K. Ghali, P. Ponikowski, S. D. Anker, B. Knusel, Y. Sun, S. M. Wasserman, D. J. van Veldhuisen. (2009) The safety and tolerability of darbepoetin alfa in patients with anaemia and symptomatic heart failure. European Journal of Heart Failure 11:11, 1071-1077
CrossRef188
Marvin A Konstam, James D Neaton, Kenneth Dickstein, Helmut Drexler, Michel Komajda, Felipe A Martinez, Gunter AJ Riegger, William Malbecq, Ronald D Smith, Soneil Guptha, Philip A Poole-Wilson. (2009) Effects of high-dose versus low-dose losartan on clinical outcomes in patients with heart failure (HEAAL study): a randomised, double-blind trial. The Lancet 374:9704, 1840-1848
CrossRef189
Giuseppe Mancia, Stéphane Laurent, Enrico Agabiti-Rosei, Ettore Ambrosioni, Michel Burnier, Mark J Caulfield, Renata Cifkova, Denis Clément, Antonio Coca, Anna Dominiczak, Serap Erdine, Robert Fagard, Csaba Farsang, Guido Grassi, Hermann Haller, Anthony Heagerty, Sverre E Kjeldsen, Wolfgang Kiowski, Jean Michel Mallion, Athanasios Manolis, Krzysztof Narkiewicz, Peter Nilsson, Michael H Olsen, Karl Heinz Rahn, Josep Redon, José Rodicio, Luis Ruilope, Roland E Schmieder, Harry AJ Struijker-Boudier, Pieter A van Zwieten, Margus Viigimaa, Alberto Zanchetti. (2009) Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. Journal of Hypertension 27:11, 2121-2158
CrossRef190
Elske Sieswerda, Elvira C van Dalen, Aleida Postma, Huib N Caron, Leontien CM Kremer, Elske Sieswerda. 2009. Medical interventions for treating anthracycline-induced symptomatic and asymptomatic cardiotoxicity during and after treatment for childhood cancer. .
CrossRef191
T. Sawada, H. Yamada, B. Dahlof, H. Matsubara, . (2009) Effects of valsartan on morbidity and mortality in uncontrolled hypertensive patients with high cardiovascular risks: KYOTO HEART Study. European Heart Journal 30:20, 2461-2469
CrossRef192
Kunal Chaudhary, Ravi Nistala, Adam Whaley-Connell. (2009) Dual renin-angiotensin system blockade in the ONTARGET study: Clinically relevant risk for the kidney?. Current Hypertension Reports 11:5, 375-381
CrossRef193
Sheldon W. Tobe, Monica O. Dai. (2009) Outcomes of antiproteinuric RAAS blockade: High-dose compared with dual therapy. Current Hypertension Reports 11:5, 345-353
CrossRef194
James E. Frampton, Lesley J. Scott. (2009) Amlodipine/Valsartan Single-Pill Combination. American Journal Cardiovascular Drugs 9:5, 309-330
CrossRef195
Jan Basile, Peter P. Toth. (2009) Angiotensin Receptor Blockers: Role in Hypertension Management, Cardiovascular Risk Reduction, and Nephropathy. Southern Medical Journal 102, S1-S12
CrossRef196
Brenda S. Thompson. (2009) Sudden Cardiac Death and Heart Failure. AACN Advanced Critical Care 20:4, 356-365
CrossRef197
Roberto Latini, Serge Masson. (2009) Biomarkers of Myocyte Injury in Heart Failure. Heart Failure Clinics 5:4, 529-536
CrossRef198
Andrew S. Bomback, Robert Toto. (2009) Dual Blockade of the Renin–Angiotensin–Aldosterone System: Beyond the ACE Inhibitor and Angiotensin-II Receptor Blocker Combination. American Journal of Hypertension 22:10, 1032-1040
CrossRef199
C Venkata S Ram. (2009) Direct inhibition of renin: a physiological approach to treat hypertension and cardiovascular disease. Future Cardiology 5:5, 453-465
CrossRef200
Rainer Düsing, Felicity Sellers. (2009) ACE inhibitors, angiotensin receptor blockers and direct renin inhibitors in combination: a review of their role after the ONTARGET trial. Current Medical Research and Opinion 25:9, 2287-2301
CrossRef201
Alan H. Gradman. (2009) Role of Angiotensin II Type 1 Receptor Antagonists in the Treatment of Hypertension in Patients Aged ≥65 Years. Drugs & Aging 26:9, 751-767
CrossRef202
Parminder S. Chaggar, Chris J. Malkin, Steven M. Shaw, Simon G. Williams, Kevin S. Channer. (2009) Neuroendocrine Effects on the Heart and Targets for Therapeutic Manipulation in Heart Failure. Cardiovascular Therapeutics 27:3, 187-193
CrossRef203
Stephan Dobner, Deon Bezuidenhout, Padmini Govender, Peter Zilla, Neil Davies. (2009) A Synthetic Non-degradable Polyethylene Glycol Hydrogel Retards Adverse Post-infarct Left Ventricular Remodeling. Journal of Cardiac Failure 15:7, 629-636
CrossRef204
Jan Basile. (2009) Lessons learned from the ONTARGET and TRANSCEND trials. Current Atherosclerosis Reports 11:5, 371-376
CrossRef205
Eileen M. Hsich, Ileana L. Piña. (2009) Heart Failure in Women. Journal of the American College of Cardiology 54:6, 491-498
CrossRef206
Rigas Kalaitzidis, George Bakris. (2009) Management of hypertension in patients with diabetes: the place of angiotensin-II receptor blockers. Diabetes, Obesity and Metabolism 11:8, 757-769
CrossRef207
Alan S. Maisel. (2009) Cardiovascular and Renal Surrogate Markers in the Clinical Management of Hypertension. Cardiovascular Drugs and Therapy 23:4, 317-326
CrossRef208
Robert M. Califf, Yuliya Lokhnygina, Eric J. Velazquez, John J.V. McMurray, Jeffrey D. Leimberger, Eldrin F. Lewis, Rafael Diaz, Jan Murin, Marc A. Pfeffer. (2009) Usefulness of Beta Blockers in High-Risk Patients After Myocardial Infarction in Conjunction With Captopril and/or Valsartan (from the VALsartan In Acute Myocardial Infarction [VALIANT] Trial). The American Journal of Cardiology 104:2, 151-157
CrossRef209
J. Susie Woo, Jeffrey L. Probstfield. (2009) The role of ACE inhibitors and angiotensin receptor blockers in the treatment of hypertension and cardiovascular disease. Current Cardiovascular Risk Reports 3:4, 255-263
CrossRef210
Peter Sleight. (2009) Clinical evidence from ONTARGET: the value of an angiotensin II receptor blocker and an angiotensin-converting enzyme inhibitor. Journal of Hypertension 27:Suppl 5, S23-S29
CrossRef211
Gregory Hess, Ronald Preblick, Jerrold Hill, Craig A. Plauschinat, Joseph Yaskin. (2009) Effects of Angiotensin-Converting Enzyme Inhibitor or Angiotensin Receptor Blocker Therapy After Hospital Discharge on Subsequent Rehospitalization for Acute Myocardial Infarction and Heart Failure. Congestive Heart Failure 15:4, 170-175
CrossRef212
Hisao Ogawa, Shokei Kim-Mitsuyama, Tomio Jinnouchi, Kunihiko Matsui, Kikuo Arakawa. (2009) Rationale, design and patient baseline characteristics of OlmeSartan and calcium antagonists randomized (OSCAR) study: a study comparing the incidence of cardiovascular events between high-dose angiotensin II receptor blocker (ARB) monotherapy and combination therapy of ARB with calcium channel blocker in Japanese elderly high-risk hypertensive patients (ClinicalTrials. gov no. NCT00134160). Hypertension Research 32:7, 575-580
CrossRef213
Rie Futai, Takahide Ito, Yasunori Kawanishi, Fumio Terasaki, Yasushi Kitaura. (2009) Olmesartan ameliorates myocardial function independent of blood pressure control in patients with mild-to-moderate hypertension. Heart and Vessels 24:4, 294-300
CrossRef214
John J.V. McMurray, Christopher B. Granger, Jan Östergren, Salim Yusuf, Marc A. Pfeffer, Karl Swedberg. (2009) Dual Renin-Angiotensin System Blockade in Heart Failure. Journal of the American College of Cardiology 54:3, 278
CrossRef215
Bertram Pitt. (2009) Multiple renin-angiotensin-aldosterone-blocking agents in heart failure: How much is too much?. Current Heart Failure Reports 6:2, 112-116
CrossRef216
Amir Ravandi, Koon K Teo. (2009) Blocking the renin–angiotensin system: dual- versus mono-therapy. Expert Review of Cardiovascular Therapy 7:6, 667-674
CrossRef217
H. R. Zandbergen, M. W. M. Schellings. (2009) Molecular imaging of ventricular remodeling. Journal of Nuclear Cardiology 16:3, 456-465
CrossRef218
M Mazerska, M Myśliwiec. (2009) Telmisartan lowers albuminuria in type 2 diabetic patients treated with angiotensin enzyme inhibitors. Advances in Medical Sciences 54:1, 37-40
CrossRef219
Veselin Mitrovic, Karl-Friedrich Appel, Nicolaos Proskynitopoulos, Seyfettin Dereli, Christian Wilhelm Hamm. (2009) Effects of candesartan cilexetil “add-on” treatment in congestive heart failure outpatients in daily practice. Clinical Research in Cardiology 98:6, 379-389
CrossRef220
Keita Inanaga, Toshihiro Ichiki, Hirohide Matsuura, Ryohei Miyazaki, Toru Hashimoto, Kotaro Takeda, Kenji Sunagawa. (2009) Resveratrol attenuates angiotensin II-induced interleukin-6 expression and perivascular fibrosis. Hypertension Research 32:6, 466-471
CrossRef221
Kaivan Khavandi, Ali Khavandi, Omar Asghar, Adam Greenstein, Sarah Withers, Anthony M. Heagerty, Rayaz A. Malik. (2009) Diabetic cardiomyopathy – a distinct disease?. Best Practice & Research Clinical Endocrinology & Metabolism 23:3, 347-360
CrossRef222
HoWon Lee, Amgad N. Makaryus, Samy I. McFarlane. (2009) ONTARGET: Use of ramipril, telmisartan, or both in patients with high cardiovascular risks. Current Diabetes Reports 9:3, 185-187
CrossRef223
Michael R. MacDonald, Mark C. Petrie, Miles Fisher, John J. V. McMurray. (2009) Pharmacologic management of patients with both heart failure and diabetes. Current Heart Failure Reports 6:2, 126-132
CrossRef224
Gerrit Hagenah, Dennis Beil. (2009) Prevalence of Cheyne–Stokes respiration in modern treated congestive heart failure. Sleep and Breathing 13:2, 181-185
CrossRef225
Nadia A. Khan, Brenda Hemmelgarn, Robert J. Herman, Chaim M. Bell, Jeff L. Mahon, Lawrence A. Leiter, Simon W. Rabkin, Michael D. Hill, Raj Padwal, Rhian M. Touyz, Pierre Larochelle, Ross D. Feldman, Ernesto L. Schiffrin, Norman R.C. Campbell, Gordon Moe, Ramesh Prasad, Malcolm O. Arnold, Tavis S. Campbell, Alain Milot, James A. Stone, Charlotte Jones, Richard I. Ogilvie, Pavel Hamet, George Fodor, George Carruthers, Kevin D. Burns, Marcel Ruzicka, Jacques deChamplain, George Pylypchuk, Robert Petrella, Jean-Martin Boulanger, Luc Trudeau, Robert A. Hegele, Vincent Woo, Phil McFarlane, Michel Vallée, Jonathan Howlett, Simon L. Bacon, Patrice Lindsay, Richard E. Gilbert, Richard Z. Lewanczuk, Sheldon Tobe. (2009) The 2009 Canadian Hypertension Education Program recommendations for the management of hypertension: Part 2 – therapy. Canadian Journal of Cardiology 25:5, 287-298
CrossRef226
Massimo Volpe, Giuliano Tocci, Sebastiano Sciarretta, Paolo Verdecchia, Bruno Trimarco, Giuseppe Mancia. (2009) Angiotensin II receptor blockers and myocardial infarction: an updated analysis of randomized clinical trials. Journal of Hypertension 27:5, 941-946
CrossRef227
Pedro Armario, Raquel Hernández Del Rey, Anna Oliveras. (2009) Papel actual de los antagonistas de los receptores de la angiotensina II y de sus combinaciones en el tratamiento de la hipertensión arterial. Medicina Clínica 132:20, 792-796
CrossRef228
Krishna K. Gaddam, Anil Verma, Mark Thompson, Rohit Amin, Hector Ventura. (2009) Hypertension and Cardiac Failure in its Various Forms. Medical Clinics of North America 93:3, 665-680
CrossRef229
Maha A. Mohamed, Matthew R. Weir. (2009) Renin Angiotensin System Inhibition in the Older Person: A Review. Clinics in Geriatric Medicine 25:2, 245-257
CrossRef230
R. M. Nixon, E. Müller, A. Lowy, H. Falvey. (2009) Valsartan vs. other angiotensin II receptor blockers in the treatment of hypertension: a meta-analytical approach. International Journal of Clinical Practice 63:5, 766-775
CrossRef231
R. H. G. Schwinger. (2009) Herzinsuffizienztherapie im Lichte von ONTARGET und TRANSCEND. Clinical Research in Cardiology Supplements 4:S2, 192-195
CrossRef232
Mariell Jessup, William T. Abraham, Donald E. Casey, Arthur M. Feldman, Gary S. Francis, Theodore G. Ganiats, Marvin A. Konstam, Donna M. Mancini, Peter S. Rahko, Marc A. Silver, Lynne Warner Stevenson, Clyde W. Yancy. (2009) 2009 Focused Update: ACCF/AHA Guidelines for the Diagnosis and Management of Heart Failure in Adults. Journal of the American College of Cardiology 53:15, 1343-1382
CrossRef233
Sharon Ann Hunt, William T. Abraham, Marshall H. Chin, Arthur M. Feldman, Gary S. Francis, Theodore G. Ganiats, Mariell Jessup, Marvin A. Konstam, Donna M. Mancini, Keith Michl, John A. Oates, Peter S. Rahko, Marc A. Silver, Lynne Warner Stevenson, Clyde W. Yancy. (2009) 2009 Focused Update Incorporated Into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults. Journal of the American College of Cardiology 53:15, e1-e90
CrossRef234
Jun Iwanami, Masaki Mogi, Masaru Iwai, Masatsugu Horiuchi. (2009) Inhibition of the renin–angiotensin system and target organ protection. Hypertension Research 32:4, 229-237
CrossRef235
Saraswathy Manickavasagam, Ramanna Merla, Michael M Koerner, Ken Fujise, Sanjay Kunapuli, Salvatore Rosanio, Alejandro Barbagelata. (2009) Management of hypertension in chronic heart failure. Expert Review of Cardiovascular Therapy 7:4, 423-433
CrossRef236
Donah Zachariah, Philip A. Kalra, Paul R. Kalra. (2009) OPTIMAL MANAGEMENT OF CHRONIC HEART FAILURE IN PATIENTS WITH CHRONIC KIDNEY DISEASE. Journal of Renal Care 35:1, 2-10
CrossRef237
M. Dalla Vestra, N. Simioni, A. Masiero. (2009) Renal effects of dual renin–angiotensin–aldosterone system blockade in patients with diabetic nephropathy. International Urology and Nephrology 41:1, 119-126
CrossRef238
Henry Krum, William T Abraham. (2009) Heart failure. The Lancet 373:9667, 941-955
CrossRef239
Betina T. Blak, C. Daniel Mullins, Fadia T. Shaya, Linda Simoni-Wastila, Catherine E. Cooke, Matthew R. Weir. (2009) Prescribing Trends and Drug Budget Impact of the ARBs in the UK. Value in Health 12:2, 302-308
CrossRef240
U.C. Hoppe, M. Böhm, H. Drexler, G. Hasenfuß, B. Lemke, A. Osterspey, M. Pauschinger. (2009) Kommentar zu den ESC-Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008. Der Kardiologe 3:1, 16-23
CrossRef241
B Dahlöf. (2009) Management of cardiovascular risk with RAS inhibitor/CCB combination therapy. Journal of Human Hypertension 23:2, 77-85
CrossRef242
Susanne W.M. van den Borne, Satoshi Isobe, H. Reinier Zandbergen, Peng Li, Artiom Petrov, Nathan D. Wong, Shinichiro Fujimoto, Ai Fujimoto, Dagfinn Lovhaug, Jos F.M. Smits, Mat J.A.P. Daemen, W. Matthijs Blankesteijn, Chris Reutelingsperger, Faiez Zannad, Navneet Narula, Mani A. Vannan, Bertram Pitt, Leonard Hofstra, Jagat Narula. (2009) Molecular Imaging for Efficacy of Pharmacologic Intervention in Myocardial Remodeling. JACC: Cardiovascular Imaging 2:2, 187-198
CrossRef243
M. Baumhakel, U. Muller, M. Bohm. (2009) Influence of gender of physicians and patients on guideline-recommended treatment of chronic heart failure in a cross-sectional study. European Journal of Heart Failure 11:3, 299-303
CrossRef244
Taiji Furukawa, Taketo Hatsuno, Yasunari Ueno, Kensuke Nagaoka, Yuji Watari, Takeshi Yamakawa, Toshio Sagawa, Takaaki Isshiki. (2009) Relationship Between Decrease in Ambulatory Blood Pressure and Heart Rate Variability Due to the Effects of Taking Olmesartan Medoxomil. Clinical Drug Investigation 29:4, 257-264
CrossRef245
Kathy Berra, Nancy Houston Miller. (2009) Inhibiting the renin-angiotensin system: Why and in which patients. Journal of the American Academy of Nurse Practitioners 21:1, 66-75
CrossRef246
L. Michael PrisantMD. (2009) Target-organ protection with combination renin-angiotensin-system blockade. Clinical Cardiology 32:1, 4-12
CrossRef247
F. Orso, S. Baldasseroni, G. Fabbri, L. Gonzini, D. Lucci, C. D'Ambrosi, M. Gobbi, G. Lecchi, S. Randazzo, G. Masotti, L. Tavazzi, A. P. Maggioni, . (2009) Role of beta-blockers in patients admitted for worsening heart failure in a real world setting: data from the Italian Survey on Acute Heart Failure. European Journal of Heart Failure 11:1, 77-84
CrossRef248
Philip R. Liebson, Ezra A. Amsterdam. (2009) Ongoing Telmisartan Alone and in Combination With Ramipril Global Endpoint Trial (ONTARGET): Implications for Reduced Cardiovascular Risk. Preventive Cardiology 12:1, 43-50
CrossRef249
Yasuko Okano, Kouichi Tamura, Shinitirou Masuda, Motoko Ozawa, Osamu Tochikubo, Satoshi Umemura. (2009) Effects of Angiotensin II Receptor Blockers on the Relationships Between Ambulatory Blood Pressure and Anti-Hypertensive Effects, Autonomic Function, and Health-Related Quality of Life. Clinical and Experimental Hypertension 31:8, 680-689
CrossRef250
AD Johnson, Y Gong, D Wang, TY Langaee, J Shin, RM Cooper-DeHoff, NJ Schork, P Binkley, CJ Pepine, JA Johnson, W Sadee. (2009) Promoter Polymorphisms in ACE (Angiotensin I–Converting Enzyme) Associated With Clinical Outcomes in Hypertension. Clinical Pharmacology & Therapeutics 85:1, 36-44
CrossRef251
Domenic A. Sica. 2009. Renin–Angiotensin Blockade: Therapeutic Agents. , 189-201.
CrossRef252
Massie, Barry M., Carson, Peter E., McMurray, John J., Komajda, Michel, McKelvie, Robert, Zile, Michael R., Anderson, Susan, Donovan, Mark, Iverson, Erik, Staiger, Christoph, Ptaszynska, Agata, . (2008) Irbesartan in Patients with Heart Failure and Preserved Ejection Fraction. New England Journal of Medicine 359:23, 2456-2467
Full Text253
(2008) Guía de práctica clínica de la Sociedad Europea de Cardiología (ESC) para el diagnóstico y tratamiento de la insuficiencia cardiaca aguda y crónica (2008). Revista Española de Cardiología 61:12, 1329.e1-1329.e70
CrossRef254
George V. Moukarbel, Scott D. Solomon. (2008) Treatment of asymptomatic left ventricular dysfunction. Current Treatment Options in Cardiovascular Medicine 10:6, 476-485
CrossRef255
Benjamin W Van Tassell, Przemyslaw Radwanski, Matthew Movsesian, Mark A Munger. (2008) Combination Therapy with β-Adrenergic Receptor Antagonists and Phosphodiesterase Inhibitors for Chronic Heart Failure. Pharmacotherapy 28:12, 1523-1530
CrossRef256
J. Paul Rocchiccioli, John J.V. McMurray. (2008) Medical management of advanced heart failure. Progress in Palliative Care 16:5, 229-240
CrossRef257
Bodh I. Jugdutt. (2008) Pleiotropic effects of cardiac drugs on healing post-MI. The good, bad, and ugly. Heart Failure Reviews 13:4, 439-452
CrossRef258
Susanne W.M. van den Borne, Satoshi Isobe, Johan W. Verjans, Artiom Petrov, Dagfinn Lovhaug, Peng Li, H. Reinier Zandbergen, Youping Ni, Peter Frederik, Jun Zhou, Bente Arbo, Astri Rogstad, Alan Cuthbertson, Salah Chettibi, Chris Reutelingsperger, W. Matthijs Blankesteijn, Jos F.M. Smits, Mat J.A.P. Daemen, Faiez Zannad, Mani A. Vannan, Navneet Narula, Bertram Pitt, Leonard Hofstra, Jagat Narula. (2008) Molecular Imaging of Interstitial Alterations in Remodeling Myocardium After Myocardial Infarction. Journal of the American College of Cardiology 52:24, 2017-2028
CrossRef259
Steven D. Crowley, Thomas M. Coffman. (2008) In hypertension, the kidney breaks your heart. Current Cardiology Reports 10:6, 470-476
CrossRef260
Paolo Verdecchia, Fabio Angeli, Giovanni Mazzotta, Chiara Dembech, Gianpaolo Reboldi. (2008) Single and dual blockade of the renin-angiotensin system in high-risk patients without heart failure: Lessons from ONTARGET. Current Cardiovascular Risk Reports 2:6, 417-419
CrossRef261
C. Venkata S. Ram, Prakash C. Deedwania. (2008) Angiotensin Receptor Blockers and Cardiovascular Protection: Are We ONTARGET?. The American Journal of Cardiology 102:9, 1281-1283
CrossRef262
C. Venkata S. Ram. (2008) ONTARGET study of telmisartan, ramipril, or both in high-risk patients. Current Hypertension Reports 10:5, 345-348
CrossRef263
, K. Dickstein, A. Cohen-Solal, G. Filippatos, J. J.V. McMurray, P. Ponikowski, P. A. Poole-Wilson, A. Stromberg, D. J. van Veldhuisen, D. Atar, A. W. Hoes, A. Keren, A. Mebazaa, M. Nieminen, S. G. Priori, K. Swedberg, , A. Vahanian, J. Camm, R. De Caterina, V. Dean, K. Dickstein, G. Filippatos, C. Funck-Brentano, I. Hellemans, S. D. Kristensen, K. McGregor, U. Sechtem, S. Silber, M. Tendera, P. Widimsky, J. L. Zamorano, , M. Tendera, A. Auricchio, J. Bax, M. Bohm, U. Corra, P. della Bella, P. M. Elliott, F. Follath, M. Gheorghiade, Y. Hasin, A. Hernborg, T. Jaarsma, M. Komajda, R. Kornowski, M. Piepoli, B. Prendergast, L. Tavazzi, J.-L. Vachiery, F. W. A. Verheugt, J. L. Zamorano, F. Zannad. (2008) ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). European Heart Journal 29:19, 2388-2442
CrossRef264
M. Angelyn Bethel, Rury Holman, Steven M. Haffner, Robert M. Califf, Alice Huntsman-Labed, Tsushung A. Hua, John McMurray. (2008) Determining the most appropriate components for a composite clinical trial outcome. American Heart Journal 156:4, 633-640
CrossRef265
Gordon Moe, Andrea Konig, Peter Liu, Bodh I. Jugdutt. (2008) Selective type 1 angiotensin II receptor blockade attenuates oxidative stress and regulates angiotensin II receptors in the canine failing heart. Molecular and Cellular Biochemistry 317:1-2, 97-104
CrossRef266
Dae-Hyeok Kim, Woong-Gil Choi, Jun Kwan, Keum-Soo Park, Woo-Hyung Lee. (2008) Effects of Early Losartan Therapy on Ventricular Late Potentials in Acute Myocardial Infarction. Annals of Noninvasive Electrocardiology 13:4, 371-377
CrossRef267
Hilde LE Smets, Johan FF De Haes, André De Swaef, Philippe G Jorens, Gert A Verpooten. (2008) Exposure of the elderly to potential nephrotoxic drug combinations in Belgium. Pharmacoepidemiology and Drug Safety 17:10, 1014-1019
CrossRef268
Toshio Ogihara, Akira Fujimoto, Kazuwa Nakao, Takao Saruta. (2008) ARB candesartan and CCB amlodipine in hypertensive patients: the CASE-J trial. Expert Review of Cardiovascular Therapy 6:9, 1195-1201
CrossRef269
Fei Yu, Rui Chen, Takashi Takahashi, Hiroyuki Sumino, Shigeto Morimoto, Takeshi Nakahashi, Kunimitsu Iwai, Masayuki Matsumoto, Tsugiyasu Kanda. (2008) Candesartan improves myocardial damage in obese mice with viral myocarditis and induces cardiac adiponectin. International Journal of Cardiology 129:3, 414-421
CrossRef270
Matthew R. Weir. (2008) Are we “ONTARGET” yet with regard to optimal antihypertensive regimens?. Current Hypertension Reports 10:5, 385-386
CrossRef271
Julian Segura, Luis M. Ruilope. (2008) Hyperkalemia Risk and Treatment of Heart Failure. Heart Failure Clinics 4:4, 455-464
CrossRef272
Robert M. Califf, Mitradev Boolell, Steven M. Haffner, M. Angelyn Bethel, John McMurray, Anil Duggal, Rury R. Holman. (2008) Prevention of diabetes and cardiovascular disease in patients with impaired glucose tolerance: Rationale and design of the Nateglinide And Valsartan in Impaired Glucose Tolerance Outcomes Research (NAVIGATOR) Trial. American Heart Journal 156:4, 623-632
CrossRef273
Ron Blankstein, George L. Bakris. (2008) Changes in Kidney Function Following Heart Failure Treatment: Focus on Renin-Angiotensin System Blockade. Heart Failure Clinics 4:4, 425-438
CrossRef274
Simon Maybaum, Gayathri Kamalakannan, Sandhya Murthy. (2008) Cardiac Recovery During Mechanical Assist Device Support. Seminars in Thoracic and Cardiovascular Surgery 20:3, 234-246
CrossRef275
Theresa A McDonagh. (2008) Challenges in advanced chronic heart failure: drug therapy. Future Cardiology 4:5, 517-525
CrossRef276
Alain Cohen-Solal, Florence Beauvais, Damien Logeart. (2008) Heart Failure and Diabetes Mellitus: Epidemiology and Management of an Alarming Association. Journal of Cardiac Failure 14:7, 615-625
CrossRef277
Serge Masson, Roberto Latini, Inder S. Anand, Simona Barlera, Laura Angelici, Tarcisio Vago, Gianni Tognoni, Jay N. Cohn. (2008) Prognostic Value of Changes in N-Terminal Pro-Brain Natriuretic Peptide in Val-HeFT (Valsartan Heart Failure Trial). Journal of the American College of Cardiology 52:12, 997-1003
CrossRef278
M. C. Shibata, R. T. Tsuyuki, N. Wiebe. (2008) The effects of angiotensin-receptor blockers on mortality and morbidity in heart failure: a systematic review. International Journal of Clinical Practice 62:9, 1397-1402
CrossRef279
Daniel Sacristán, María Marques, José J Zamorano-León, Manuel Luque, Juan Armengol, Juan del Castillo, Javier Martín, Eva Delpón, Priscila Ramos-Mozo, Teresa P de Prada, Juan Tamargo, Alberto Barrientos, Carlos Macaya, Antonio López-Farré. (2008) Modifications by Olmesartan medoxomil treatment of the platelet protein profile of moderate hypertensive patients. PROTEOMICS - CLINICAL APPLICATIONS 2:9, 1300-1312
CrossRef280
Jay N Cohn. (2008) Does the angiotensin receptor blocker telmisartan prevent morbid atherosclerotic events?. Nature Clinical Practice Cardiovascular Medicine 5:9, 526-527
CrossRef281
Helmy Siragy, Jiqian Huang, David C Lieb. (2008) The development of the direct renin inhibitor aliskiren: treating hypertension and beyond. Expert Opinion on Emerging Drugs 13:3, 417-430
CrossRef282
Norman K Hollenberg. (2008) Influencing the natural history of hypertension: is it the blood pressure achieved, the drug, or the drug dose?. Journal of Hypertension 26:8, 1527-1532
CrossRef283
W B White, J M Cleveland, R L Rolleri. (2008) Utility of semiautomatic clinic and 24-h ambulatory blood pressure measurements to evaluate combination therapy: the Ramipril–Hydrochlorothiazide Hypertension Trial. Journal of Human Hypertension 22:8, 559-568
CrossRef284
Helmy M. Siragy. (2008) Evidence for benefits of angiotensin receptor blockade beyond blood pressure control. Current Hypertension Reports 10:4, 261-267
CrossRef285
Marc A. Simon, John Watson, J. Timothy Baldwin, William R. Wagner, Harvey S. Borovetz. (2008) Current and Future Considerations in the Use of Mechanical Circulatory Support Devices*. Annual Review of Biomedical Engineering 10:1, 59-84
CrossRef286
CHERYL R. KILLINGSWORTH, MARIAN K. RIPPY, RENU VIRMANI, DENNIS L. ROLLINS, DAVID C. McGIFFIN, RAYMOND E. IDEKER. (2008) Evaluation of a Novel Ventricular Support Device with Defibrillation Capabilities in Canine and Porcine Animal Models. Journal of Cardiovascular Electrophysiology 19:8, 851-857
CrossRef287
Brian K. Dockery, John D. Bisognano. (2008) Direct renin inhibition: An analysis of possible benefits. Current Hypertension Reports 10:4, 313-318
CrossRef288
K-H. Ladwig, F. Lederbogen, H. Völler, C. Albus, C. Herrmann-Lingen, J. Jordan, V. Köllner, J. Jünger, H. Lange, K. Fritzsche. (2008) Positionspapier zur Bedeutung von psychosozialen Faktoren in der Kardiologie. Der Kardiologe 2:4, 274-287
CrossRef289
C. Venkata S. Ram. (2008) Angiotensin Receptor Blockers: Current Status and Future Prospects. The American Journal of Medicine 121:8, 656-663
CrossRef290
Michael Kindermann, M. Bohm. (2008) Aktuelle konservative Therapie der chronischen Herzinsuffizienz. Zeitschrift für Herz-,Thorax- und Gefäßchirurgie 22:4, 184-196
CrossRef291
S. Henz, M. T. Maeder, S. Huber, M. Schmid, M. Loher, T. Fehr. (2008) Influence of drugs and comorbidity on serum potassium in 15 000 consecutive hospital admissions. Nephrology Dialysis Transplantation 23:12, 3939-3945
CrossRef292
Chiyo Ootaki, Michifumi Yamashita, Yoshio Ootaki, Keiji Kamohara, Stephan Weber, Ryan S. Klatte, William A. Smith, Alex L. Massiello, Steven N. Emancipator, Leonard A.R. Golding, Kiyotaka Fukamachi. (2008) Reduced Pulsatility Induces Periarteritis in Kidney: Role of the Local Renin–Angiotensin System. The Journal of Thoracic and Cardiovascular Surgery 136:1, 150-158
CrossRef293
Nicholas B Norgard, Jennifer E Stark. (2008) Pharmacotherapy for Heart Failure with Left Ventricular Dysfunction: Beyond Angiotensin-Converting Enzyme Inhibitors and β-Blockers. Pharmacotherapy 28:7, 920-931
CrossRef294
Katarzyna Kolasinska-Malkowska, Krzysztof J Filipiak, Adrian Gwizdala, Andrzej Tykarski. (2008) Current possibilities of ACE inhibitor and ARB combination in arterial hypertension and its complications. Expert Review of Cardiovascular Therapy 6:5, 759-771
CrossRef295
William J. Bommer. (2008) Use of Angiotensin-Converting Enzyme Inhibitor/Angiotensin II Receptor Blocker Therapy to Reduce Cardiovascular Events in High-Risk Patients: Part 1. Preventive Cardiology 11:3, 148-154
CrossRef296
F. Rodríguez Artalejo, P. Guallar-Castillón, C. Montoto Otero, M. Conde Herrera, C. Carreño Ochoa, A.I. Tabuenca Martín, M. Olcoz Chiva, P. Conthe, J.R. Banegas, C. Rodríguez Pascual. (2008) El autocuidado y el conocimiento del manejo de la enfermedad predicen la rehospitalización en ancianos con insuficiencia cardíaca. Revista Clínica Española 208:6, 269-275
CrossRef297
Alice Stanton. (2008) Now that we have a direct renin inhibitor, what should we do with it?. Current Hypertension Reports 10:3, 194-200
CrossRef298
Noritaka Yasuda, Hiroshi Akazawa, Yingjie Qin, Yunzeng Zou, Issei Komuro. (2008) A novel mechanism of mechanical stress-induced angiotensin II type 1–receptor activation without the involvement of angiotensin II. Naunyn-Schmiedeberg's Archives of Pharmacology 377:4-6, 393-399
CrossRef299
William B. White, David A. Calhoun, Rita Samuel, Addison A. Taylor, Dion H. Zappe, Das Purkayastha. (2008) Improving Blood Pressure Control: Increase the Dose of Diuretic or Switch to a Fixed-Dose Angiotensin Receptor Blocker/Diuretic? The Valsartan Hydrochlorothiazide Diuretic for Initial Control and Titration to Achieve Optimal Therapeutic Effect (Val-DICTAT. The Journal of Clinical Hypertension 10:6, 450-458
CrossRef300
Alejandro de la Sierra, Manuel Gorostidi, Rafael Marín, Josep Redón, José R. Banegas, Pedro Armario, Juan García Puig, Julio Zarco, José L. Llisterri, Carlos Sanchís, Benjamín Abarca, Vicente Palomo, Ramón Gomis, Alfonso Otero, Fernando Villar, Jesús Honorato, Juan Tamargo, José M. Lobos, Juan Macías-Núñez, Antonio Sarría, Pedro Aranda, Luis M. Ruilope. (2008) Evaluación y tratamiento de la hipertensión arterial en España. Documento de consenso. Medicina Clínica 131:3, 104-116
CrossRef301
Patricia A. Howard. (2008) Cardiovascular Therapeutics - Is Combined Angiotensin Converting Enzyme Inhibitor and Angiotensin Receptor Blocker Therapy Safe in Heart Failure Patients?. Hospital Pharmacy 43:5, 362-365
CrossRef302
Johan W.H. Verjans, Dagfinn Lovhaug, Navneet Narula, Artiom D. Petrov, Bård Indrevoll, Emma Bjurgert, Tatiana B. Krasieva, Lizette B. Petersen, Grete M. Kindberg, Magne Solbakken, Alan Cuthbertson, Mani A. Vannan, Chris P.M. Reutelingsperger, Bruce J. Tromberg, Leonard Hofstra, Jagat Narula. (2008) Noninvasive Imaging of Angiotensin Receptors After Myocardial Infarction. JACC: Cardiovascular Imaging 1:3, 354-362
CrossRef303
Aysha Arshad, Anisha Mandava, Ganesh Kamath, Dan Musat. (2008) Sudden Cardiac Death and the Role of Medical Therapy. Progress in Cardiovascular Diseases 50:6, 420-438
CrossRef304
Daiju Fukuda, Masataka Sata. (2008) Role of bone marrow renin–angiotensin system in the pathogenesis of atherosclerosis. Pharmacology & Therapeutics 118:2, 268-276
CrossRef305
McMurray, John J.V., . (2008) ACE Inhibitors in Cardiovascular Disease — Unbeatable?. New England Journal of Medicine 358:15, 1615-1616
Full Text306
The ONTARGET Investigators. (2008) Telmisartan, Ramipril, or Both in Patients at High Risk for Vascular Events. New England Journal of Medicine 358:15, 1547-1559
Full Text307
Rachid Lakhdar, Mouaz H. Al-Mallah, David E. Lanfear. (2008) Safety and Tolerability of Angiotensin-Converting Enzyme Inhibitor Versus the Combination of Angiotensin-Converting Enzyme Inhibitor and Angiotensin Receptor Blocker in Patients With Left Ventricular Dysfunction: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Journal of Cardiac Failure 14:3, 181-188
CrossRef308
Claudio Ferri, Giuseppe Croce, Giovambattista Desideri. (2008) Role of combination therapy in the treatment of hypertension: Focus on valsartan plus amlodipine. Advances in Therapy 25:4, 300-320
CrossRef309
Thomas Dieterle, Matthias Pfisterer, Hanspeter Brunner-La Rocca. (2008) Heart failure in the elderly. Aging Health 4:2, 137-155
CrossRef310
Moiz M. Shafiq, Dileep V. Menon, Ronald G. Victor. (2008) Oral Direct Renin Inhibition: Premise, Promise, and Potential Limitations of a New Antihypertensive Drug. The American Journal of Medicine 121:4, 265-271
CrossRef311
Jalal K Ghali, JoAnn Lindenfeld. (2008) Sex differences in response to chronic heart failure therapies. Expert Review of Cardiovascular Therapy 6:4, 555-565
CrossRef312
Leo Chi-Chiu Kum, Gabriel Wai-Kwok Yip, Pui-Wai Lee, Yat-Yin Lam, Eugene B. Wu, Anna Kin-Yin Chan, Jeffrey Wing-Hong Fung, Joseph Yat-Sun Chan, Qing Zhang, Shun-Ling Kong, Cheuk-Man Yu. (2008) Comparison of angiotensin-converting enzyme inhibitor alone and in combination with irbesartan for the treatment of heart failure. International Journal of Cardiology 125:1, 16-21
CrossRef313
Jay N. Cohn, Jesse M. Goldman. (2008) Establishing A New Option for Target-organ Protection: Rationale for ARB Plus ACE Inhibitor Combination Therapy. American Journal of Hypertension 21:3, 248-256
CrossRef314
Margaret S. Pepe, Yingye Zheng, Yuying Jin, Ying Huang, Chirag R. Parikh, Wayne C. Levy. (2008) Evaluating the ROC performance of markers for future events. Lifetime Data Analysis 14:1, 86-113
CrossRef315
José Luis Llisterri Caro, Vivencio Barrios Alonso. (2008) Papel de las nuevas combinaciones a dosis fijas en el tratamiento de la hipertensión arterial. Medicina Clínica 130:9, 342-344
CrossRef316
Robert C. Bourge, William T. Abraham, Philip B. Adamson, Mark F. Aaron, Juan M. Aranda, Anthony Magalski, Michael R. Zile, Andrew L. Smith, Frank W. Smart, Mark A. O’Shaughnessy, Mariell L. Jessup, Brandon Sparks, David L. Naftel, Lynne Warner Stevenson. (2008) Randomized Controlled Trial of an Implantable Continuous Hemodynamic Monitor in Patients With Advanced Heart Failure. Journal of the American College of Cardiology 51:11, 1073-1079
CrossRef317
Maurizio Gasparini, François Regoli, Carlo Ceriotti, Paola Galimberti, Renato Bragato, Stefano De Vita, Daniela Pini, Bruno Andreuzzi, Maurizio Mangiavacchi, Catherine Klersy. (2008) Remission of left ventricular systolic dysfunction and of heart failure symptoms after cardiac resynchronization therapy: Temporal pattern and clinical predictors. American Heart Journal 155:3, 507-514
CrossRef318
John R. Kapoor. (2008) Effect of Combination Angiotensin-Converting Enzyme and Angiotensin Receptor Blocker Therapy on Heart Failure Mortality and Morbidity. The American Journal of Cardiology 101:5, 744-745
CrossRef319
William B. White, Debra Murwin, Steven G. Chrysant, Stephen E. Koval, Giora Davidai, Robert Guthrie. (2008) Effects of the angiotensin II receptor blockers telmisartan versus valsartan in combination with hydrochlorothiazide: a large, confirmatory trial. Blood Pressure Monitoring 13:1, 21-27
CrossRef320
John A. McClung, Michele Nanna, Wilbert S. Aronow. 2008. Cardiomyopathies in the Elderly. , 493-516.
CrossRef321
Ken Kiyono, Junichiro Hayano, Eiichi Watanabe, Zbigniew R. Struzik, Yoshiharu Yamamoto. (2008) Non-Gaussian heart rate as an independent predictor of mortality in patients with chronic heart failure. Heart Rhythm 5:2, 261-268
CrossRef322
Dalane W. Kitzman, Jerome L. Fleg. 2008. Heart Failure. , 542-576.
CrossRef323
Alan H. Gradman, Rishi Kad. (2008) Renin Inhibition in Hypertension. Journal of the American College of Cardiology 51:5, 519-528
CrossRef324
Christine K Choy, Jo E Rodgers, Jean M Nappi, Stuart T Haines. (2008) Type 2 Diabetes Mellitus and Heart Failure. Pharmacotherapy 28:2, 170-192
CrossRef325
ANNE S. KANDERIAN, AJAY BHARGAVA, GARY S. FRANCIS. 2008. General Treatment of Diastolic Heart Failure. , 415-427.
CrossRef326
Enrique Galve. (2008) Fármacos antialdosterónicos: su papel en la insuficiencia cardíaca. Medicina Clínica 130:1, 30-34
CrossRef327
Ki Hong Lee, Myung Ho Jeong, Young Keun Ahn, Woo Seok Lee, Dae Ho Jung, Jeong Gwan Cho, Jong Chun Park, Jung Chaee Kang, Seok Kyu Oh, Nam Ho Kim, Kyung Ho Yun, Nam Jin Yoo, Yong Moon, Jay Young Rhew, Ji Hyun Lim, Seong Hee Jeon, Ok Young Park, Seung Uk Lee, Dong Goo Kang. (2008) The Comparative Clinical Effects of Valsartan and Ramipril in Patients With Heart Failure. Korean Circulation Journal 38:2, 101
CrossRef328
C. Loirat. (2008) Tratamiento de la hipertensi??n arterial en el ni??o. EMC - Pediatr??a 43:4, 1-11
CrossRef329
Lawrence Liao, Larry A Allen, David J Whellan. (2008) Economic Burden of Heart Failure in??the Elderly. PharmacoEconomics 26:6, 447-462
CrossRef330
Matthew R. Weir. (2008) Risk-Based Classification of Hypertension and the Role of Combination Therapy. The Journal of Clinical Hypertension 10:s1, 4-12
CrossRef331
Greg L Plosker, Dean M Robinson. (2008) Amlodipine/Valsartan. Drugs 68:3, 373-381
CrossRef332
Darcy A. Lamb, David F. Blackburn, Anne M. PausJenssen, William M. Semchuk, Patrick Robertson. (2008) Heart failure: Back to basics for pharmacists. Canadian Pharmacists Journal 141:1, 48-57
CrossRef333
Hui-Ping Gong, Wei Zhang, Li Li, Hong-Wei Tan, Zhi-Yong Ma, Xue-Zhen Zhong, Zhi-Hao Wang, Tao Song, Yun Zhang, Ming Zhong. (2008) Possible Beneficial Effect of??Olmesartan Medoxomil on??Left??Atrial??Function in Patients??with Hypertension. Clinical Drug Investigation 28:4, 241-249
CrossRef334
David H G Smith. (2008) Comparison of Angiotensin II Type 1 Receptor Antagonists in the Treatment of Essential Hypertension. Drugs 68:9, 1207-1225
CrossRef335
Chiung-Zuan Chiu, Jun-Jack Cheng. (2007) Congestive Heart Failure in the Elderly. International Journal of Gerontology 1:4, 143-152
CrossRef336
Hoang Thai, David Guarraia, Nicholle Johnson, Steven Goldman, Mohamed A Gaballa. (2007) Valsartan Therapy in Heart Failure After Myocardial Infarction: The Role of Endothelial Dependent Vasorelaxation. Journal of Cardiovascular Pharmacology 50:6, 703-707
CrossRef337
J. M. Flack. (2007) Maximising antihypertensive effects of angiotensin II receptor blockers with thiazide diuretic combination therapy: focus on irbesartan/hydrochlorothiazide. International Journal of Clinical Practice 61:12, 2093-2102
CrossRef338
Lidia Staszewsky, Maylene Wong, Serge Masson, Simona Barlera, Elisa Carretta, Aldo P. Maggioni, Inder S. Anand, Jay N. Cohn, Gianni Tognoni, Roberto Latini. (2007) Clinical, Neurohormonal, and Inflammatory Markers and Overall Prognostic Role of Chronic Obstructive Pulmonary Disease in Patients With Heart Failure: Data From the Val-HeFT Heart Failure Trial. Journal of Cardiac Failure 13:10, 797-804
CrossRef339
Ankur A. Karnik, Anjali V. Fields, Richard P. Shannon. (2007) Diabetic cardiomyopathy. Current Hypertension Reports 9:6, 467-473
CrossRef340
Alipio Mangas Rojas, Francisco Gómez Rodríguez. (2007) Tratamiento multifactorial de la arteriosclerosis. Medicina Clínica 129:20, 785-796
CrossRef341
Maryse Palardy, Anique Ducharme, Eileen O’Meara. (2007) Inhibiting the renin-angiotensin system with ACE inhibitors or ARBs after MI. Current Heart Failure Reports 4:4, 190-197
CrossRef342
Masoor Kamalesh. (2007) Heart Failure in Diabetes and Related Conditions. Journal of Cardiac Failure 13:10, 861-873
CrossRef343
Murat Özdemir, Uğur Arslan, Sedat Türkoğlu, Serhat Balcioğlu, Atiye Çengel. (2007) Losartan Improves Heart Rate Variability and Heart Rate Turbulence in Heart Failure Due to Ischemic Cardiomyopathy. Journal of Cardiac Failure 13:10, 812-817
CrossRef344
Mathias B. Forrester. (2007) Valsartan ingestions among adults reported to Texas poison control centers, 2000 to 2005. Journal of Medical Toxicology 3:4, 157-163
CrossRef345
N Glorioso, G Argiolas, F Filigheddu, C Troffa, F Cocco, E Bulla, P Bulla, R Zaninello, S Degortes, S Pitzoi, F Frau, S Fadda, P Pinna Parpaglia, G Bernini, M Bardini, F Fallo, L Malatino, G Regolisti, C Ferri, D Cusi, A Sciacqua, F Perticone, E Degli Esposti, C Baraccani, G Parati, F Veglio, P Mulatero, T A Williams, F Macciardi, B Stancanelli. (2007) Conceptual basis and methodology of the SOPHIA study. Pharmacogenomics 8:11, 1497-1509
CrossRef346
G. Mathur, J. G. F. Cleland, E. Rodrigues, G. K. Davis. (2007) Role of angiotensin receptor blockers in the prevention and management of ischaemic stroke. European Journal of Neurology 14:11, 1201-1209
CrossRef347
Jay N. Cohn. (2007) Reducing cardiovascular risk by blockade of the renin-angiotensin-aldosterone system. Advances in Therapy 24:6, 1290-1304
CrossRef348
Wilbert S. Aronow. (2007) Treatment of Heart Failure with Abnormal Left Ventricular Systolic Function in the Elderly. Heart Failure Clinics 3:4, 423-436
CrossRef349
Wilbert S. Aronow. (2007) Heart Failure–Complicating Acute Myocardial Infarction. Heart Failure Clinics 3:4, 465-475
CrossRef350
M R Weir. (2007) Targeting mechanisms of hypertensive vascular disease with dual calcium channel and renin–angiotensin system blockade. Journal of Human Hypertension 21:10, 770-779
CrossRef351
G. Mathur, B. Noronha, E. Rodrigues, G. Davis. (2007) The role of angiotensin II type 1 receptor blockers in the prevention and management of diabetes mellitus. Diabetes, Obesity and Metabolism 9:5, 617-629
CrossRef352
Michel Azizi, Grégoire Wuerzner. (2007) Rationale for Combining Blockers of the Renin-Angiotensin System. Seminars in Nephrology 27:5, 544-554
CrossRef353
S G Chrysant, B Dimas, M Shiraz. (2007) Treatment of hypertension with olmesartan medoxomil, alone and in combination with a diuretic: an update. Journal of Human Hypertension 21:9, 699-708
CrossRef354
U.C. Hoppe. (2007) Leitliniengerechte Therapie der chronischen Herzinsuffizienz. Der Internist 48:9, 929-937
CrossRef355
Yoshiharu Horie, Jitsuo Higaki, Masahiro Takeuchi. (2007) Design, statistical analysis and sample size calculation of dose response study of telmisartan and hydrochlorothiazide. Contemporary Clinical Trials 28:5, 647-653
CrossRef356
Michael A. Weber. (2007) Secondary analysis of the VALUE trial: Intriguing new questions. Current Hypertension Reports 9:4, 261-263
CrossRef357
Carlos Caramelo, Soledad Justo, Paloma Gil. (2007) Anemia en la insuficiencia cardiaca: fisiopatología, patogenia, tratamiento e incógnitas. Revista Española de Cardiología 60:8, 848-860
CrossRef358
Barry H. Greenberg, William T. Abraham, Nancy M. Albert, Karen Chiswell, Robert Clare, Wendy Gattis Stough, Mihai Gheorghiade, Christopher M. O'Connor, Jie Lena Sun, Clyde W. Yancy, James B. Young, Gregg C. Fonarow. (2007) Influence of diabetes on characteristics and outcomes in patients hospitalized with heart failure: A report from the Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF). American Heart Journal 154:2, 277.e1-277.e8
CrossRef359
Eiichi Watanabe, Tomoharu Arakawa, Tatsushi Uchiyama, MaoQing Tong, Kenji Yasui, Hiroshi Takeuchi, Toshiaki Terasawa, Itsuo Kodama, Hitoshi Hishida. (2007) Prognostic significance of circadian variability of RR and QT intervals and QT dynamicity in patients with chronic heart failure. Heart Rhythm 4:8, 999-1005
CrossRef360
J. Thomas Heywood, Gregg C. Fonarow, Maria Rosa Costanzo, Vandana S. Mathur, John R. Wigneswaran, Janet Wynne. (2007) High Prevalence of Renal Dysfunction and Its Impact on Outcome in 118,465 Patients Hospitalized With Acute Decompensated Heart Failure: A Report From the ADHERE Database. Journal of Cardiac Failure 13:6, 422-430
CrossRef361
G.K. Aulakh, R.K. Sodhi, M. Singh. (2007) An update on non-peptide angiotensin receptor antagonists and related RAAS modulators. Life Sciences 81:8, 615-639
CrossRef362
Suzanne Oparil, Steven A Yarows, Samir Patel, Hui Fang, Jack Zhang, Andrew Satlin. (2007) Efficacy and safety of combined use of aliskiren and valsartan in patients with hypertension: a randomised, double-blind trial. The Lancet 370:9583, 221-229
CrossRef363
Martin Cadeiras, Manuel Prinz von Bayern, Mario C. Deng. (2007) Cardiac Transplantation: Any Role Left?. Heart Failure Clinics 3:3, 321-347
CrossRef364
Srinivasa R Kalidindi, WH Wilson Tang, Gary S Francis. (2007) Drug Insight: aldosterone-receptor antagonists in heart failure—the journey continues. Nature Clinical Practice Cardiovascular Medicine 4:7, 368-378
CrossRef365
Giuliano Tocci, Sebastiano Sciarretta, Caterina Facciolo, Massimo Volpe. (2007) Antihypertensive strategy based on angiotensin II receptor blockers: a new gateway to reduce risk in hypertension. Expert Review of Cardiovascular Therapy 5:4, 767-776
CrossRef366
Srinivas Iyengar, William T. Abraham. (2007) Diuretics for the treatment of acute decompensated heart failure. Heart Failure Reviews 12:2, 125-130
CrossRef367
Frieder Braunschweig. (2007) Therapeutic and diagnostic role of electrical devices in acute heart failure. Heart Failure Reviews 12:2, 157-166
CrossRef368
Jennifer Cowger Matthews, Todd F. Dardas, Keith D. Aaronson. (2007) Heart transplantation: Assessment of heart failure mortality risk. Current Heart Failure Reports 4:2, 103-109
CrossRef369
Jay N. Cohn, S. William Tam, Inder S. Anand, Anne L. Taylor, Michael L. Sabolinski, Manuel Worcel. (2007) Isosorbide Dinitrate and Hydralazine in a Fixed-Dose Combination Produces Further Regression of Left Ventricular Remodeling in a Well-Treated Black Population With Heart Failure: Results From A-HeFT. Journal of Cardiac Failure 13:5, 331-339
CrossRef370
Henry Krum, Roberto Latini, Aldo P. Maggioni, Inder Anand, Serge Masson, Elisa Carretta, Franco Ingrillì, Giacinto Pettinati, Robert Glazer, Gianni Tognoni, Jay Cohn. (2007) Statins and symptomatic chronic systolic heart failure: A post-hoc analysis of 5010 patients enrolled in Val-HeFT. International Journal of Cardiology 119:1, 48-53
CrossRef371
Scott D Solomon, Rajesh Janardhanan, Anil Verma, Mikhail Bourgoun, William L Daley, Das Purkayastha, Yves Lacourcière, Stephen E Hippler, Harold Fields, Tasneem Z Naqvi, Sharon L Mulvagh, J Malcolm O Arnold, James D Thomas, Michael R Zile, Gerard P Aurigemma. (2007) Effect of angiotensin receptor blockade and antihypertensive drugs on diastolic function in patients with hypertension and diastolic dysfunction: a randomised trial. The Lancet 369:9579, 2079-2087
CrossRef372
Seiichiro Saegusa, Yu Fei, Takashi Takahashi, Hiroyuki Sumino, Junji Moriya, Ken Kawaura, Jun-ichi Yamakawa, Tohoru Itoh, Shigeto Morimoto, Takeshi Nakahashi, Kunimitsu Iwai, Masayuki Matsumoto, Tsugiyasu Kanda. (2007) Oral Administration of Candesartan Improves the Survival of Mice with Viral Myocarditis through Modification of Cardiac Adiponectin Expression. Cardiovascular Drugs and Therapy 21:3, 155-160
CrossRef373
Roland E. Schmieder, Joachim Schrader, Walter Zidek, Ulrich Tebbe, W. Dieter Paar, Peter Bramlage, D. Pittrow, Michael Böhm. (2007) Low-grade albuminuria and cardiovascular risk. Clinical Research in Cardiology 96:5, 247-257
CrossRef374
Kamran Akram, Brian L. Pearlman. (2007) Congestive heart failure-related anemia and a role for erythropoietin. International Journal of Cardiology 117:3, 296-305
CrossRef375
Steven D. Crowley, Thomas M. Coffman. (2007) In hypertension, the kidney rules. Current Hypertension Reports 9:2, 148-153
CrossRef376
Kouichi Tamura, Yutaka Tanaka, Yuko Tsurumi, Koichi Azuma, Atsu-Ichiro Shigenaga, Hiromichi Wakui, Shin-Ichiro Masuda, Miyuki Matsuda. (2007) The role of angiotensin AT1 receptor-associated protein in renin-angiotensin system regulation and function. Current Hypertension Reports 9:2, 121-127
CrossRef377
Giuseppe Boriani, Cinzia Valzania, Igor Diemberger, Mauro Biffi, Cristian Martignani, Matteo Bertini, Matteo Ziacchi, Giulia Domenichini, Davide Saporito, Claudio Rapezzi, Angelo Branzi. (2007) Potential of non-antiarrhythmic drugs to provide an innovative upstream approach to the pharmacological prevention of sudden cardiac death. Expert Opinion on Investigational Drugs 16:5, 605-623
CrossRef378
(2007) Blood pressure-dependent and independent effects of agents that inhibit the renin–angiotensin system. Journal of Hypertension 25:5, 951-958
CrossRef379
Heath E. Saltzman, Kumar Sharma, Paul J. Mather, Sharon Rubin, Suzanne Adams, David Joshua Whellan. (2007) Renal dysfunction in heart failure patients: what is the evidence?. Heart Failure Reviews 12:1, 37-47
CrossRef380
Nabil Uddin, J. Herbert Patterson. (2007) Current Guidelines for Treatment of Heart Failure: 2006 Update. Pharmacotherapy 27:4 Part 2, 12S-17S
CrossRef381
Mark E Dunlap. (2007) New Studies Influencing Treatment of Heart Failure: 2006 Update. Pharmacotherapy 27:4 Part 2, 3S-11S
CrossRef382
David T. Nash. (2007) Rationale for Combination Therapy in Hypertension Management: Focus on Angiotensin Receptor Blockers and Thiazide Diuretics. Southern Medical Journal 100:4, 386-392
CrossRef383
Iwan C. C. Horst, Adriaan A. Voors, Dirk J. Veldhuisen. (2007) Treatment of heart failure with ACE inhibitors and beta-blockers. Clinical Research in Cardiology 96:4, 193-195
CrossRef384
Uta C. Hoppe. (2007) Treatment of heart failure with ACE inhibitors and beta-blockers. Clinical Research in Cardiology 96:4, 196-198
CrossRef385
Marie Hudson, Karin Humphries, Jack V Tu, Hassan Behlouli, Richard Sheppard, Louise Pilote. (2007) Angiotensin II Receptor Blockers for the Treatment of Heart Failure: A Class Effect?. Pharmacotherapy 27:4, 526-534
CrossRef386
Natasha C. Salazar, Juhsien Chen, Howard A. Rockman. (2007) Cardiac GPCRs: GPCR signaling in healthy and failing hearts. Biochimica et Biophysica Acta (BBA) - Biomembranes 1768:4, 1006-1018
CrossRef387
Neubauer, Stefan, . (2007) The Failing Heart — An Engine Out of Fuel. New England Journal of Medicine 356:11, 1140-1151
Full Text388
Zhenqi Liu. (2007) The renin-angiotensin system and insulin resistance. Current Diabetes Reports 7:1, 34-42
CrossRef389
Atsuhiro Ichihara, Yuki Kaneshiro, Mariyo Sakoda, Tomoko Takemitsu, Hiroshi Itoh. (2007) Add-on Amlodipine Improves Arterial Function and Structure in Hypertensive Patients Treated With an Angiotensin Receptor Blocker. Journal of Cardiovascular Pharmacology 49:3, 161-166
CrossRef390
Jacques de Champlain, Maria Karas, Linda Assouline, Reginald Nadeau, A. Robert LeBlanc, Bruno Dubé, Pierre Larochelle. (2007) Effects of Valsartan or Amlodipine Alone or in Combination on Plasma Catecholamine Levels at Rest and During Standing in Hypertensive Patients. The Journal of Clinical Hypertension 9:3, 168-178
CrossRef391
Jacoba P Greving, Petra Denig, Dick de Zeeuw, Flora M Haaijer-Ruskamp. (2007) Claims in advertisements for antihypertensive drugs in a Dutch medical journal. Journal of Hypertension 25:3, 713-722
CrossRef392
Yohannes Gebreegziabher, Amgad N Makaryus, John N Makaryus, Samy I McFarlane. (2007) Heart failure: metabolic derangements and therapeutic rationale. Expert Review of Cardiovascular Therapy 5:2, 331-343
CrossRef393
Michel White, Serge Lepage, Joel Lavoie, Simon De Denus, Marie-Hélène Leblanc, Denis Gossard, Lucette Whittom, Normand Racine, Anique Ducharme, Farida Dabouz, Jean-Lucien Rouleau, Rhian Touyz. (2007) Effects of Combined Candesartan and ACE Inhibitors on BNP, Markers of Inflammation and Oxidative Stress, and Glucose Regulation in Patients With Symptomatic Heart Failure. Journal of Cardiac Failure 13:2, 86-94
CrossRef394
Mayu Nishio, Yasushi Sakata, Toshiaki Mano, Junichi Yoshida, Tomohito Ohtani, Yasuharu Takeda, Takeshi Miwa, Tohru Masuyama, Kazuhiro Yamamoto, Masatsugu Hori. (2007) Therapeutic effects of angiotensin II type 1 receptor blocker at an advanced stage of hypertensive diastolic heart failure. Journal of Hypertension 25:2, 455-461
CrossRef395
Asterios Karagiannis, Dimitri P Mikhailidis, Vasilios G Athyros, Anna I Kakafika, Konstantinos Tziomalos, Evangelos N Liberopoulos, Matilda Florentin, Moses Elisaf. (2007) The role of renin–angiotensin system inhibition in the treatment of hypertension in metabolic syndrome: are all the angiotensin receptor blockers equal?. Expert Opinion on Therapeutic Targets 11:2, 191-205
CrossRef396
Wilbert S. Aronow. (2007) Heart-Failure–Complicating Acute Myocardial Infarction. Clinics in Geriatric Medicine 23:1, 123-139
CrossRef397
Pitchai Balakumar ., Manjeet Singh .. (2007) Recent Advances in Pharmacotherapy for Heart Failure: Future Directions. Trends in Medical Research 2:2, 61-71
CrossRef398
Wilbert S. Aronow. (2007) Treatment of Heart Failure with Abnormal Left Ventricular Systolic Function in the Elderly. Clinics in Geriatric Medicine 23:1, 61-81
CrossRef399
Eman Hamad, Paul J Mather, Siva Srinivasan, Sharon Rubin, David J Whellan, Arthur M Feldman. (2007) Pharmacologic Therapy of Chronic Heart Failure. American Journal of Cardiovascular Drugs 7:4, 235-248
CrossRef400
Sverre E Kjeldsen, Tonje A Aksnes, Alex de la Sierra, Luis M Ruilope. (2007) Amlodipine and valsartan: calcium channel blockers/angiotensin II receptor blockers combination for hypertension. Therapy 4:1, 31-40
CrossRef401
Gregor Leibundgut, Matthias Pfisterer, Hans-Peter Brunner-La Rocca. (2007) Drug Treatment of Chronic Heart Failure in the Elderly. Drugs & Aging 24:12, 991-1006
CrossRef402
Komei Tanaka, Masahiro Ito, Makoto Kodama, Hiroki Maruyama, Makoto Hoyano, Wataru Mitsuma, Noriaki Iino, Satoru Hirono, Yuji Okura, Fumitake Gejyo, Naohito Tanabe, Yoshifusa Aizawa. (2007) Longitudinal Change in Renal Function in Patients With Idiopathic Dilated Cardiomyopathy Without Renal Insufficiency at Initial Diagnosis. Circulation Journal 71:12, 1927-1931
CrossRef403
Steven D. Crowley, Susan B. Gurley, Thomas M. Coffman. (2007) AT1 Receptors and Control of Blood Pressure: The Kidney and More…. Trends in Cardiovascular Medicine 17:1, 30-34
CrossRef404
Maureen P. Flattery, Domenic A. Sica. (2007) Angiotensin-Converting Enzyme Inhibitor-Related Angioedema: Recognition and Treatment. Progress in Cardiovascular Nursing 22:1, 47-51
CrossRef405
David H G Smith. (2007) Fixed-Dose Combination Antihypertensives and Reduction in Target Organ Damage. American Journal of Cardiovascular Drugs 7:6, 413-422
CrossRef406
Michio Nakanishi, Masaki Harada, Ichiro Kishimoto, Koichiro Kuwahara, Rika Kawakami, Yasuaki Nakagawa, Shinji Yasuno, Satoru Usami, Hideyuki Kinoshita, Yuichiro Adachi, Akiyoshi Fukamizu, Yoshihiko Saito, Kazuwa Nakao. (2007) Genetic Disruption of Angiotensin II Type 1a Receptor Improves Long-Term Survival of Mice With Chronic Severe Aortic Regurgitation. Circulation Journal 71:8, 1310-1316
CrossRef407
Domenic A Sica. (2007) Combination ACE Inhibitor and Angiotensin Receptor Blocker Therapy-Future Considerations. The Journal of Clinical Hypertension 9:1, 78-86
CrossRef408
Robert M. Califf, . (2007) Benefit assessment of therapeutic products: the Centers for Education and Research on Therapeutics. Pharmacoepidemiology and Drug Safety 16:1, 5-16
CrossRef409
M.D. Cheitlin. (2007) Mode of Death in Advanced Heart Failure: The Comparison of Medical, Pacing, and Defibrillation Therapies in Heart Failure (COMPANION) Trial. Yearbook of Cardiology 2007, 319-321
CrossRef410
Aldo P. Maggioni, Bernadette Darne, Dan Atar, Eric Abadie, Bertram Pitt, Faiez Zannad. (2007) FDA and CPMP Rulings on Subgroup Analyses. Cardiology 107:2, 97-102
CrossRef411
Marsha A. Raebel, David L. McClure, Steven R. Simon, K. Arnold Chan, Adrianne Feldstein, Susan E. Andrade, Jennifer Elston Lafata, Douglas Roblin, Robert L. Davis, Margaret J. Gunter, Richard Platt. (2007) Laboratory monitoring of potassium and creatinine in ambulatory patients receiving angiotensin converting enzyme inhibitors and angiotensin receptor blockers. Pharmacoepidemiology and Drug Safety 16:1, 55-64
CrossRef412
Takayoshi Tsutamoto, Hiroshi Sakai, Toshinari Tanaka, Masanori Fujii, Takashi Yamamoto, Atsuyuki Wada, Masato Ohnishi, Minoru Horie. (2007) Comparison of Active Renin Concentration and Plasma Renin Activity as a Prognostic Predictor in Patients With Heart Failure. Circulation Journal 71:6, 915-921
CrossRef413
Inder S. Anand, S. William Tam, Thomas S. Rector, Anne L. Taylor, Michael L. Sabolinski, W. Tad Archambault, Kirkwood F. Adams, Adeoye Y. Olukotun, Manuel Worcel, Jay N. Cohn. (2007) Influence of Blood Pressure on the Effectiveness of a Fixed-Dose Combination of Isosorbide Dinitrate and Hydralazine in the African-American Heart Failure Trial. Journal of the American College of Cardiology 49:1, 32-39
CrossRef414
Jill M. Gelow, James C. Fang. (2006) Update in the Approach to and Management of Heart Failure. Southern Medical Journal 99:12, 1346-1355
CrossRef415
Toni L Ripley, Jennifer S Chonlahan, Robin E Germany. (2006) Candesartan in heart failure. Clinical Interventions in Aging 1:4, 357-366
CrossRef416
Masako Saka, Koji Obata, Sahoko Ichihara, Xian Wu Cheng, Hirotaka Kimata, Akiko Noda, Hideo Izawa, Kohzo Nagata, Mitsuhiro Yokota. (2006) ATTENUATION OF VENTRICULAR HYPERTROPHY AND FIBROSIS IN RATS BY PITAVASTATIN: POTENTIAL ROLE OF THE RhoA?EXTRACELLULAR SIGNAL-REGULATED KINASE?SERUM RESPONSE FACTOR SIGNALLING PATHWAY. Clinical and Experimental Pharmacology and Physiology 33:12, 1164-1171
CrossRef417
John D. Harding, Mariell Jessup. (2006) New Directions in the Medical Management of Heart Failure. Seminars in Thoracic and Cardiovascular Surgery 17:4, 334-342
CrossRef418
Roberto Latini, Serge Masson, Lidia Staszewsky, Simona Barlera. (2006) Neurohormonal modulation in heart failure of ischemic etiology: Correlates with left ventricular remodeling. Current Heart Failure Reports 3:4, 157-163
CrossRef419
Samuel F. Sears, Lauren A. Stutts, Juan M. Aranda, Eileen M. Handberg, Jamie B. Conti. (2006) Managing Congestive Heart Failure Patient Factors in the Device Era. Congestive Heart Failure 12:6, 335-340
CrossRef420
Satish C. Govind, Lars-Åke Brodin, Jacek Nowak, S. S. Ramesh, Samir K. Saha. (2006) Acute administration of a single dose of valsartan improves left ventricular functions: a pilot study to assess the role of tissue velocity echocardiography in patients with systemic arterial hypertension in the TVE-valsartan study I. Clinical Physiology and Functional Imaging 26:6, 351-356
CrossRef421
N Khalifeh, A Vychytil, W H Hörl. (2006) The role of peritoneal dialysis in the management of treatment-resistant congestive heart failure: A European perspective. Kidney International 70, S72-S75
CrossRef422
Claudio Borghi, Sibel Ertek, Arrigo FG Cicero. (2006) Irbesartan: a review of its use alone and in combination with hydrochlorothiazide. Therapy 3:6, 733-749
CrossRef423
Steven M. Schwartz, David L. Wessel. (2006) Medical cardiovascular support in acute viral myocarditis in children. Pediatric Critical Care Medicine 7:Supplement, S12-S16
CrossRef424
A Heagerty. (2006) Optimizing hypertension management in clinical practice. Journal of Human Hypertension 20:11, 841-849
CrossRef425
Dan R. Berlowitz, Donald R. Miller, Susan A. Oliveria, Fran Cunningham, Andres Gomez-Caminero, James A. Rothendler. (2006) Differential associations of beta-blockers with hemorrhagic events for chronic heart failure patients on warfarin. Pharmacoepidemiology and Drug Safety 15:11, 799-807
CrossRef426
Giovanni FM Strippoli, Allison Tong, Suetonia C Palmer, Grahame J Elder, Jonathan C Craig, Giovanni FM Strippoli. 2006. Calcimimetics for secondary hyperparathyroidism in chronic kidney disease patients. .
CrossRef427
Giovanni FM Strippoli, Carmen Bonifati, Maria E Craig, Sankar D Navaneethan, Jonathan C Craig, Giovanni FM Strippoli. 2006. Angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists for preventing the progression of diabetic kidney disease. .
CrossRef428
2006. Hypertension. .
CrossRef429
Kiran K. Khush, David D. Waters. (2006) Effects of Statin Therapy on the Development and Progression of Heart Failure: Mechanisms and Clinical Trials. Journal of Cardiac Failure 12:8, 664-674
CrossRef430
Kumudha Ramasubbu, Biykem Bozkurt, Douglas L Mann. (2006) Mechanisms of idiopathic dilated cardiomyopathies. Current Opinion in Organ Transplantation 11:5, 553-559
CrossRef431
Robert S McKelvie. (2006) Candesartan for the management of heart failure: more than an alternative. Expert Opinion on Pharmacotherapy 7:14, 1945-1956
CrossRef432
Nicolas W Shammas. 2006. Congestive Heart Failure: Epidemiology, Pathophysiology, and Current Therapies. , 525-544.
CrossRef433
Leanne Groban, John Butterworth. (2006) Perioperative Management of Chronic Heart Failure. Anesthesia & Analgesia 103:3, 557-575
CrossRef434
Michel Azizi. (2006) Renin inhibition. Current Opinion in Nephrology and Hypertension 15:5, 505-510
CrossRef435
Michael W. Rich. (2006) Heart Failure in Older Adults. Medical Clinics of North America 90:5, 863-885
CrossRef436
William B. White, Henry A. Punzi, Debra Murwin, Stephen E. Koval, Giora Davidai, Joel M. Neutel. (2006) Effects of the Angiotensin II Receptor Blockers Telmisartan vs Valsartan in Combination With Hydrochlorothiazide 25 mg Once Daily for the Treatment of Hypertension. The Journal of Clinical Hypertension 8:9, 626-633
CrossRef437
Claudio Rigatto, Patrick Parfrey. (2006) Therapy Insight: management of cardiovascular disease in the renal transplant recipient. Nature Clinical Practice Nephrology 2:9, 514-526
CrossRef438
A. I. MALININ, S. ONG, L. M. MAKAROV, E. Y. PETUKHOVA, V. L. SEREBRUANY. (2006) Platelet inhibition beyond conventional antiplatelet agents: expanding role of angiotensin receptor blockers, statins and selective serotonin reuptake inhibitors. International Journal of Clinical Practice 60:8, 993-1002
CrossRef439
Riccardo Sarzani, Paolo Dessì-Fulgheri. (2006) Angiotensin receptor blockers and myocardial infarction: the importance of dosage. Journal of Hypertension 24:8, 1679-1681
CrossRef440
Aldo P. Maggioni. (2006) Efficacy of Angiotensin Receptor Blockers in Cardiovascular Disease. Cardiovascular Drugs and Therapy 20:4, 295-308
CrossRef441
James P. Tsikouris, Craig D. Cox, Jan S. Simoni, Charles F. Seifert, Miranda C. Peek, Gary E. Meyerrose. (2006) Lack of effect on coronary atherosclerotic disease biomarkers with modest dosing of an angiotensin-converting enzyme inhibitor, angiotensin II type-1 receptor blocker, and the combination. Coronary Artery Disease 17:5, 439-445
CrossRef442
Michael A. Crouch. (2006) Pharmacotherapy Implications of Revised Chronic Heart Failure Guidelines. The Consultant Pharmacist 21:7, 576-582
CrossRef443
HIDEYUKI KAMOCHI, YOSHIO YAMANOUCHI, KEIJIRO SAKU. (2006) Effects of Angiotensin Converting Enzyme Inhibitor and Angiotensin II Receptor Blocker on Ventricular Defibrillation Threshold. Pacing and Clinical Electrophysiology 29:7, 747-752
CrossRef444
K. ODEDRA, A. FERRO. (2006) Neurohormones and heart failure: the importance of aldosterone. International Journal of Clinical Practice 60:7, 835-846
CrossRef445
KNUT T. LAPPEGARD, HANNE BJORNSTAD. (2006) Anti-Inflammatory Effect of Cardiac Resynchronization Therapy. Pacing and Clinical Electrophysiology 29:7, 753-758
CrossRef446
Brian R Dulin, Henry Krum. (2006) Drug therapy of chronic heart failure in the elderly: the current state of clinical-trial evidence. Current Opinion in Cardiology 21:4, 393-399
CrossRef447
Robert S McKelvie. (2006) Current and future uses of candesartan in the treatment of heart failure. Future Cardiology 2:4, 391-402
CrossRef448
María G. Crespo Leiro, María J. Paniagua Martín. (2006) Insuficiencia cardiaca. ¿Son diferentes las mujeres?. Revista Española de Cardiología 59:7, 725-735
CrossRef449
Sabu Thomas, Edward Geltman. (2006) What is the Optimal Angiotensin-Converting Enzyme Inhibitor Dose in Heart Failure?. Congestive Heart Failure 12:4, 213-218
CrossRef450
Josef Stehlik, Matthew A Movsesian. (2006) Inhibitors of cyclic nucleotide phosphodiesterase 3 and 5 as therapeutic agents in heart failure. Expert Opinion on Investigational Drugs 15:7, 733-742
CrossRef451
Maria Tokmakova, Scott D Solomon. (2006) Inhibiting the renin–angiotensin system in myocardial infarction and heart failure: lessons from SAVE, VALIANT and CHARM, and other clinical trials. Current Opinion in Cardiology 21:4, 268-272
CrossRef452
J.J. Braszko. (2006) D2 dopamine receptor blockade prevents cognitive effects of Ang IV and des-Phe6 Ang IV. Physiology & Behavior 88:1-2, 152-159
CrossRef453
Bernard MY Cheung. (2006) Therapeutic potential of angiotensin receptor blockers in hypertension. Expert Opinion on Investigational Drugs 15:6, 625-635
CrossRef454
Serge Masson, Roberto Latini, Inder S. Anand, Simona Barlera, Dianne Judd, Monica Salio, Francesco Perticone, Giampaolo Perini, Gianni Tognoni, Jay N. Cohn. (2006) The Prognostic Value of Big Endothelin-1 in More Than 2,300 Patients With Heart Failure Enrolled in the Valsartan Heart Failure Trial (Val-HeFT). Journal of Cardiac Failure 12:5, 375-380
CrossRef455
Antonia Agustí, Inmaculada Danés, Dolores Rodríguez, José Casas. (2006) Novedades en el tratamiento de la insuficiencia cardíaca. Atención Primaria 38:2, 107-115
CrossRef456
Rachele Adorisio, Leonardo De Luca, Joseph Rossi, Mihai Gheorghiade. (2006) Pharmacological treatment of chronic heart failure. Heart Failure Reviews 11:2, 109-123
CrossRef457
Monica Colvin Adams, Syed Sohail Ali. (2006) Who should pay for home monitoring of heart failure?. Current Cardiology Reports 8:3, 191-197
CrossRef458
Wilbert S. Aronow. (2006) Epidemiology, Pathophysiology, Prognosis, and Treatment of Systolic and Diastolic Heart Failure. Cardiology in Review 14:3, 108-124
CrossRef459
Christian Torp-Pedersen, Lars Køber. (2006) Does candesartan benefit patients with heart failure?. Nature Clinical Practice Cardiovascular Medicine 3:5, 250-251
CrossRef460
Jochen Springer, Gerasimos Filippatos, Yoshihiro J Akashi, Stefan D Anker. (2006) Prognosis and therapy approaches of cardiac cachexia. Current Opinion in Cardiology 21:3, 229-233
CrossRef461
Jay N. Cohn, Peter E. Carson, Christopher O'Connor, Cristina Opasich, Ileana L. Piña, Marino Scherillo, Gianfranco Sinagra, Lynne Warner-Stevenson, Felix E. Tristani, Alberto Volpi. (2006) Prognosis and Mechanism of Death in Treated Heart Failure: Data From the Placebo Arm of Val-HeFT. Congestive Heart Failure 12:3, 127-131
CrossRef462
A. A. Mangoni, S. H. D. Jackson. (2006) The implications of a growing evidence base for drug use in elderly patients Part 2 - ACE inhibitors and angiotensin receptor blockers in heart failure and high cardiovascular risk patients. British Journal of Clinical Pharmacology 61:5, 502-512
CrossRef463
Markus Flesch, Erland Erdmann. (2006) The problem of polypharmacy in heart failure. Current Cardiology Reports 8:3, 217-225
CrossRef464
Nisha B Mistry, Arne S Westheim, Sverre E Kjeldsen. (2006) The angiotensin receptor antagonist valsartan: a review of the literature with a focus on clinical trials. Expert Opinion on Pharmacotherapy 7:5, 575-581
CrossRef465
Hoang M. Thai, Bao Q. Do, Trung D. Tran, Mohamed A. Gaballa, Steven Goldman. (2006) Aldosterone Antagonism Improves Endothelial-Dependent Vasorelaxation in Heart Failure via Upregulation of Endothelial Nitric Oxide Synthase Production. Journal of Cardiac Failure 12:3, 240-245
CrossRef466
John G.F. Cleland, Andrew Charlesworth, Jacobus Lubsen, Karl Swedberg, Willem J. Remme, Leif Erhardt, Andrea Di Lenarda, Michel Komajda, Marco Metra, Christian Torp-Pedersen, Philip A. Poole-Wilson. (2006) A Comparison of the Effects of Carvedilol and Metoprolol on Well-Being, Morbidity, and Mortality (the “Patient Journey”) in Patients With Heart Failure. Journal of the American College of Cardiology 47:8, 1603-1611
CrossRef467
Bodh I Jugdutt. (2006) Valsartan in the treatment of heart attack survivors. Vascular Health and Risk Management 2:2, 125-138
CrossRef468
Srinivas Iyengar, William T. Abraham. (2006) Diuretic resistance in heart failure. Current Heart Failure Reports 3:1, 41-45
CrossRef469
Steven G. Chrysant, George S. Chrysant. (2006) The Pleiotropic Effects of Angiotensin Receptor Blockers. The Journal of Clinical Hypertension 8:4, 261-268
CrossRef470
M. Böhm, N. Werner, M. Kindermann. (2006) Stand der medikamentösen Therapie bei chronischer Herzinsuffizienz. Clinical Research in Cardiology 95:S4, 36-56
CrossRef471
Gastone Sabbadini, Marco Metra, Andrea Di Lenarda, Savina Nodari, Gianfranco Sinagra, Livio Dei Cas. (2006) Managing heart failure in the very old. Aging Health 2:2, 253-275
CrossRef472
Grégoire Wuerzner, Michel Burnier. (2006) Effects of selective angiotensin II and β1-receptor blockade on renal haemodynamics and sodium handling during orthostatic stress in healthy individuals. Journal of Hypertension 24:Suppl 1, S89-S93
CrossRef473
R. Asmar. (2006) Targeting effective blood pressure control with angiotensin receptor blockers. International Journal of Clinical Practice 60:3, 315-320
CrossRef474
Sven Wassmann, Georg Nickenig. (2006) Pathophysiological regulation of the AT1-receptor and implications for vascular disease. Journal of Hypertension 24:Suppl 1, S15-S21
CrossRef475
Ulrich P. Jorde. (2006) Suppression of the Renin???Angiotensin???Aldosterone System in Chronic Heart Failure. Cardiology in Review 14:2, 81-87
CrossRef476
Lilian Grigorian Shamagian, Alfonso Varela Roman, Pilar Mazón Ramos, Pedro Rigueiro Veloso, Manuel Angel Bandin Dieguez, Jose Ramon Gonzalez-Juanatey. (2006) Angiotensin-Converting Enzyme Inhibitors Prescription Is Associated With Longer Survival Among Patients Hospitalized for Congestive Heart Failure Who Have Preserved Systolic Function: A Long-Term Follow-Up Study. Journal of Cardiac Failure 12:2, 128-133
CrossRef477
Robert M. Carey. (2006) Should we employ combination ACEI and ARB therapy in primary hypertension?. Current Hypertension Reports 8:2, 101-102
CrossRef478
Jan B Östergren. (2006) Angiotensin receptor blockade with candesartan in heart failure: findings from the Candesartan in Heart failure — Assessment of Reduction in Mortality and morbidity (CHARM) programme. Journal of Hypertension 24:Suppl 1, S3-S7
CrossRef479
Adam J Weinberg, Dion H Zappe, Rajeev Ramadugu, Marc S Weinberg. (2006) Long-term safety of high-dose angiotensin receptor blocker therapy in hypertensive patients with chronic kidney disease. Journal of Hypertension 24:Suppl 1, S95-S99
CrossRef480
Thomas S. Rector, Inder S. Anand, Jay N. Cohn. (2006) Relationships Between Clinical Assessments and Patients' Perceptions of the Effects of Heart Failure on Their Quality of Life. Journal of Cardiac Failure 12:2, 87-92
CrossRef481
Michael M. Givertz. 2006. Diet, Metabolic Syndrome, and Obesity. , 37-58.
CrossRef482
John McMurray, Scott Solomon, Karen Pieper, Shelby Reed, Jean Rouleau, Eric Velazquez, Harvey White, Jonathan Howlett, Karl Swedberg, Aldo Maggioni, Lars Køber, Frans Van de Werf, Rob Califf, Marc Pfeffer. (2006) The Effect of Valsartan, Captopril, or Both on Atherosclerotic Events After Acute Myocardial Infarction. Journal of the American College of Cardiology 47:4, 726-733
CrossRef483
Eulàlia Roig Minguell. (2006) ¿Es posible la resincronización en nuestro medio?. Medicina Clínica 126:4, 132-134
CrossRef484
Heart Failure Society of America. (2006) Section 7: Heart Failure in Patients With Left Ventricular Systolic Dysfunction. Journal of Cardiac Failure 12:1, e38-e57
CrossRef485
R. Düsing. (2006) Angiotensin II-receptor blocker dosages: How high should we go?. International Journal of Clinical Practice 60:2, 179-183
CrossRef486
Heart Failure Society of America. (2006) Section 13: Evaluation and Therapy for Heart Failure in the Setting of Ischemic Heart Disease. Journal of Cardiac Failure 12:1, e104-e111
CrossRef487
G Neil Thomas, Paul Chan, Brian Tomlinson. (2006) The Role of Angiotensin II Type 1 Receptor Antagonists in Elderly Patients with Hypertension. Drugs & Aging 23:2, 131-155
CrossRef488
Wilbert S. Aronow. (2006) Treatment of Systolic and Diastolic Heart Failure in the Elderly. Journal of the American Medical Directors Association 7:1, 29-36
CrossRef489
Michel Burnier, Anne Zanchi. (2006) Blockade of the renin–angiotensin–aldosterone system: a key therapeutic strategy to reduce renal and cardiovascular events in patients with diabetes. Journal of Hypertension 24:1, 11-25
CrossRef490
Mark J. Eisenberg, Laura C. Gioia. (2006) Angiotensin II Receptor Blockers in Congestive Heart Failure. Cardiology in Review 14:1, 26-34
CrossRef491
Elijah Sounders. (2006) Building on the Specialist's Antihypertensive Treatment Recommendation: It's Just the Beginning. The Journal of Clinical Hypertension 8:s1, 31-39
CrossRef492
J. Malcolm O. Arnold, Peter Liu, Catherine Demers, Paul Dorian, Nadia Giannetti, Haissam Haddad, George A. Heckman, Jonathan G. Howlett, Andrew Ignaszewski, David E. Johnstone, Philip Jong, Robert S. McKelvie, Gordon W. Moe, John D. Parker, Vivek Rao, Heather J. Ross, Errol J. Sequeira, Anna M. Svendsen, Koon Teo, Ross T. Tsuyuki, Michel White. (2006) Canadian Cardiovascular Society consensus conference recommendations on heart failure 2006: Diagnosis and management. Canadian Journal of Cardiology 22:1, 23-45
CrossRef493
Tsutomu Yamazaki. (2006) Proposed New Score to Rate the Strength of Evidence and Its Application to Large-Scale Clinical Trials of Angiotensin-Receptor Blockers. Circulation Journal 70:9, 1155-1158
CrossRef494
Kambiz Kalantarinia, Mark D. Okusa. (2006) The renin-angiotensin system and its blockade in diabetic renal and cardiovascular disease. Current Diabetes Reports 6:1, 8-16
CrossRef495
Yoshihisa Matsumura, Jun Takata, Hiroaki Kitaoka, Toru Kubo, Yuichi Baba, Eri Hoshikawa, Tomoyuki Hamada, Makoto Okawa, Nobuhiko Hitomi, Kyoko Sato, Naohito Yamasaki, Toshikazu Yabe, Takashi Furuno, Masanori Nishinaga, Yoshinori Doi. (2006) Long-Term Prognosis of Dilated Cardiomyopathy Revisited. Circulation Journal 70:4, 376-383
CrossRef496
Ernst R Schwarz, Pramod Sanghi. (2006) Conivaptan: a selective vasopressin antagonist for the treatment of heart failure. Expert Review of Cardiovascular Therapy 4:1, 17-23
CrossRef497
Naofumi Ikeda, Shigeyuki Nishimura, Shunei Kyo, Nobuyuki Komiyama, Kazuo Matsumoto, Tsutomu Inoue, Hiromichi Suzuki. (2006) Valsartan Cardio-Renal Protection in Patients Undergoing Coronary Angiography Complicated With Chronic Renal Insufficiency (VAL-CARP) Trial. Circulation Journal 70:5, 548-552
CrossRef498
W.J. Elliott. (2006) Comparison of Antihypertensive Effects of an Angiotensin-Converting Enzyme Inhibitor, a Calcium Antagonist and a Diuretic in Patients With Hypertension Not Controlled by Angiotensin Receptor Blocker Monotherapy. Yearbook of Cardiology 2006, 78-80
CrossRef499
Keith C. Ferdinand, Elijah Sounders. (2006) Hypertension-Related Morbidity and Mortality in African Americans?Why We Need to Do Better. The Journal of Clinical Hypertension 8:s1, 21-30
CrossRef500
Noritoshi Nagaya, Kenji Kangawa. (2006) Therapeutic Potential of Ghrelin in the Treatment of Heart Failure. Drugs 66:4, 439-448
CrossRef501
Artur Beltrame Ribeiro. (2006) Angiotensin II antagonists – therapeutic benefits spanning the cardiovascular disease continuum from hypertension to heart failure and diabetic nephropathy. Current Medical Research and Opinion 22:1, 1-16
CrossRef502
Eisuke Amiya, Kengo Tanabe, Yuji Ikari, Yoshihiro Nakajima, Kazuhiro Hara. (2006) Prolonged QRS Duration and Severity of Mitral Regurgitation are Unfavorable Prognostic Markers of Heart Failure in Patients With Nonischemic Dilated Cardiomyopathy. Circulation Journal 70:1, 57-62
CrossRef503
Randall E. Williams. (2006) The effect of neurohormonal antagonists in reducing heart failure hospitalizations. Current Medical Research and Opinion 22:1, 139-150
CrossRef504
B M Y Cheung, G T Y Cheung, I J Lauder, C-P Lau, C R Kumana. (2006) Meta-analysis of large outcome trials of angiotensin receptor blockers in hypertension. Journal of Human Hypertension 20:1, 37-43
CrossRef505
W. S. Aronow. (2005) Drug Treatment of Systolic and of Diastolic Heart Failure in Elderly Persons. The Journals of Gerontology Series A: Biological Sciences and Medical Sciences 60:12, 1597-1605
CrossRef506
Massimo Volpe, Giuseppe Mancia, Bruno Trimarco. (2005) Angiotensin II receptor blockers and myocardial infarction: deeds and misdeeds. Journal of Hypertension 23:12, 2113-2118
CrossRef507
Ulf Landmesser, Helmut Drexler. (2005) Chronic heart failure: an overview of conventional treatment versus novel approaches. Nature Clinical Practice Cardiovascular Medicine 2:12, 628-638
CrossRef508
Yoshihiro J. Akashi, Jochen Springer, Stefan D. Anker. (2005) Cachexia in chronic heart failure: Prognostic implications and novel therapeutic approaches. Current Heart Failure Reports 2:4, 198-203
CrossRef509
Brian D. Lowes, Simon F. Shakar, Marco Metra, Arthur M. Feldman, Eric Eichhorn, J. William Freytag, Michael J. Gerber, Jean-Francois Liard, Craig Hartman, Rick Gorczynski, Gwyn Evans, Jennifer V. Linseman, Jennifer Stewart, Alastair D. Robertson, Ellen B. Roecker, David L. Demets, Michael R. Bristow. (2005) Rationale and Design of the Enoximone Clinical Trials Program. Journal of Cardiac Failure 11:9, 659-669
CrossRef510
Peter Carson, Inder Anand, Christopher O’Connor, Brian Jaski, Jonathan Steinberg, Amy Lwin, JoAnn Lindenfeld, Jalil Ghali, Jodi H. Barnet, Arthur M. Feldman, Michael R. Bristow. (2005) Mode of Death in Advanced Heart Failure. Journal of the American College of Cardiology 46:12, 2329-2334
CrossRef511
Juan M. Aranda, Gregory W. Woo, Richard S. Schofield, Eileen M. Handberg, James A. Hill, Anne B. Curtis, Samuel F. Sears, J. Sean Goff, Daniel F. Pauly, Jamie B. Conti. (2005) Management of Heart Failure After Cardiac Resynchronization Therapy. Journal of the American College of Cardiology 46:12, 2193-2198
CrossRef512
Cristina Sierra, Alejandro de la Sierra. (2005) Antihypertensive, cardiovascular, and pleiotropic effects of angiotensin-receptor blockers. Current Opinion in Internal Medicine 4:6, 583-589
CrossRef513
Steven R. Goldsmith, Mihai Gheorghiade. (2005) Vasopressin Antagonism in Heart Failure. Journal of the American College of Cardiology 46:10, 1785-1791
CrossRef514
Vishal Bhatia, Ruchi Bhatia, Boban Mathew. (2005) Angiotensin Receptor Blockers in Congestive Heart Failure. Cardiology in Review 13:6, 297-303
CrossRef515
Jonathan Sackner-Bernstein. (2005) Reducing the risks of sudden death and heart failure post myocardial infarction: Utility of optimized pharmacotherapy. Clinical Cardiology 28:S1, 19-27
CrossRef516
Keith C Ferdinand. (2005) Isosorbide dinitrate and hydralazine hydrochloride: a review of efficacy and safety. Expert Review of Cardiovascular Therapy 3:6, 993-1001
CrossRef517
G. de Gevigney, S. Fol, F. Delahaye. (2005) Données physiopathologiques et implications thérapeutiques au cours de l'insuffisance cardiaque gauche. La Revue de Médecine Interne 26:11, 874-884
CrossRef518
Harjot K. Saini, Yan-Jun Xu, Amarjit S. Arneja, Paramjit S. Tappia, Naranjan S. Dhalla. (2005) Pharmacological basis of different targets for the treatment of atherosclerosis. Journal of Cellular and Molecular Medicine 9:4, 818-839
CrossRef519
Lisa Mielniczuk, Lynne Warner Stevenson. (2005) Angiotensin-converting enzyme inhibitors and angiotensin II type I receptor blockers in the management of congestive heart failure patients: what have we learned from recent clinical trials?. Current Opinion in Internal Medicine 4:5, 529-534
CrossRef520
M.G. Crespo Leiro, R. Marzoa Rivas, M.J. Paniagua Martín, A. Castro Beiras. (2005) Miocardiopatías: concepto, clasificación. Miocardiopatía dilatada idiopática. Medicine - Programa de Formación Médica Continuada Acreditado 9:42, 2765-2774
CrossRef521
Clyde W. Yancy. (2005) Heart Failure in African Americans. The American Journal of Cardiology 96:7, 3-12
CrossRef522
Cristina Sierra, Alejandro de la Sierra. (2005) Antihypertensive, cardiovascular, and pleiotropic effects of angiotensin-receptor blockers. Current Opinion in Internal Medicine 4:5, 469-475
CrossRef523
V. Barrios Alonso, C. Escobar Cervantes, A. Calderón Montero. (2005) ARA II en insuficiencia cardíaca crónica. Coincidencias y divergencias. ¿Efecto de clase?. Revista Clínica Española 205:10, 499-506
CrossRef524
Michael A. Crouch. (2005) Chronic Heart Failure: Developments and Perspectives. The Consultant Pharmacist 20:9, 751-765
CrossRef525
Cristina Sierra, Alejandro de la Sierra. (2005) Antihypertensive, cardiovascular, and pleiotropic effects of angiotensin-receptor blockers. Current Opinion in Nephrology and Hypertension 14:5, 435-441
CrossRef526
John V Terrovitis, Maria I Anastasiou-Nana, John N Nanas. (2005) Out-patient management of chronic heart failure. Expert Opinion on Pharmacotherapy 6:11, 1857-1881
CrossRef527
Sharon Ann Hunt, William T. Abraham, Marshall H. Chin, Arthur M. Feldman, Gary S. Francis, Theodore G. Ganiats, Mariell Jessup, Marvin A. Konstam, Donna M. Mancini, Keith Michl, John A. Oates, Peter S. Rahko, Marc A. Silver, Lynne Warner Stevenson, Clyde W. Yancy, Elliott M. Antman, Sidney C. Smith, Cynthia D. Adams, Jeffrey L. Anderson, David P. Faxon, Valentin Fuster, Jonathan L. Halperin, Loren F. Hiratzka, Sharon Ann Hunt, Alice K. Jacobs, Rick Nishimura, Joseph P. Ornato, Richard L. Page, Barbara Riegel. (2005) ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult—Summary Article. Journal of the American College of Cardiology 46:6, 1116-1143
CrossRef528
Srinivas Iyengar, William T Abraham. (2005) Role of medical therapy in the device era for the treatment of heart failure. Expert Review of Cardiovascular Therapy 3:5, 783-785
CrossRef529
(2005) Guías de Práctica Clínica sobre el diagnóstico y tratamiento de la insuficiencia cardíaca crónica. Versión resumida (actualización 2005). Revista Española de Cardiología 58:9, 1062-1092
CrossRef530
(2005) Rationale and Design of a Randomized Trial to Assess the Effects of β-blocker in Diastolic Heart Failure; Japanese Diastolic Heart Failure Study (J-DHF). Journal of Cardiac Failure 11:7, 542-547
CrossRef531
Sharon Ann Hunt. (2005) ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult. Journal of the American College of Cardiology 46:6, e1-e82
CrossRef532
Lars Køber, Christian Torp-Pedersen. (2005) Valsartan: the past, present and future. Future Cardiology 1:5, 591-598
CrossRef533
Sandeep A. Kamath, Clyde W. Yancy. (2005) Treatment of the african-american patient with congestive heart failure. Current Treatment Options in Cardiovascular Medicine 7:4, 307-315
CrossRef534
Sverre E Kjeldsen, Hans R Brunner, Gordon T McInnes, Pelle Stolt. (2005) Valsartan in the treatment of hypertension. Aging Health 1:1, 27-36
CrossRef535
Daniel J. Garry, Sean C. Goetsch, Amanda J. McGrath, Pradeep P.A. Mammen. (2005) Alternative Therapies for Orthotopic Heart Transplantation. The American Journal of the Medical Sciences 330:2, 88-101
CrossRef536
Pedro Monteiro, Ana I. Duarte, Lino M. Gonçalves, Luís A. Providência. (2005) Valsartan improves mitochondrial function in hearts submitted to acute ischemia. European Journal of Pharmacology 518:2-3, 158-164
CrossRef537
U. C. Hoppe, M. Böhm, R. Dietz, P. Hanrath, H. K. Kroemer, A. Osterspey, A. A. Schmaltz, E. Erdmann. (2005) Leitlinien zur Therapie der chronischen Herzinsuffizienz. Zeitschrift für Kardiologie 94:8, 488-509
CrossRef538
Massimo Volpe, Giuliano Tocci, Erika Pagannone. (2005) Angiotensin II-receptor antagonist in the treatment of hypertension. Current Hypertension Reports 7:4, 287-293
CrossRef539
Hiromitsu Miyamoto, Hisashi Kai, Hiroyuki Nakaura, Katsunori Osada, Yoshihiko Mizuta, Akira Matsumoto, Tsutomu Imaizumi. (2005) Safety and Efficacy of Repeated Sauna Bathing in Patients With Chronic Systolic Heart Failure: A Preliminary Report. Journal of Cardiac Failure 11:6, 432-436
CrossRef540
Tomie Kawada, Fujiko Masui, Asaki Tezuka, Takashi Ebisawa, Hiroyuki Kumagai, Mikio Nakazawa, Teruhiko Toyo-oka. (2005) A novel scheme of dystrophin disruption for the progression of advanced heart failure. Biochimica et Biophysica Acta (BBA) - Proteins & Proteomics 1751:1, 73-81
CrossRef541
Sanne de Vogel, Ewout J Hoorn, Vasilios Papademetriou. (2005) Losartan in cardiovascular disease. Future Cardiology 1:4, 433-446
CrossRef542
Constança S Cruz, Luzia S Cruz, Gustavo S Domingues, Carlos A Marcílio de Souza. (2005) New strategies for treatment of heart failure with aldosterone antagonists and the risk of hyperkalaemia. Expert Opinion on Drug Safety 4:4, 677-688
CrossRef543
Kenneth L. Choi, George L. Bakris. (2005) Hypertension Treatment Guidelines: Practical Implications. Seminars in Nephrology 25:4, 198-209
CrossRef544
Michael Wiederkehr, Robert Toto, Andrew Z. Fenves, C. Venkata S. Ram. (2005) Hypertension and the Kidney. Seminars in Nephrology 25:4, 236-245
CrossRef545
Franz H. Messerli, Ehud Grossman. (2005) Therapeutic Controversies in Hypertension. Seminars in Nephrology 25:4, 227-235
CrossRef546
Jacoba P. Greving, Petra Denig, Willem Jan van der Veen, Frank W. Beltman, Miriam C. J. M. Sturkenboom, Dick de Zeeuw, Flora M. Haaijer-Ruskamp. (2005) Uptake of angiotensin II receptor blockers in the treatment of hypertension. European Journal of Clinical Pharmacology 61:5-6, 461-466
CrossRef547
Cosme García, Josep Lupón, Agustín Urrutia, Beatriz González, Joan Herreros, Salvador Altimir, Ramon Coll, Montserrat Prats, Celestino Rey-Joly, Vicente Valle. (2005) Significado pronóstico de la diabetes mellitus en una población con insuficiencia cardíaca: mortalidad e ingreso por insuficiencia cardíaca al cabo de un año. Medicina Clínica 125:5, 161-165
CrossRef548
Frederick A. Spencer, Theo Meyer. (2005) Heart failure and shock complicating acute coronary syndromes. Current Cardiology Reports 7:4, 276-282
CrossRef549
Spyridon Koulouris, Phivos Symeonides, Konstantinos Triantafyllou, Georgios Ioannidis, Ilias Karabinos, Theofanis Katostaras, Mahmud El-Ali, Theodoros Theodoridis, Ekaterini Vratsista, Nikolaos Thalassinos, Vassiliki Kokkinou, Ioannis Nanas, Stamatios Stamatelopoulos, Pavlos Toutouzas. (2005) Comparison of the Effects of Ramipril Versus Telmisartan in Reducing Serum Levels of High-Sensitivity C-Reactive Protein and Oxidized Low-Density Lipoprotein Cholesterol in Patients With Type 2 Diabetes Mellitus. The American Journal of Cardiology 95:11, 1386-1388
CrossRef550
Reinhard Rychlik, Hanna Rulhoff. (2005) Socioeconomic relevance of selected treatment strategies in patients with chronic heart failure. Expert Review of Pharmacoeconomics & Outcomes Research 5:3, 277-286
CrossRef551
T. Barry Levine, Arlene B. Levine. (2005) Clinical update: The role of angiotensin II receptor blockers in patients with left ventricular dysfunction (Part II of II). Clinical Cardiology 28:6, 277-280
CrossRef552
Dean G. Smith, Annamaria Cerulli, Feride H. Frech. (2005) Use of valsartan for the treatment of heart-failure patients not receiving ACE inhibitors: A budget impact analysis. Clinical Therapeutics 27:6, 951-959
CrossRef553
I.P. Garrido Bravo, J.Á. Rodríguez Fernández, J. García de Lara, A. Castro Beiras. (2005) Tratamiento de la insuficiencia cardíaca crónica. Medicine - Programa de Formación Médica Continuada Acreditado 9:35, 2318-2326
CrossRef554
Osama A. Ibrahim, Mark E. Dunlap. (2005) Combination pharmacologic therapies for heart failure: What next after angiotensin-converting enzyme inhibitors and beta-blockers?. Current Heart Failure Reports 2:2, 89-93
CrossRef555
Rafael Marín, Álex de la Sierra, Pedro Armario, Carlos Campo, José R. Banegas, Manuel Gorostidi. (2005) Guía sobre el diagnóstico y tratamiento de la hipertensión arterial en España 2005. Medicina Clínica 125:1, 24-34
CrossRef556
Mary Rose Fabi, John R. Teerlink. (2005) The addition of angiotensin receptor blockers to angiotens-inconverting enzyme inhibitors—What has time told us?. Current Heart Failure Reports 2:2, 59-64
CrossRef557
M Volpe, L M Ruilope, G T McInnes, B Waeber, M A Weber. (2005) Angiotensin-II receptor blockers: benefits beyond blood pressure reduction?. Journal of Human Hypertension 19:5, 331-339
CrossRef558
Giuseppina Majani, Anna Giardini, Cristina Opasich, Robert Glazer, Allen Hester, Gianni Tognoni, Jay N. Cohn, Luigi Tavazzi. (2005) Effect of Valsartan on Quality of Life When Added to Usual Therapy for Heart Failure: Results From The Valsartan Heart Failure Trial. Journal of Cardiac Failure 11:4, 253-259
CrossRef559
John JV McMurray, Marc A Pfeffer. (2005) Heart failure. The Lancet 365:9474, 1877-1889
CrossRef560
Roland E Schmieder. (2005) Optimizing therapeutic strategies to achieve renal and cardiovascular risk reduction in diabetic patients with angiotensin receptor blockers. Journal of Hypertension 23:5, 905-911
CrossRef561
L. R. Erhardt. (2005) A review of the current evidence for the use of angiotensin-receptor blockers in chronic heart failure. International Journal of Clinical Practice 59:5, 571-578
CrossRef562
Victor Dzau. (2005) The cardiovascular continuum and renin–angiotensin–aldosterone system blockade. Journal of Hypertension 23:Suppl 1, S9-S17
CrossRef563
Michael A Weber. (2005) Managing the patient at risk for a second stroke. Journal of Hypertension 23:Suppl 1, S41-S47
CrossRef564
Aldo Pietro Maggioni, Gianna Fabbri. (2005) VALIANT (VALsartan In Acute myocardial iNfarcTion) trial. Expert Opinion on Pharmacotherapy 6:3, 507-512
CrossRef565
Shu Kasama, Takuji Toyama, Hisao Kumakura, Yoshiaki Takayama, Shuichi Ichikawa, Tadashi Suzuki, Masahiko Kurabayashi. (2005) Effects of candesartan on cardiac sympathetic nerve activity in patients with congestive heart failure and preserved left ventricular ejection fraction. Journal of the American College of Cardiology 45:5, 661-667
CrossRef566
Aldo P. Maggioni, Cristina Opasich, Inder Anand, Simona Barlera, Emanuele Carbonieri, Lucio Gonzini, Luigi Tavazzi, Roberto Latini, Jay Cohn. (2005) Anemia in Patients With Heart Failure: Prevalence and Prognostic Role in a Controlled Trial and in Clinical Practice. Journal of Cardiac Failure 11:2, 91-98
CrossRef567
Sheila A Doggrell. (2005) CHARMed – the effects of candesartan in heart failure. Expert Opinion on Pharmacotherapy 6:3, 513-516
CrossRef568
Tomoaki Nakata, Takeru Wakabayashi, Michifumi Kyuma, Toru Takahashi, Kazufumi Tsuchihashi, Kazuaki Shimamoto. (2005) Cardiac metaiodobenzylguanidine activity can predict the long-term efficacy of angiotensin-converting enzyme inhibitors and/or beta-adrenoceptor blockers in patients with heart failure. European Journal of Nuclear Medicine and Molecular Imaging 32:2, 186-194
CrossRef569
Bertram Pitt. (2005) Should chronic heart failure patients with reduced left-ventricular ejection fraction receive angiotensin-receptor blockers?. Nature Clinical Practice Cardiovascular Medicine 2:2, 70-71
CrossRef570
Jun Watanabe, Nobuyuki Shiba, Tsuyoshi Shinozaki, Yoshito Koseki, Akihiko Karibe, Tatsuya Komaru, Masahito Miura, Mitsumasa Fukuchi, Kouhei Fukahori, Masahito Sakuma, Yutaka Kagaya, Kunio Shirato. (2005) Prognostic value of plasma brain natriuretic peptide combined with left ventricular dimensions in predicting sudden death of patients with chronic heart failure. Journal of Cardiac Failure 11:1, 50-55
CrossRef571
Olaf Hedrich, Richard D. Patten, David Nofrio. (2005) Current treatment options for CHF management: Focus on the renin-angiotensin-aldosterone system. Current Treatment Options in Cardiovascular Medicine 7:1, 3-13
CrossRef572
Sverre E Kjeldsen, Ingrid Os, Aud H??ieggen, Kim Beckey, Gilbert W Gleim, Suzanne Oparil. (2005) Fixed-Dose Combinations in the Management of Hypertension. American Journal of Cardiovascular Drugs 5:1, 17-22
CrossRef573
Luis M. Ruilope, Enrico Agabiti Rosei, George L. Bakris, Giuseppe Mancia, Neil R. Poulter, Stefano Taddei, Thomas Unger, Massimo Volpe, Bernard Waeber, Faiez Zannad. (2005) Angiotensin receptor blockers: Therapeutic targets and cardiovascular protection. Blood Pressure 14:4, 196-209
CrossRef574
Caroline Fenton, Lesley J Scott. (2005) Candesartan Cilexetil. Drugs 65:4, 537-558
CrossRef575
Bertram Pitt. (2005) The Role of Aldosterone Blockade in Patients with Heart Failure. Heart Failure Reviews 10:1, 79-83
CrossRef576
Peter A Meredith. (2005) Angiotensin II Receptor Antagonists Alone and Combined with Hydrochlorothiazide. American Journal of Cardiovascular Drugs 5:3, 171-183
CrossRef577
Hannelore Hampl, Lars Hennig, Christian Rosenberger, Masoud Amirkhalily, Lutz Gogoll, Eberhard Riedel, Armin Scherhag. (2005) Effects of Optimized Heart Failure Therapy and Anemia Correction with Epoetin β on Left Ventricular Mass in Hemodialysis Patients. American Journal of Nephrology 25:3, 211-220
CrossRef578
Arduino A Mangoni. (2005) Cardiovascular Drug Therapy in Elderly Patients. Drugs & Aging 22:11, 913-941
CrossRef579
Maurizio Destro, Rossana Scabrosetti, Alessandro Vanasia, Amedeo Mugellini. (2005) Comparative efficacy of valsartan and olmesartan in mild-to-moderate hypertension: Results of 24-hour ambulatory blood pressure monitoring. Advances in Therapy 22:1, 32-43
CrossRef580
Ryotaro Wake, Shokei Kim-Mitsuyama, Yasukatsu Izumi, Kaoru Yoshida, Yasuhiro Izumiya, Tokihito Yukimura, Masayuki Shiota, Minoru Yoshiyama, Junichi Yoshikawa, Hiroshi Iwao. (2005) Beneficial Effect of Candesartan on Rat Diastolic Heart Failure. Journal of Pharmacological Sciences 98:4, 372-379
CrossRef581
Catherine Demers, Anita Mody, Koon K Teo, Robert S McKelvie. (2005) ACE Inhibitors in Heart Failure. American Journal of Cardiovascular Drugs 5:6, 351-359
CrossRef582
Tetsufumi Yamamoto, Masataka Sata, Daiju Fukuda, Shinichi Takamoto. (2005) The angiotensin II type 1 receptor blocker valsartan attenuates graft vasculopathy. Basic Research in Cardiology 100:1, 84-91
CrossRef583
P. Cía Gómez, A. Martínez Berganza, J.I. Pérez Calvo. (2004) Tratamiento farmacológico de la hipertensión arterial. Medicine - Programa de Formación Médica Continuada Acreditado 9:23, 1481-1493
CrossRef584
Brian K. Irons, James P. Tsikouris, Audra A. Thomas. (2004) The Use of Angiotensin Receptor Blockers in the Treatment of Chronic Heart Failure. Journal of Cardiovascular Pharmacology 44:6, 718-724
CrossRef585
Jay N. Cohn. (2004) New therapeutic strategies for heart failure: left ventricular remodeling as a target. Journal of Cardiac Failure 10:6, S200-S201
CrossRef586
Christoph H. Gleiter, Christine Jägle, Ursula Gresser, Klaus Mörike. (2004) Candesartan. Cardiovascular Drug Reviews 22:4, 263-284
CrossRef587
Andrew Boyle, Monica Colvin-Adams. (2004) Recipient selection and management. Seminars in Thoracic and Cardiovascular Surgery 16:4, 358-363
CrossRef588
Taylor, Anne L., Ziesche, Susan, Yancy, Clyde, Carson, Peter, D'Agostino, Ralph Jr., Ferdinand, Keith, Taylor, Malcolm, Adams, Kirkwood, Sabolinski, Michael, Worcel, Manuel, Cohn, Jay N., . (2004) Combination of Isosorbide Dinitrate and Hydralazine in Blacks with Heart Failure. New England Journal of Medicine 351:20, 2049-2057
Full Text589
Christian N. Gring, Gary S. Francis. (2004) A hard look at angiotensin receptor blockers in heart failure. Journal of the American College of Cardiology 44:9, 1841-1846
CrossRef590
Dennis M. McNamara, Richard Holubkov, Lisa Postava, Karen Janosko, Guy A. MacGowan, Michael Mathier, Srinivas Murali, Arthur M. Feldman, Barry London. (2004) Pharmacogenetic interactions between angiotensin-converting enzyme inhibitor therapy and the angiotensin-converting enzyme deletion polymorphism in patients with congestive heart failure. Journal of the American College of Cardiology 44:10, 2019-2026
CrossRef591
Robert E Hobbs. (2004) Guidelines for the Diagnosis and Management of Heart Failure. American Journal of Therapeutics 11:6, 467-472
CrossRef592
Maziar Azadpour, Gervasio A Lamas. (2004) AT1 receptor blockade for the prevention of cardiovascular events after myocardial infarction. Expert Review of Cardiovascular Therapy 2:6, 891-902
CrossRef593
John C Somberg, Janos Molnar. (2004) The Pharmacologic Treatment of Heart Failure. American Journal of Therapeutics 11:6, 480-488
CrossRef594
Jiyoong Kim, Takashi Washio, Masakazu Yamagishi, Yoshio Yasumura, Satoshi Nakatani, Kazuhiko Hashimura, Akihisa Hanatani, Kazuo Komamura, Kunio Miyatake, Soichiro Kitamura, Hitonobu Tomoike, Masafumi Kitakaze. (2004) A Novel Data Mining Approach to the Identification of Effective Drugs or Combinations for Targeted Endpoints?Application to Chronic Heart Failure as a New Form of Evidence-based Medicine. Cardiovascular Drugs and Therapy 18:6, 483-489
CrossRef595
Liviu Klein, Mihai Gheorghiade. (2004) Coronary artery disease and prevention of heart failure. Medical Clinics of North America 88:5, 1209-1235
CrossRef596
Steven Kang, David S. Cannom. (2004) Current role of device therapy to reduce sudden cardiac death in heart failure. Current Heart Failure Reports 1:3, 104-110
CrossRef597
Sidney Goldstein. (2004) The changing epidemiology of sudden death in heart failure. Current Heart Failure Reports 1:3, 93-97
CrossRef598
Sri Sundaram, Jeffrey J. Goldberger. (2004) Risk stratification and epidemiology of sudden death. Current Cardiology Reports 6:5, 333-338
CrossRef599
Clyde W. Yancy. (2004) The prevention of heart failure in minority communities and discrepancies in health care delivery systems. Medical Clinics of North America 88:5, 1347-1368
CrossRef600
Niels H. Andersen, Carl E. Mogensen. (2004) Dual blockade of the renin angiotensin system in diabetic and nondiabetic kidney disease. Current Hypertension Reports 6:5, 369-376
CrossRef601
Clyde W. Yancy, Gregg C. Fonarow. (2004) Quality of care and outcomes in acute decompensated heart failure: The ADHERE registry. Current Heart Failure Reports 1:3, 121-128
CrossRef602
Jocelyn D. Jones, Keecia D. King, Frank S. Emanuel. (2004) Hypertension: A Clinical Pharmacist's Synopsis of JNC 7. American Journal of Pharmaceutical Education 68:3, 71
CrossRef603
Lars H. Lund, Donna Mancini. (2004) Heart failure in women. Medical Clinics of North America 88:5, 1321-1345
CrossRef604
Palmer, Biff F., . (2004) Managing Hyperkalemia Caused by Inhibitors of the Renin–Angiotensin–Aldosterone System. New England Journal of Medicine 351:6, 585-592
Full Text605
Olaf Hedrich, Mark Jacob, Paul J. Hauptman. (2004) Progression of coronary artery disease in non-ischemic dilated cardiomyopathy. Coronary Artery Disease 15:5, 291-297
CrossRef606
C Sierra, Luis M Ruilope. (2004) Novel antihypertensive agents. Expert Opinion on Investigational Drugs 13:8, 987-998
CrossRef607
Steven G. Chrysant, George S. Chrysant. (2004) Clinical Experience With Angiotensin Receptor Blockers With Particular Reference to Valsartan. The Journal of Clinical Hypertension 6:8, 445-451
CrossRef608
Jan A Staessen, Willem H Birkenh??ger. (2004) VALUE. Journal of Hypertension 22:8, 1431-1434
CrossRef609
Richard D. Patten, Prem Soman. (2004) Prevention and reversal of LV remodeling with neurohormonal inhibitors. Current Treatment Options in Cardiovascular Medicine 6:4, 313-325
CrossRef610
Ali Ahmed, Louis J. Dell???Italia. (2004) Use of Beta-Blockers in Older Adults with Chronic Heart Failure. The American Journal of the Medical Sciences 328:2, 100-111
CrossRef611
Jan Östergren. (2004) Candesartan for the treatment of hypertension and heart failure. Expert Opinion on Pharmacotherapy 5:7, 1589-1597
CrossRef612
W.H Wilson Tang, Anjli Maroo, James B Young. (2004) Ischemic heart disease and congestive heart failure in diabetic patients. Medical Clinics of North America 88:4, 1037-1061
CrossRef613
Helmy M. Siragy. (2004) Clinical Trials Report. Current Hypertension Reports 6:4, 255-256
CrossRef614
Niall McLaughlin, Todd W. B. Gehr, Domenic A. Sica. (2004) Aldosterone-receptor antagonism and end-stage renal disease. Current Hypertension Reports 6:4, 327-330
CrossRef615
Inder Anand, John McMurray, Jay N Cohn, Marvin A Konstam, Thomas Notter, Kurt Quitzau, Frank Ruschitzka, Thomas F Lüscher. (2004) Long-term effects of darusentan on left-ventricular remodelling and clinical outcomes in the EndothelinA Receptor Antagonist Trial in Heart Failure (EARTH): randomised, double-blind, placebo-controlled trial. The Lancet 364:9431, 347-354
CrossRef616
Michael A. Weber. (2004) Angiotensin II Receptor Blockers in Older Patients. The American Journal of Geriatric Cardiology 13:4, 197-205
CrossRef617
Stephen Scheidt, Nanette K. Wenger, Michael A. Weber. (2004) The Elderly and Cardiovascular Disease: Some Differences, but Many Similarities to Their Younger Counterparts. The American Journal of Geriatric Cardiology 13:4, 178-179
CrossRef618
Jan J. Braszko. (2004) Involvement of D1 dopamine receptors in the cognitive effects of angiotensin IV and des-Phe6 angiotensin IV. Peptides 25:7, 1195-1203
CrossRef619
Matthew R. Weir. (2004) Angiotensin II Receptor Blockers: The Importance of Dose in Cardiovascular and Renal Risk Reduction. The Journal of Clinical Hypertension 6:6, 315-325
CrossRef620
Yunzeng Zou, Hiroshi Akazawa, Yingjie Qin, Masanori Sano, Hiroyuki Takano, Tohru Minamino, Noriko Makita, Koji Iwanaga, Weidong Zhu, Sumiyo Kudoh, Haruhiro Toko, Koichi Tamura, Minoru Kihara, Toshio Nagai, Akiyoshi Fukamizu, Satoshi Umemura, Taroh Iiri, Toshiro Fujita, Issei Komuro. (2004) Mechanical stress activates angiotensin II type 1 receptor without the involvement of angiotensin II. Nature Cell Biology 6:6, 499-506
CrossRef621
Stevo Julius, Sverre E Kjeldsen, Michael Weber, Hans R Brunner, Steffan Ekman, Lennart Hansson, Tsushung Hua, John Laragh, Gordon T McInnes, Lada Mitchell, Francis Plat, Anthony Schork, Beverly Smith, Alberto Zanchetti. (2004) Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. The Lancet 363:9426, 2022-2031
CrossRef622
Maylene Wong, Lidia Staszewsky, Roberto Latini, Simona Barlera, Robert Glazer, Nora Aknay, Allen Hester, Inder Anand, Jay N Cohn. (2004) Severity of left ventricular remodeling defines outcomes and response to therapy in heart failure. Journal of the American College of Cardiology 43:11, 2022-2027
CrossRef623
Javed Butler, Patrick G. Arbogast, James Daugherty, Manoj K. Jain, Wayne A. Ray, Marie R. Griffin. (2004) Outpatient utilization of angiotensin-converting enzyme inhibitors among heart failure patients after hospital discharge. Journal of the American College of Cardiology 43:11, 2036-2043
CrossRef624
Jochen Müller-Ehmsen, Robert HG Schwinger. (2004) TNF and congestive heart failure: therapeutic possibilities. Expert Opinion on Therapeutic Targets 8:3, 203-209
CrossRef625
Steven R. Goldsmith. (2004) Interactions between the sympathetic nervous system and the RAAS in heart failure. Current Heart Failure Reports 1:2, 45-50
CrossRef626
R. Buchhorn. (2004) Medikamentöse Therapie der Herzinsuffizienz im Kindesalter. Monatsschrift Kinderheilkunde 152:6, 659-665
CrossRef627
Monica R Shah, Lynne W Stevenson. (2004) Searching for evidence: refractory questions in advanced heart failure. Journal of Cardiac Failure 10:3, 210-218
CrossRef628
Pablo Navarro, Robert Moskowitz, Thierry H. Le Jemtel. (2004) Inhibition of RAAS—When is it too much?. Current Heart Failure Reports 1:2, 57-64
CrossRef629
Ettore Malacco, Massimo Santonastaso, Natale A. Varì, Anna Gargiulo, Vitaliano Spagnuolo, Federico Bertocchi, Paolo Palatini, PREVAIL Study Investigators. (2004) Comparison of valsartan 160 mg with lisinopril 20 mg, given as monotherapy or in combination with a diuretic, for the treatment of hypertension: The blood pressure reduction and tolerability of valsartan in comparison with lisinopril (PREVAIL) study. Clinical Therapeutics 26:6, 855-865
CrossRef630
(2004) Vasopressin versus Epinephrine for Cardiopulmonary Resuscitation. New England Journal of Medicine 350:21, 2206-2209
Full Text631
Peter Jacobsen, Kasper Rossing, Hans-Henrik Parving. (2004) Single versus dual blockade of the renin-angiotensin system (angiotensin-converting enzyme inhibitors and/or angiotensin II receptor blockers) in diabetic nephropathy. Current Opinion in Nephrology and Hypertension 13:3, 319-324
CrossRef632
Ileana L. Piña. (2004) Clinical trials report. Current Cardiology Reports 6:3, 159-161
CrossRef633
Stefan D Anker, Ewa A Jankowska, Darlington O Okonko. (2004) Therapeutic patents for chronic heart failure: a review of patent applications from 1996 to 2002. Expert Opinion on Therapeutic Patents 14:5, 639-654
CrossRef634
Mariell Jessup, Ileana L Piña. (2004) Is it important to examine gender differences in the epidemiology and outcome of severe heart failure?. The Journal of Thoracic and Cardiovascular Surgery 127:5, 1247-1252
CrossRef635
Inder S. Anand. (2004) Is too much neurohormonal blockade harmful?. Current Cardiology Reports 6:3, 169-175
CrossRef636
Mathias Zimmermann, Thomas Unger. (2004) Challenges in improving prognosis and therapy: The Ongoing Telmisartan Alone and in Combination with Ramipril Global End point Trial Programme. Expert Opinion on Pharmacotherapy 5:5, 1201-1208
CrossRef637
Sumit R Majumdar, Finlay A McAlister, Marilyn Cree, Wei-Ching Chang, Milton Packer, Paul W Armstrong. (2004) Do evidence-based treatments provide incremental benefits to patients with congestive heart failure already receiving angiotensin-converting enzyme inhibitors? A secondary analysis of one-year outcomes from the assessment of treatment with lisinopril and survival (ATLAS) study. Clinical Therapeutics 26:5, 694-703
CrossRef638
Maylene Wong, Luigi Tavazzi. (2004) Effect of Drug Therapy for Heart Failure on Quality of Life. The Journal of Clinical Hypertension 6:5, 256-261
CrossRef639
William B Hood, Jr., Antonio L Dans, Gordon H Guyatt, Roman Jaeschke, John JV McMurray, William B Hood, Jr.. 2004. Digitalis for treatment of heart failure in patients in sinus rhythm. .
CrossRef640
Jay N Cohn. (2004) Blood pressure and the therapy of advanced heart failure. Journal of the American College of Cardiology 43:8, 1430-1431
CrossRef641
Amar M Salam. (2004) Angiotensin receptor blockers in acute myocardial infarction. Expert Opinion on Investigational Drugs 13:4, 427-430
CrossRef642
Yasuchika Takeishi, Osamu Minamihaba, Sou Yamauchi, Takanori Arimoto, Osamu Hirono, Hiroki Takahashi, Hideyuki Akiyama, Takuya Miyamoto, Joji Nitobe, Naoki Nozaki, Hidetada Tachibana, Masaki Okuyama, Akio Fukui, Isao Kubota, Akio Okada, Kazuei Takahashi. (2004) Dynamic 123 I-BMIPP single-photon emission computed tomography in patients with congestive heart failure: Effect of angiotensin ii type-1 receptor blockade. Clinical Cardiology 27:4, 204-210
CrossRef643
William B. Hood, Antonio L. Dans, Gordon H. Guyatt, Roman Jaeschke, John J.V. McMurray. (2004) Digitalis for treatment of congestive heart failure in patients in sinus rhythm: a systematic review and meta-analysis. Journal of Cardiac Failure 10:2, 155-164
CrossRef644
Bernhard R Winkelmann. (2004) American Heart Association Scientific Sessions. Expert Opinion on Investigational Drugs 13:4, 435-445
CrossRef645
Joel M. Neutel, David H.G. Smith, Micheal A. Weber, Antonia C. Wang, Harvey N. Masonson. (2004) Use of an Olmesartan Medoxomil-Based Treatment Algorithm for Hypertension Control. The Journal of Clinical Hypertension 6:4, 168-399
CrossRef646
Robert S McKelvie. (2004) The therapeutic potential of angiotensin II receptor blockers in the treatment of heart failure. Expert Opinion on Investigational Drugs 13:3, 245-253
CrossRef647
Massimo Volpe. (2004) Hypertension therapy: Mixing, matching, and meeting targets. Advances in Therapy 21:2, 107-122
CrossRef648
Walter Raasch, Olaf J??hren, Stefan Schwartz, Annabella Gieselberg, Peter Dominiak. (2004) Combined blockade of AT1-receptors and ACE synergistically potentiates antihypertensive effects in SHR. Journal of Hypertension 22:3, 611-618
CrossRef649
Norman Sharpe. (2004) Pharmacologic effects on cardiac remodeling. Current Heart Failure Reports 1:1, 9-13
CrossRef650
Steven G Chrysant, George S Chrysant. (2004) Antihypertensive efficacy of olmesartan medoxomil alone and in combination with hydrochlorothiazide. Expert Opinion on Pharmacotherapy 5:3, 657-667
CrossRef651
L-B Tan, D. Schlosshan, S. G. Williams. (2004) The benefits of valsartan in the treatment of heart failure: results from Val-HeFT. International Journal of Clinical Practice 58:2, 184-191
CrossRef652
Frank Hermann, Frank T. Ruschitzka, Ernesto L. Schiffrin. (2004) Clinical trials report. Current Hypertension Reports 6:1, 45-50
CrossRef653
G.William Dec. (2004) Management of heart failure: crossing boundary over to the surgical country. Surgical Clinics of North America 84:1, 1-25
CrossRef654
Jianyi Zhang, Jagat Narula. (2004) Molecular biology of myocardial recovery. Surgical Clinics of North America 84:1, 223-242
CrossRef655
Elena M.V. de Cavanagh, Barbara Piotrkowski, Cesar G. Fraga. (2004) Concerted action of the renin–angiotensin system, mitochondria, and antioxidant defenses in aging. Molecular Aspects of Medicine 25:1-2, 27-36
CrossRef656
Bodh I Jugdutt, Vijayan Menon. (2004) Valsartan-induced cardioprotection involves angiotensin II type 2 receptor upregulation in dog and rat models of in vivo reperfused myocardial infarction. Journal of Cardiac Failure 10:1, 74-82
CrossRef657
Carlos Ferrario, Michael Moore. (2004) AII antagonists in hypertension, heart failure, and diabetic nephropathy: focus on losartan. Current Medical Research and Opinion 20:3, 279-293
CrossRef658
Riccardo Sarzani, Paolo Dess??-Fulgheri, Alessandro Rappelli. (2004) Angiotensin Receptor Blockers and Target-Organ Protection Beyond Blood Pressure Control. High Blood Pressure & Cardiovascular Prevention 11:2, 65-73
CrossRef659
Toru Kinugawa, Masahiko Kato, Kazuhide Ogino, Shuichi Osaki, Osamu Igawa, Ichiro Hisatome, Chiaki Shigemasa. (2004) Effects of Angiotensin II Type 1 Receptor Antagonist, Losartan, on Ventilatory Response to Exercise and Neurohormonal Profiles in Patients with Chronic Heart Failure. The Japanese Journal of Physiology 54:1, 15-21
CrossRef660
Ryo Matsumoto, Minoru Yoshiyama, Takashi Omura, Shokei Kim, Yasuhiro Nakamura, Yasukatsu Izumi, Kaname Akioka, Hiroshi Iwao, Kazuhide Takeuchi, Junichi Yoshikawa. (2004) Effects of Aldosterone Receptor Antagonist and Angiotensin II Type I Receptor Blocker on Cardiac Transcriptional Factors and mRNA Expression in Rats With Myocardial Infarction. Circulation Journal 68:4, 376-382
CrossRef661
Hitoshi Suzuki, Kazuhira Maehara, Hiroyuki Yaoita, Yukio Maruyama. (2004) Altered Effects of Angiotensin II Type 1 and Type 2 Receptor Blockers on Cardiac Norepinephrine Release and Inotropic Responses During Cardiac Sympathetic Nerve Stimulation in Aorto-Caval Shunt Rats. Circulation Journal 68:7, 683-690
CrossRef662
Clyde W. Yancy. (2004) Introduction: Heart Failure in African Americans. Congestive Heart Failure 10:1, 12-12
CrossRef663
Sushma A Mengi, Naranjan S Dhalla. (2004) Carnitine Palmitoyltransferase-I, a New Target for the Treatment of Heart Failure. American Journal of Cardiovascular Drugs 4:4, 201-209
CrossRef664
Yoshihiko Seino. (2004) Back to the Future: Pathophysiology and Therapeutic Strategies in Heart Failure. Journal of Nippon Medical School 71:6, 421-425
CrossRef665
John E. Macdonald, Allan D. Struthers. (2004) What is the optimal serum potassium level in cardiovascular patients?. Journal of the American College of Cardiology 43:2, 155-161
CrossRef666
Shigetake Sasayama. (2004) Optimising Outcomes in End-Stage Heart Failure Differences in Therapeutic Responses between Diverse Ethnic Groups. Drug Safety 27:Supplement 1, 19-24
CrossRef667
Nicholas L M Cruden, David E Newby. (2004) Angiotensin Antagonism in Patients with Heart Failure. American Journal of Cardiovascular Drugs 4:6, 345-353
CrossRef668
Gregoire Wuerzner, Arnaud Chiclero, Marc Maillard, Jurg Nussberger, Hans R. Brunner, Michel Burnier. (2004) Angiotensin II receptor blockade prevents acute renal sodium retention induced by low levels of orthostatic stress. Kidney International 65:1, 238-244
CrossRef669
Makoto KODAMA, Hitoshi TACHIKAWA, Takeshi KASHIMURA, Manabu HAYASHI, Tsuyoshi YOSHIDA, Haruo HANAWA, Yoshifusa AIZAWA, Mikio NAKAZAWA, Kenichi WATANABE. (2004) Effects of humoral factors on left ventricular remodeling under chronic heart failure.. Folia Pharmacologica Japonica 123:2, 63-70
CrossRef670
Motohiko CHACHIN, Tsuyoshi OHMURA, Naoyuki HAYASHI, Yoichiro NISHIMURA, Hisashi SATOH. (2004) Pharmacological and clinical profile of telmisartan, a selective angiotensin II type-1 receptor blocker. Folia Pharmacologica Japonica 124:1, 31-39
CrossRef671
A. Siebenhofer, J. Plank, K. Horvath, A. Berghold, A. J. Sutton, R. Sommer, T. R. Pieber. (2004) Angiotensin receptor blockers as anti-hypertensive treatment for patients with diabetes mellitus: meta-analysis of controlled double-blind randomized trials. Diabetic Medicine 21:1, 18-25
CrossRef672
Thomas Unger, Gordon T McInnes, Joel M Neutel, Michael B??hm. (2004) The Role of Olmesartan Medoxomil in the Management of Hypertension. Drugs 64:24, 2731-2739
CrossRef673
Roberto Latini, Serge Masson, Lidia Staszewsky, Aldo P Maggioni. (2004) Valsartan for the treatment of heart failure. Expert Opinion on Pharmacotherapy 5:1, 181-193
CrossRef674
Adelle Dawson, Justine I Davies, Allan D Struthers. (2004) The role of aldosterone in heart failure and the clinical benefits of aldosterone blockade. Expert Review of Cardiovascular Therapy 2:1, 29-36
CrossRef675
Massimo Volpe. (2004) Evidence-Based Indications in Hypertensive Patients. High Blood Pressure & Cardiovascular Prevention 11:1, 1-7
CrossRef676
Katherine F Croom, Gillian M Keating. (2004) Valsartan. American Journal of Cardiovascular Drugs 4:6, 395-404
CrossRef677
Yoshio Yasumura, Kunio Miyatake, Hiroshi Okamoto, Takeshi Miyauchi, Masatoshi Kawana, Takayoshi Tsutamoto, Masafumi Kitakaze, Hiroaki Matsubara, Hideyuki Takaoka, Teisuke Anzai, Hideo Himeno, Hiroyuki Yokoyama, Koichi Yokoya, Uichirou Shintani, Katsuji Hashimoto, Yukihiro Koretsune, Yukio Nakamura, Katsuji Imai, Shingo Maruyama, Yoshiko Masaoka, Michihito Sekiya, Teruo Shiraki, Hisanori Shinohara, Keizaburo Ozono, Tatsuru Matsuoka, Yuji Miyao, Fumikazu Nomura. (2004) Rationale for the Use of Combination Angiotensin-Converting Enzyme Inhibitor and Angiotensin II Receptor Blocker Therapy in Heart Failure. Circulation Journal 68:4, 361-366
CrossRef678
Ileana L Piña. (2003) A better survival for women with heart failure? it's not so simple…. Journal of the American College of Cardiology 42:12, 2135-2138
CrossRef679
Rajan Krishnamani, Mohamad El-Zaru, David DeNofrio. (2003) Contemporary medical, surgical, and device therapies for end-stage heart failure. Current Treatment Options in Cardiovascular Medicine 5:6, 487-499
CrossRef680
John W Funder. (2003) The role of mineralocorticoid receptor antagonists in the treatment of cardiac failure. Expert Opinion on Investigational Drugs 12:12, 1963-1969
CrossRef681
Pfeffer, Marc A., McMurray, John J.V., Velazquez, Eric J., Rouleau, Jean-Lucien, Køber, Lars, Maggioni, Aldo P., Solomon, Scott D., Swedberg, Karl, Van de Werf, Frans, White, Harvey, Leimberger, Jeffrey D., Henis, Marc, Edwards, Susan, Zelenkofske, Steven, Sellers, Mary Ann, Califf, Robert M., . (2003) Valsartan, Captopril, or Both in Myocardial Infarction Complicated by Heart Failure, Left Ventricular Dysfunction, or Both. New England Journal of Medicine 349:20, 1893-1906
Full Text682
Mann, Douglas L., Deswal, Anita, . (2003) Angiotensin-Receptor Blockade in Acute Myocardial Infarction — A Matter of Dose. New England Journal of Medicine 349:20, 1963-1965
Full Text683
MG Gama, G Rocha. (2003) The CHARM programme. The Lancet 362:9396, 1676
CrossRef684
Scott D. Solomon, Marc A. Pfeffer. (2003) Aldosterone antagonism and myocardial infarction. Journal of the American College of Cardiology 42:9, 1674-1676
CrossRef685
Juan M. Aranda, C. Richard Conti. (2003) Angiotensin II blockade: A therapeutic strategy with wide applications. Clinical Cardiology 26:11, 500-502
CrossRef686
Ileana L. Pi??a, Carol Buchter. (2003) Heart Failure in Women. Cardiology in Review 11:6, 337-344
CrossRef687
Renke Maas, Rainer H Böger. (2003) Antihypertensive therapy: special focus on drug interactions. Expert Opinion on Drug Safety 2:6, 549-579
CrossRef688
Ulrich P Jorde, Marshal T Fox. (2003) The CHARM programme. The Lancet 362:9396, 1677
CrossRef689
WH Wilson Tang, Gary S Francis. (2003) Novel pharmacological treatments for heart failure. Expert Opinion on Investigational Drugs 12:11, 1791-1801
CrossRef690
K. Ravi Acharya, Edward D. Sturrock, James F. Riordan, Mario R. W. Ehlers. (2003) Ace revisited: A new target for structure-based drug design. Nature Reviews Drug Discovery 2:11, 891-902
CrossRef691
Domenic A. Sica. (2003) Combination Angiotensin-Converting Enzyme Inhibitor and Angiotensin Receptor Blocker Therapy: Its Role in Clinical Practice. The Journal of Clinical Hypertension 5:6, 414-420
CrossRef692
Daniel Lemogoum, Yackoob Kassim Seedat, Abdul FattahBiola Mabadeje, Shanti Mendis, Pascal Bovet, Basden Onwubere, Kathleen Ngu Blackett, Claude Lenfant, Jean Ren??M'buyamba Kabangu, Pierre Block, Mohamed Belhocine, Jean Paul Degaute. (2003) Recommendations for prevention, diagnosis and management of hypertension and cardiovascular risk factors in sub-Saharan Africa. Journal of Hypertension 21:11, 1993-2000
CrossRef693
George L. Bakris, Nauman Tarif, Henry R. Black. 2003. Arterial Hypertension in Diabetes: Etiology and Treatment. .
CrossRef694
Marc S. Weinberg, Nicholas Kaperonis, George L. Bakris. (2003) How high should an ACE inhibitor or angiotensin receptor blocker be dosed in patients with diabetic nephropathy?. Current Hypertension Reports 5:5, 418-425
CrossRef695
Steven G Chrysant. (2003) Fixed combination therapy of hypertension: focus on valsartan/hydrochlorothiazide combination (Diovan®/HCT). Expert Review of Cardiovascular Therapy 1:3, 335-343
CrossRef696
Issam Zineh, Richard S. Schofield, Julie A. Johnson. (2003) The Evolving Role of Nesiritide in Advanced or Decompensated Heart Failure. Pharmacotherapy 23:10, 1266-1280
CrossRef697
A. Nap, J. C. Balt, M. J. Mathy, P. A. van Zwieten. (2003) AT1-receptor blockade and sympathetic neurotransmission in cardiovascular disease. Autonomic and Autacoid Pharmacology 23:5-6, 285-296
CrossRef698
Steven G Chrysant, George S Chrysant. (2003) Pharmacological profile and clinical use of moexipril. Expert Review of Cardiovascular Therapy 1:3, 345-352
CrossRef699
Jay Lakkis, Wei X. Lu, Matthew R. Weir. (2003) RAAS escape: A real clinical entity that may be important in the progression of cardiovascular and renal disease. Current Hypertension Reports 5:5, 408-417
CrossRef700
Christopher B Granger, John JV McMurray, Salim Yusuf, Peter Held, Eric L Michelson, Bertil Olofsson, Jan Östergren, Marc A Pfeffer, Karl Swedberg. (2003) Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial. The Lancet 362:9386, 772-776
CrossRef701
Yasushi Sakata, Kazuhiro Yamamoto, Toshiaki Mano, Nagahiro Nishikawa, Junichi Yoshida, Hiroyuki Nakayama, Kinya Otsu, Keiichiro Suzuki, Michihiko Tada, Masatsugu Hori, Takeshi Miwa, Tohru Masuyama. (2003) Angiotensin II type 1 receptor blockade prevents diastolic heart failure through modulation of Ca2+ regulatory proteins and extracellular matrix. Journal of Hypertension 21:9, 1737-1745
CrossRef702
William E. Chavey, Barry E. Bleske, John M. Nicklas. (2003) Controversies in the Use of Beta Blockers in Heart Failure. Congestive Heart Failure 9:5, 255-262
CrossRef703
John JV McMurray, Jan Östergren, Karl Swedberg, Christopher B Granger, Peter Held, Eric L Michelson, Bertil Olofsson, Salim Yusuf, Marc A Pfeffer. (2003) Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. The Lancet 362:9386, 767-771
CrossRef704
Marc A Pfeffer, Karl Swedberg, Christopher B Granger, Peter Held, John JV McMurray, Eric L Michelson, Bertil Olofsson, Jan Östergren, Salim Yusuf. (2003) Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. The Lancet 362:9386, 759-766
CrossRef705
Harvey D White. (2003) Candesartan and heart failure: the allure of CHARM. The Lancet 362:9386, 754-755
CrossRef706
Salim Yusuf, Marc A Pfeffer, Karl Swedberg, Christopher B Granger, Peter Held, John JV McMurray, Eric L Michelson, Bertil Olofsson, Jan Östergren. (2003) Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. The Lancet 362:9386, 777-781
CrossRef707
Kurt A. Wargo, Kenneth Chong, Evelyn C. Y. Chan. (2003) Acute Renal Failure Secondary to Angiotensin II Receptor Blockade in a Patient with Bilateral Renal Artery Stenosis. Pharmacotherapy 23:9, 1199-1204
CrossRef708
Richard F. Wright. (2003) Therapies for preventing heart failure. Current Treatment Options in Cardiovascular Medicine 5:4, 337-343
CrossRef709
Akihiko Igawa, Takashi Nozawa, Nozomu Fujii, Bun-ichi Kato, Hidetsugu Asanoi, Hiroshi Inoue. (2003) Long-term treatment with Low-Dose, but not High-Dose, guanethidine improves ventricular function and survival of rats with heart failure after myocardial infarction. Journal of the American College of Cardiology 42:3, 541-548
CrossRef710
Steven J. Hussein, John R. Teerlink. (2003) Novel pharmacologic therapy of heart failure. Current Treatment Options in Cardiovascular Medicine 5:4, 321-335
CrossRef711
R. E. Gilbert, H. Krum, J. Wilkinson-Berka, D. J. Kelly. (2003) The renin-angiotensin system and the long-term complications of diabetes: pathophysiological and therapeutic considerations. Diabetic Medicine 20:8, 607-621
CrossRef712
Amar Mohammad Salam. (2003) Selective aldosterone blockade with eplerenone in patients with congestive heart failure. Expert Opinion on Investigational Drugs 12:8, 1423-1427
CrossRef713
Massimo Volpe, Beatrice Musumeci, Paola De Paolis, Carmine Savoia, Alberto Morganti. (2003) Angiotensin II AT2 receptor subtype. Journal of Hypertension 21:8, 1429-1443
CrossRef714
Michael W. Rich. (2003) Drug Therapy Of Heart Failure in the Elderly. The American Journal of Geriatric Cardiology 12:4, 235-242
CrossRef715
Rosaire P. Gray, John S. Yudkin. 2003. Clinical Features and Treatment of Coronary Heart Disease in Diabetes. .
CrossRef716
Robert L. Scott. (2003) Is Heart Failure in African Americans a Distinct Entity?. Congestive Heart Failure 9:4, 193-196
CrossRef717
Noritoshi Nagaya, Kenji Kangawa. (2003) Ghrelin, a novel growth hormone-releasing peptide, in the treatment of chronic heart failure. Regulatory Peptides 114:2-3, 71-77
CrossRef718
Ursula C. Brewster, John F. Setaro, Mark A. Perazella. (2003) The Renin-Angiotensin-Aldosterone System: Cardiorenal Effects and Implications for Renal and Cardiovascular Disease States. The American Journal of the Medical Sciences 326:1, 15-24
CrossRef719
Wilbert S. Aronow. (2003) Epidemiology, Pathophysiology, Prognosis, and Treatment of Systolic and Diastolic Heart Failure in Elderly Patients. Heart Disease 5:4, 279-294
CrossRef720
Michelle Kittleson, Shelley Hurwitz, Monica R Shah, Anju Nohria, Eldrin Lewis, Michael Givertz, James Fang, John Jarcho, Gilbert Mudge, Lynne W Stevenson. (2003) Development of circulatory-renal limitations to angiotensin-converting enzyme inhibitors identifies patients with severe heart failure and early mortality. Journal of the American College of Cardiology 41:11, 2029-2035
CrossRef721
Jessup, Mariell, Brozena, Susan, . (2003) Heart Failure. New England Journal of Medicine 348:20, 2007-2018
Full Text722
Andrew D. Feingold, David DeNofrio. (2003) Management issues for patients with coronary artery disease and heart failure. Current Cardiology Reports 5:3, 216-222
CrossRef723
William C. Cushman. (2003) The Burden of Uncontrolled Hypertension: Morbidity and Mortality Associated With Disease Progression. The Journal of Clinical Hypertension 5:3, 14-22
CrossRef724
Ali Ahmed. (2003) Use of spironolactone in heart failure patients receiving angiotensin-converting enzyme inhibitors and beta-blockers. Journal of the American College of Cardiology 41:10, 1851-1852
CrossRef725
Stephen S Gottlieb. (2003) The neurohormonal paradigm:have we gone too far?. Journal of the American College of Cardiology 41:9, 1458-1459
CrossRef726
Mandeep R Mehra, Patricia A Uber, Gary S Francis. (2003) Heart failure therapy at a crossroad: are there limits to the neurohormonal model?. Journal of the American College of Cardiology 41:9, 1606-1610
CrossRef727
Susan K. Maue, James H. Jackson, Bruce A. Weiss, Marc L. Rivo, Vishu Jhaveri, Barbara Lennert. (2003) The Hypertension Management Program: Identifying Opportunities for Improvement. The Journal of Clinical Hypertension 5:3, 33-40
CrossRef728
Christine M. Logar, Charles A. Herzog, Srinivasan Beddhu. (2003) Diagnosis and Therapy of Coronary Artery Disease in Renal Failure, End-Stage Renal Disease, and Renal Transplant Populations. The American Journal of the Medical Sciences 325:4, 214-227
CrossRef729
Takafumi Koji, Katsuya Onishi, Kaoru Dohi, Ryuji Okamoto, Masaki Tanabe, Tetsuya Kitamura, Masaaki Ito, Naoki Isaka, Tsutomu Nobori, Takeshi Nakano. (2003) Addition of Angiotensin II Receptor Antagonist to an ACE Inhibitor in Heart Failure Improves Cardiovascular Function by a Bradykinin-Mediated Mechanism. Journal of Cardiovascular Pharmacology 41:4, 632-639
CrossRef730
James H. O’Keefe, Jared T. Lurk, Ravindra C. Kahatapitiya, Janet A. Haskin. (2003) The renin-angiotensin-aldosterone system as a target in coronary disease. Current Atherosclerosis Reports 5:2, 124-130
CrossRef731
Domenic A. Sica. (2003) Aldosterone Receptor Blockade: A Therapy Resurrected. Heart Disease 5:2, 85-88
CrossRef732
Philip A Poole-Wilson. (2003) ACE inhibitors and ARBs in chronic heart failure: the established, the expected, and the pragmatic. Medical Clinics of North America 87:2, 373-389
CrossRef733
P. Manohar, I. L. Pina. (2003) Therapeutic Role of Angiotensin II Receptor Blockers in the Treatment of Heart Failure. Mayo Clinic Proceedings 78:3, 334-338
CrossRef734
J. Herbert Patterson. (2003) Angiotensin II Receptor Blockers in Heart Failure. Pharmacotherapy 23:2, 173-182
CrossRef735
Takeshi Kashimura, Manabu Hayashi, Makoto Kodama, Mikio Nakazawa, Satoru Abe, Tsuyoshi Yoshida, Hitoshi Tachikawa, Haruo Hanawa, Kiminori Kato, Kenichi Watanabe, Yoshifusa Aizawa. (2003) Effects of Imidapril and TA-606 on Rat Dilated Cardiomyopathy After Myocarditis. Japanese Heart Journal 44:5, 735-744
CrossRef736
Mariell Jessup. (2003) The less familiar face of heart failure. Journal of the American College of Cardiology 41:2, 224-226
CrossRef737
George Suzuki, Takayuki Mishima, Elaine J Tanhehco, Victor G Sharov, Anastassia Todor, Sharad Rostogi, Ramesh C Gupta, Pervaiz A Chaudhry, Petros V Anagnostopoulos, Omar Nass, Sidney Goldstein, Hani N Sabbah. (2003) Effects of the AT 1 -receptor antagonist eprosartan on the progression of left ventricular dysfunction in dogs with heart failure. British Journal of Pharmacology 138:2, 301-309
CrossRef738
Toshio OGIHARA, Kunio HIWADA, Shigeto MORIMOTO, Hiroaki MATSUOKA, Masayuki MATSUMOTO, Shuichi TAKISHITA, Kazuaki SHIMAMOTO, Kazuyuki SHIMADA, Isao ABE, Yasuyoshi OUCHI, Hisaichiro TSUKIYAMA, Shigehiro KATAYAMA, Yutaka IMAI, Hiromichi SUZUKI, Katsuhiko KOHARA, Kohya OKAISHI, Hiroshi MIKAMI. (2003) Guidelines for Treatment of Hypertension in the Elderly. 2002 Revised Version.. Hypertension Research 26:1, 1-36
CrossRef739
Tsuguya FUKUI, Mahbubur RAHMAN, Koichi HAYASHI, Kazuo TAKEDA, Jitsuo HIGAKI, Tosiya SATO, Masanori FUKUSHIMA, Junichi SAKAMOTO, Satoshi MORITA, Toshio OGIHARA, Kohshiro FUKIYAMA, Masatoshi FUJISHIMA, Takao SARUTA. (2003) Candesartan Antihypertensive Survival Evaluation in Japan (CASE-J) Trial of Cardiovascular Events in High-Risk Hypertensive Patients: Rationale, Design, and Methods. Hypertension Research 26:12, 979-990
CrossRef740
Alice Stanton. (2003) Therapeutic Potential of Renin Inhibitors in the Management of Cardiovascular Disorders. American Journal of Cardiovascular Drugs 3:6, 389-394
CrossRef741
Yoshito Koseki, Jun Watanabe, Tsuyoshi Shinozaki, Masahito Sakuma, Tatsuya Komaru, Mitsumasa Fukuchi, Masahito Miura, Akihiko Karibe, Yuji Kon-no, Hirotaka Numaguchi, Mototsugu Ninomiya, Yutaka Kagaya, Kunio Shirato, the CHART Investigators. (2003) Characteristics and 1-Year Prognosis of Medically Treated Patients With Chronic Heart Failure in Japan. Circulation Journal 67:5, 431-436
CrossRef742
Ali Ahmed. (2003) American College of Cardiology/American Heart Association Chronic Heart Failure Evaluation and Management Guidelines: Relevance to the Geriatric Practice. Journal of the American Geriatrics Society 51:1, 123-126
CrossRef743
Eckart Jungmann. (2003) Prevention and Treatment of Diabetic Nephropathy in Older Patients. Drugs & Aging 20:6, 419-435
CrossRef744
Gordon T. McInnes. (2003) The expanding role of angiotensin receptor blockers in the management of the elderly hypertensive. Current Medical Research and Opinion 19:5, 452-455
CrossRef745
Stuart D. Russell, Tracy DeWald. (2003) Vasopressin Receptor Antagonists. American Journal of Cardiovascular Drugs 3:1, 13-20
CrossRef746
D. J. Campbell. (2002) Renin-angiotensin system inhibition: how much is too much of a good thing?. Internal Medicine Journal 32:12, 616-620
CrossRef747
Paul A Gould, David M Kaye. (2002) Clinical treatment regimens for chronic heart failure: a review. Expert Opinion on Pharmacotherapy 3:11, 1569-1576
CrossRef748
Joseph L. Izzo, Marvin Moser. (2002) Clinical Impact of Renin-Angiotensin System Blockade: Angiotensin-Converting Enzyme Inhibitors vs. Angiotensin Receptor Antagonists. The Journal of Clinical Hypertension 4, 11-31
CrossRef749
Mandeep R. Mehra, Patricia A. Uber, Srinivasa Potluri. (2002) Renin Angiotensin Aldosterone and Adrenergic Modulation in Chronic Heart Failure: Contemporary Concepts. The American Journal of the Medical Sciences 324:5, 267-275
CrossRef750
Michel F Rousseau, Olivier Gurné, Daniel Duprez, Walter Van Mieghem, Annie Robert, Sylvie Ahn, Laurence Galanti, Jean-Marie Ketelslegers. (2002) Beneficial neurohormonal profile of spironolactone in severe congestive heart failure. Journal of the American College of Cardiology 40:9, 1596-1601
CrossRef751
Sheila A Doggrell. (2002) Angiotensin AT-1 receptor antagonism: complementary or alternative to ACE inhibition in cardiovascular and renal disease?. Expert Opinion on Pharmacotherapy 3:11, 1543-1556
CrossRef752
Mohamad El-Zaru, David Nofrio. (2002) End-stage heart failure: Surgical therapy and implantable devices. Current Treatment Options in Cardiovascular Medicine 4:6, 511-520
CrossRef753
Mark Greathouse. (2002) A Review of Olmesartan Medoxomil Monotherapy: Antihypertensive Efficacy Similar to That of Other Angiotensin II Receptor Blocker/Hydrochlorothiazide Combinations?. Congestive Heart Failure 8:6, 313-320
CrossRef754
Domenic A. Sica, Henry R. Black. (2002) Angioedema in Heart Failure: Occurrence With ACE Inhibitors and Safety of Angiotensin Receptor Blocker Therapy. Congestive Heart Failure 8:6, 334-345
CrossRef755
Aldo P Maggioni, Inder Anand, Sidney O Gottlieb, Roberto Latini, Gianni Tognoni, Jay N Cohn. (2002) Effects of valsartan on morbidity and mortality in patients with heart failure not receiving angiotensin-converting enzyme inhibitors. Journal of the American College of Cardiology 40:8, 1414-1421
CrossRef756
Barry H Greenberg. (2002) Angiotensin receptor blockers in heart failure. Journal of the American College of Cardiology 40:8, 1422-1424
CrossRef757
Matthew R. Weir. (2002) Opportunities for cardiovascular risk reduction with angiotensin II receptor blockers. Current Hypertension Reports 4:5, 333-335
CrossRef758
Amy E Rudolph, Ellen G McMahon. (2002) Emerging therapies for heart failure. Expert Opinion on Emerging Drugs 7:2, 247-258
CrossRef759
Matthew R. Weir. (2002) Progressive renal and cardiovascular disease: Optimal treatment strategies. Kidney International 62:4, 1482-1492
CrossRef760
Kambiz Kalantarinia, Helmy M. Siragy. (2002) The choice of antihypertensive drugs in patients with diabetes: Angiotensin II and beyond. Current Diabetes Reports 2:5, 423-430
CrossRef761
Tobias Pischon, Arya M. Sharma. (2002) Optimizing blood pressure control in the obese patient. Current Hypertension Reports 4:5, 358-362
CrossRef762
Eva Lonn. (2002) Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in atherosclerosis. Current Atherosclerosis Reports 4:5, 363-372
CrossRef763
Motoyuki Nakamura, Seiichi Saito, Hiroaki Yoshida, Naoshi Arakawa, Shouma Sugawara, Katsuhiko Hiramori. (2002) Effects of Chronic Subdepressor Dose of Angiotensin II Type 1 Receptor Antagonist on Endothelium-Dependent Vasodilation in Patients With Congestive Heart Failure. Journal of Cardiovascular Pharmacology 40:3, 411-419
CrossRef764
Maylene Wong, Lidia Staszewsky, Roberto Latini, Simona Barlera, Alberto Volpi, Yann-Tong Chiang, Raymond L Benza, Sidney O Gottlieb, Thomas D Kleemann, Franco Rosconi, Pieter M Vandervoort, Jay N Cohn. (2002) Valsartan benefits left ventricular structure and function in heart failure: Val-HeFT echocardiographic study. Journal of the American College of Cardiology 40:5, 970-975
CrossRef765
H Morawietz, W Goettsch, M Szibor, M Barton, S Shaw, K Hakim, H.-R Zerkowski, J Holtz. (2002) Angiotensin-converting enzyme inhibitor therapy prevents upregulation of endothelin-converting enzyme-1 in failing human myocardium. Biochemical and Biophysical Research Communications 295:5, 1057-1061
CrossRef766
A. M. Pritchett, M. M. Redfield. (2002) -Blockers: New Standard Therapy for Heart Failure. Mayo Clinic Proceedings 77:8, 839-846
CrossRef767
Neil Shusterman. (2002) Risk-benefit assessment of angiotensin II receptor antagonists. Expert Opinion on Drug Safety 1:2, 137-152
CrossRef768
Lindsay Brown, Sheila A Doggrell. (2002) Present and future pharmacotherapy for heart failure. Expert Opinion on Pharmacotherapy 3:7, 915-930
CrossRef769
Howard D. Weinberger, Jennifer J. Weinberger. (2002) Use of Angiotensin-Converting Enzyme Inhibitors to Prevent Cardiovascular Disease. Primary Care Case Reviews 5:2, 61-67
CrossRef770
Philip A Poole-Wilson, Jacobus Lubsen. (2002) Losartan for cardiovascular disease in patients with and without diabetes in the LIFE study. The Lancet 359:9324, 2199
CrossRef771
Geoffrey Boner, Zemin Cao, Mark E. Cooper. (2002) Combination Antihypertensive Therapy in the Treatment of Diabetic Nephropathy. Diabetes Technology & Therapeutics 4:3, 313-321
CrossRef772
D Collette, Petra A Thürmann. (2002) Angiotensin II Type 1 receptor antagonists in chronic heart failure. Expert Opinion on Investigational Drugs 11:5, 705-716
CrossRef773
Masafumi Kitakaze, Tetsuo Minamino. (2002) Cellular mechanisms for the treatment of chronic heart failure: the nitric oxide- and adenosine-dependent pathways. Expert Opinion on Emerging Drugs 7:1, 99-110
CrossRef774
Inder S Anand, Viorel G Florea, Lloyd Fisher. (2002) Surrogate end points in heart failure. Journal of the American College of Cardiology 39:9, 1414-1421
CrossRef775
Bernard Swynghedauw. (2002) Myocardial remodelling: pharmacological targets. Expert Opinion on Investigational Drugs 11:5, 661-674
CrossRef776
Philippe Charron, Michel Komajda. (2002) Genes and their polymorphisms in mono- and multifactorial cardiomyopathies:. Pharmacogenomics 3:3, 367-378
CrossRef777
(2002) Valsartan in Chronic Heart Failure. New England Journal of Medicine 346:15, 1173-1174
Full Text778
Michael D. Schneider. (2002) Serial killer: angiotensin drives cardiac hypertrophy via TGF-β1. Journal of Clinical Investigation 109:6, 715-716
CrossRef779
Susan L. Ravnan, Marcus C. Ravnan, Prakash C. Deedwania. (2002) Diuretic Resistance and Strategies to Overcome Resistance in Patients With Congestive Heart Failure. Congestive Heart Failure 8:2, 80-85
CrossRef780
Nathalie Lapointe, Jean-Lucien Rouleau. (2002) Activation of vascular tissue angiotensin-converting enzyme (ACE) in heart failure. Journal of the American College of Cardiology 39:5, 776-779
CrossRef781
Philip Jong, Catherine Demers, Robert S McKelvie, Peter P Liu. (2002) Angiotensin receptor blockers in heart failure: meta-analysis of randomized controlled trials. Journal of the American College of Cardiology 39:3, 463-470
CrossRef782
Pierre Corvol, Pierre-Francois Plouin. (2002) Antagonistes des r??cepteurs de l???angiotensine II. Drugs 62:Special Issue 1, 53-64
CrossRef783
Keri Wellington, Diana M. Faulds. (2002) Valsartan/Hydrochlorothiazide. Drugs 62:13, 1983-2005
CrossRef784
Andrew R. Houghton. (2002) Angiotensin II Receptor Antagonists in Chronic Heart Failure. Drugs 62:10, 1433-1440
CrossRef785
Keri Wellington, Karen L. Goa. (2002) Valsartan. American Journal of Cardiovascular Drugs 2:4, 267-274
CrossRef786
Andrew Owen. (2002) Optimising the Use of ??-Blockers in Older Patients with Heart Failure. Drugs & Aging 19:9, 671-684
CrossRef787
Masaaki KIMURA, Hironobu MITANI, Yasuo ISOMURA. (2002) Preclinical and clinical profile of valsartan, a selective angiotensin II type-1 receptor blocker.. Folia Pharmacologica Japonica 120:5, 353-360
CrossRef788
Toshihiro Shimizu, Hiroshi Okamoto, Satoru Chiba, Yutaka Matsui, Takeshi Sugawara, Hisao Onozuka, Taisei Mikami, Hideki Kumamoto, Akira Kitabatake. (2002) Long-Term Combined Therapy with an Angiotensin Type I Receptor Blocker and an Angiotensin Converting Enzyme Inhibitor Prolongs Survival in Dilated Cardiomyopathy.. Japanese Heart Journal 43:5, 531-543
CrossRef789
Weber, Karl T., . (2001) Aldosterone in Congestive Heart Failure. New England Journal of Medicine 345:23, 1689-1697
Full Text
